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Abstract 
Depression is the second leading cause of disability, worldwide, and 
increasing access to its effective/preferred treatment requires more attention. 
Behavioural activation shows promise as an effective and disseminable treatment for 
depression. Time-intensive treatment provision is also shown to enhance treatment 
access and response rates, and has proven efficacy in the treatment of anxiety 
disorders. However, there has been limited exploration of time-intensive behavioural 
activation for depression, especially within outpatient settings, where depression most 
commonly presents. Therefore this study aimed to investigate the feasibility, 
effectiveness, and acceptability of time-intensive behavioural activation in primary 
care. It was hypothesised that the intervention would be associated with 
improvements in idiographic, standardised and process measures of depression and 
comorbid anxiety.  
Eight adults with major depressive disorder were recruited from three 
outpatient services into a multiple baseline single-case experimental design. All 
participants completed time-intensive behavioural activation, consisting of up to 
seven bi-weekly sessions and three optional booster sessions. 
Treatment recruitment, retention, and credibility/expectancy indicated that the 
intervention was feasible. Visual and statistical analyses showed that relative to 
baseline, the majority of participants (between five and seven) made significant 
improvements in all idiographic symptoms of depression, except anxiety. According 
to standardised measures of depression, four out of eight participants were considered 
treatment responders, with intervention effects mostly generalised to standardised 
measures of anxiety. Although only five participants completed follow-up measures, 
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the majority of progress was maintained. Process measures of activation and 
dysfunctional attitudes showed low proportions of change. The intervention was 
considered highly acceptable by participants and therapists.  
Overall this study provides new, but tentative evidence highlighting the 
potential of time-intensive BA as a feasible, effective and acceptable treatment for 
some adult outpatients with depression. The findings now warrant further, more 
rigorous evaluation of the treatment. 
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Introduction 
According to behavioural theory, depression occurs when individuals 
experience a reduction in positively reinforcing opportunities (Ferster, 1973; 
Lewinsohn, 1974). In turn, its recovery is concerned with increasing engagement in 
positively reinforcing activities while reducing negatively reinforcing patterns of 
behaviours. Indeed, these are the aims of behavioural activation, a treatment for 
depression that has received increasing attention over the past few decades. Research 
findings suggest that behavioural activation has many advantages in comparison to 
other psychological treatments for depression, and that it is as effective as other 
treatments, if not more so (Mazzucchelli, Kane, & Rees, 2009). Given depression’s 
wide-spread cost, yet existing barriers and limitations to its treatments, increasing 
access to its effective/preferred forms of treatment requires more attention. 
Behavioural activation shows particular promise as an accessible and disseminable 
treatment. Provision of time-intensive psychological interventions also holds promise 
for increasing access to treatments and they have proven efficacy in the treatment of 
anxiety disorders (Ehlers et al., 2014). However, there is limited exploration of the 
combination of the two: time-intensive behavioural activation for depression, 
especially in outpatient settings where depression is most often treated. The aims of 
this study were therefore to explore whether or not (a) time-intensive behavioural 
activation was a feasible intervention for adult outpatients with depression, (b) time-
intensive behavioural activation was effective at reducing adult outpatients’ 
idiographic measures of depression symptoms, (c) time-intensive behavioural 
activation was associated with reliable and clinically significant change in 
standardised and process measures of depression and anxiety symptoms (d) any 
existing effects were maintained after a follow-up period, and (e) to assess what were 
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participant and therapist perceptions of the acceptability of the treatment. Within the 
growing pressures of our National Health Service (NHS), an investigation that could 
guide the development of more accessible and cost-effective depression treatment 
seems highly relevant. 
Depression 
 
At a clinical level, depression is referred to as ‘major depressive disorder’ 
(MDD, see Appendix 1 for abbreviations), and is characterised by at least five criteria 
that must include persistent low mood and/or loss of interest or pleasure. Other 
symptoms can include sleep disturbance, significant weight or appetite change, 
psychomotor changes, diminished ability to concentrate, fatigue, thoughts of death or 
suicidal ideation, and a sense of worthlessness or guilt. To meet diagnostic criteria, 
symptoms must have persisted for at least two consecutive weeks, most of them 
almost daily, and must have caused clinically significant distress or functional 
impairment, without being attributable to another psychological or medical condition 
or substance use (American Psychiatric Association [APA], 2013). Within mental 
health services in the UK, regardless of whether or not all criteria for a diagnosis of 
MDD are met, depression severity is generally categorised as mild, moderate or 
severe, according to increasing functional impairment, respectively. 
The costs of depression.  Currently, depression is the second largest cause of 
disability worldwide (Ferrari et al., 2013), the most common mental health disorder 
(Steinert, Hofmann, Kruse, & Leichsenring, 2014) and owing to its increasing 
prevalence (Patten et al., 2016), it is predicted to be the leading cause of chronic 
illness in high-income countries by 2030 (World Health Organization [WHO], 2008). 
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In the UK alone prevalence of depression reaches five to 10% per year (McManus, 
Meltzer, Brugha, Bebbington, & Jenkins, 2009).  
Depression commonly co-occurs with other mental (Kessler et al., 1994) and 
physical health conditions (Rosenthal, 2003). Individual differences (e.g., 
comorbidity, life-stressors, and availability of support) cause huge variability in the 
course of depression (Bennabi et al., 2015; Hunnicutt-Ferguson, Hoxha, & Gollan, 
2012), taxing its treatment development. Unfortunately, according to a meta-analysis 
of randomised clinical trials of depression treatments, on average, 17.5% of depressed 
clients drop-out of treatment (Cooper & Conklin, 2015). Systematic reviews on the 
course of depression also report that of those who complete treatment, between 50% 
and 70% recover within 12 months, but 14% to 35% will experience an episode of 
recurrence during recovery (Richards, 2011). What is more, the rate of recurrence 
(Burcusa & Iacono, 2007), the length and severity of depression (Kendler et al., 2000) 
all increase over time and with subsequent episodes, while the rate of recovery slows 
(Richards, 2011). In fact, 10% to 17% will go on to have chronic relapsing depression 
(Steinert et al., 2014). Depression that persists for at least two years has recently been 
redefined as ‘persistent depressive disorder’, and its prevalence is estimated to be six 
percent (APA, 2013). Also, many individuals (29 - 46%) will experience ‘treatment 
resistant depression’, a failure to remit after at least two adequate trials of 
antidepressant medication (Fava & Davidson, 1996).  
  As a result of such varied treatment responses, depression can cause 
substantial costs to individual, health care service, societal and economic spending. 
The UKs latest released total annual cost of depression was £7.5 billion (McCrone, 
Dhanasiri, Patel, Knapp, & Lawton-Smith, 2008). More specifically, depression is 
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associated with detriments such as poor self-care, worsening physical illness, high 
mortality rates, absenteeism, impaired caregiver health, neglect, and implications to 
those left behind after a suicide (Donohue & Pincus, 2007).  
Treatment of depression. The majority of people receiving treatment for 
depression are adults with mild symptoms (National Institute for Health and Clinical 
Excellence [NICE], 2004), and they are most often treated within outpatient primary 
care services (Fletcher, Bower, Gask, Richards, & Saunders, 2006).The stepped-care 
model, offering the least intrusive, most cost-effective low-intensity intervention 
before clients can be ‘stepped-up’ to more complex treatments following non-
improvement, is the most widely adopted model for depression treatment within 
primary care settings (National Collaborating Centre for Mental Health [NCCMH], 
2010). In the UK, the Improving Access to Psychological Therapies (IAPT) initiative 
(Department of Health [DOH], 2008) implemented the stepped-care model in order to 
make evidence based depression treatments more accessible.  
Currently, the most recommended low-intensity treatments for mild to 
moderate depression, include cognitive behavioural therapy (CBT) based guided self-
help, computerised CBT, structured physical activity programmes and group CBT. 
Antidepressant medication (ADM) is considered when symptoms are chronic or 
response to an initial intervention proves inadequate. For these individuals, high-
intensity CBT, interpersonal therapy (IPT), or behavioural activation are also 
recommended. Combined CBT or IPT and ADM are recommended for moderate to 
severe depression treatment (NICE, 2009). During periods of being well, 
Mindfulness-Based Cognitive Therapy (MBCT) is recommended for those who have 
experienced three or more previous episodes of depression. Fundamentally though, 
18 
 
the development of patient-centred care, providing clients with treatment content and 
delivery options, is currently a key aim for mental health services (NICE, 2009). 
Despite depression’s high costs, the IAPT initiative (DOH, 2008), client 
choice, and the multitude of existing evidence based treatments for depression, 
psychological therapies have reached a plateau (Cuijpers, 2015). Response rates 
following depression treatments within IAPT are only 55% (Richards & Borglin, 
2011). What is more, substantial numbers of depressed individuals remain undetected, 
undiagnosed and untreated (Glover, Webb, & Evison, 2010; McCrone et al., 2008), 
suggesting that barriers continue to be a block to the implementation of the NICE 
guidelines for depression (Gyani, Pumphrey, Parker, Shafran, & Rose, 2012). Some 
existing barriers include characteristics of the illness itself (e.g., pessimism), stigma, 
long service waiting lists, time constraints and personal responsibilities (e.g., child 
care and work schedules) (Mohr et al., 2010).  
Much existing research on increasing access to depression treatments has 
investigated the effectiveness of more transportable low-intensity (e.g., technology-
assisted and self-administered) or less expensive (e.g., brief, group or paraprofessional 
delivered) treatments (Chartier & Provencher, 2013). As an example, technology-
assisted interventions have the potential to enhance treatment frequency and reduce 
treatment duration (in turn reducing costs), by enabling clients to access and complete 
online modules at varying rates, as well as to have contact with therapists within 24 
hours (Andersson & Cuijpers, 2009).  
Despite these benefits, some randomised controlled trials (RCTs) have 
demonstrated that acceptability of technology-assisted (Kenter, Cuijpers, Beekman, & 
van Straten, 2016) and unguided interventions (Hanson, Webb, Sheeran & Turpin, 
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2016), for depressed outpatients, is low. Another RCT concluded that in comparison 
to a telephone intervention, a face-to-face intervention lead to greater durability of 
improvement in depression symptomatology (Mohr et al., 2012). Some depressed 
individuals also have a preference for 1:1 therapy as opposed to group therapy 
(Dwight-Johnson, Sherbourne, Liao, & Wells, 2000). Therefore, in keeping with the 
aims of NICE (2009), clearly a variety of treatment choices are required to promote 
treatment access and provision of patient-centred care. 
One individual and face-to-face treatment option that could address barriers to 
treatment such as pessimism, time constraints and personal responsibilities, while 
potentially still being more rapid and less expensive, is time-intensive treatment (TT).  
Generally speaking, TT refers to treatment delivered more frequently than the 
traditional weekly session rate, and over a shorter period of time. 
Summary. Clearly, existing research indicates that depression is a complex 
affliction with increasingly far reaching effects. However, there is much room for 
increasing the success, accessibility, and retention of its treatment. As behavioural 
activation is thought to hold great promise in this regard (Kanter, Puspitasari, Santos, 
& Nagy, 2012) and TT also may, these will be the focus here, considering the 
literature (reviewed below) to suggest that there is reason to investigate the efficacy of 
both combined; time-intensive behavioural activation for depression.  
Behavioural activation  
 
Notably, numerous variants of behavioural activation exist and are often 
considered in combination as their shared components are thought to outweigh their 
differences (Dimidjian, Barrera, Martell, Munoz, & Lewinsohn, 2011). The most 
20 
 
commonly provided form of behavioural activation (Jacobson et al., 2001; Martell, 
Addis, & Jacobson, 2001), herein referred to as BA, is grounded in behavioural 
learning theory (Ferster, 1973; Lewinsohn, 1974), which, broadly speaking, proposes 
that depression can occur when individuals experience aversive events, and in order to 
cope, avoid the event as well as their related aversive thoughts and feelings. In turn, 
individuals engage in pleasant or satisfying experiences less often, and experience 
insufficient opportunities for response-contingent positive reinforcement (Lewinsohn, 
1974). Coping via avoidance can have unintended consequences such as individuals 
becoming withdrawn and engaging in excessive behaviours (e.g., rumination).  
Unfortunately, these consequences act as secondary coping strategies, maintaining the 
depression by further limiting opportunities for individuals to experience positive 
reinforcement. This can lead to even deeper depression and more unhelpful coping 
behaviours (Veale, 2008). Moreover, these behaviours can influence individuals’ 
environments (e.g., disrupting work routines), and relationships with others, which 
only serve to further maintain depression (Jacobson et al., 2001). As such, solutions to 
the problem become the problem.  
Consequently, BA aims to reduce depression by reducing avoidance 
behaviours and unhelpful reinforcement patterns, instead promoting client 
engagement in activities that are pleasurable and positively reinforcing of 
antidepressant behaviour (Martell et al., 2001). Neurobiological literature supports 
this aim, demonstrating that those who show clinical improvements in depression 
symptoms also show functional changes in brain regions that mediate reward 
responsiveness (Dichter, Felfer, Petty, Bizzell, Ernst, & Smoski, 2009). In addition, 
though speculative, and subject to individual differences, mediation analyses have 
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also implicated reinforcement (Takagaki et al., 2016), and activation (Ryba, Lejuez, & 
Hopko, 2014; Santos et al., 2016) as mechanisms of change in BA.  
 BA is not strictly protocol driven, emphasising the idiographic nature of 
depression, but it typically begins with orienting individuals to the behavioural model 
of depression. Therapists then coach clients to learn to recognise the context in which 
their unhelpful, avoidance or excessive behaviours occur, as well as to analyse 
contingencies of reinforcement that unintentionally maintain their use (functional 
analysis). BA conceptualises overt and covert (including cognitive processes such as 
rumination and self-attack) behaviours, rather than the content of thoughts. BA also 
typically consists of activity monitoring, goal setting, and gradual scheduling of goal-
directed activities that individuals either wish to do and value, or are avoiding doing, 
and are deemed more appropriate responses than their unhelpful behaviours. 
Accordingly, BA encourages individuals to act from the outside-in, according to their 
schedule, rather than to how they are feeling. Homework tends to consist of clients 
implementing their activity monitoring and scheduling, while investigating the impact 
of activities on their mood. At subsequent sessions, client activity levels are then 
reviewed, areas for development are identified, and activity schedules are established 
further. Problem solving and troubleshooting are repeatedly practiced when planning 
and reviewing activity schedules in order to amend barriers to completing activities 
that might maintain low mood. Through problem solving BA can also include some 
other therapeutic strategies (e.g., mindfulness or skills training) (Martell, Dimidjian, 
& Herman-Dunn, 2013).  
The second most widely implemented variant of behavioural activation is 
behavioural activation treatment for depression (BATD; Lejuez, Hopko, LePage, 
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Hopko, & McNeil, 2001), which also assumes that activation should mediate changes 
in mood and shares BA’s (Martell et al., 2001) aim to reduce the reinforcement of 
depressed behaviours while enhancing the reinforcement of more appropriate 
behaviours. BATD is rooted in behavioural matching theory (Herrnstein, 1970), 
which suggests that depression occurs when our environment results in reinforcers for 
depressed behaviour being more readily available than reinforcers of healthier 
behaviours. BATD differs to Martell et al.’s (2001) BA as it is briefer (eight to 15 
sessions) and it does not focus on the functional analysis of avoidance or covert 
mental behaviours. Rather, its primary focus is on activation (Hopko, Lejuez, 
Ruggiero, & Eifert, 2003; Kanter et al., 2010). 
Currently, the recommended amount of behavioural activation for persistent 
subthreshold or mild to moderate symptoms of depression (with inadequate response 
to initial interventions), and moderate to severe depression, consists of 16 to 20 
sessions delivered over 12 to 16 weeks. If deemed necessary, three or four follow-up 
sessions are also recommended (NICE, 2009).  
Advantages of behavioural activation. Despite differing treatments for 
depression, and their components, being increasingly acknowledged, by meta-
analyses and systematic reviews, as equally necessary and effective (Barth et al., 
2013; Cuijpers, 2015; Ekers, Richards, & Gilbody, 2008; Longmore & Worrell, 2007; 
Lorenzo-Luaces, Keefe, & DeRubeis, 2016; Mazzucchelli et al., 2009), behavioural 
activation and its variants are shown to exhibit some advantages over other 
recommended psychological treatments for depression.  
Empirical evidence supportive of behavioural activation has increased over the 
last few decades. One particularly influential RCT treating 241 adults diagnosed with 
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MDD demonstrated that the response rate (those making 50% decrease in outcome 
scores from baseline) of participants receiving BA was 76%. Overall, CBT, BA and 
ADM (paroxetine) were equally comparable MDD treatment options (Dimidjian et 
al., 2006). In addition, for those participants exhibiting severe symptoms, BA was as 
effective as ADM and more efficacious than CBT. Within the same sample, BA’s 
efficacy was even demonstrated for a group of depressed clients who had been 
unresponsive to previous cognitive therapy (CT) (Coffman, Martell, Dimidjian, 
Gallop, & Hollon, 2007). In addition, a two year follow-up study of the trial 
demonstrated that BA and CBT had equal durability of outcomes, and that both had 
superior durability and lower drop-out rates (9%) in comparison to ADM (Dobson et 
al., 2008).  
Dimidjian et al.’s (2006) study was limited by not measuring the competency 
of its therapists and potential bias of allegiance effects. The authors also 
acknowledged that their higher rates of ADM attrition, though not proven, could have 
been accounted for by the design of the treatment implementation. However, a later 
systematic review then also concluded that drop-out rates were lower for behavioural 
activation (4.5% vs. 22.7%) than CBT (Sturmey, 2009).Though not proven 
empirically, following regression analyses, these findings have been hypothesised to 
be related to CT attributing depression to something intrinsic, rather than natural 
responses to situational factors (Castonguay, Goldfried, Wiser, Raue, & Hayes, 1996). 
Furthermore, behavioural activation is not limited by ADMs complicating factors 
such as unpleasant side effects (e.g., weight gain), nor is it potentially complicated by 
CBT’s conceptualisation of thought content. In fact, behavioural activation is often 
referred to as ‘parsimonious’ (Jacobson et al., 1996) and less ‘complex’ than CBT 
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(Webb, Beard, Kertz, Hsu, & Bjorgvinsson, 2015). If experimentally supported, this 
might make behavioural activation more attractive to those with cognitive 
dysfunction, a common symptom of depression (APA, 2013), and for whom empirical 
evidence has concluded CBT is found to be less effective (Fournier et al., 2009).   
Meta-analyses investigating the combined efficacy of different types of 
behavioural activation (BA, BATD and activity scheduling alone) have concluded 
that behavioural activation shows superiority to brief psychotherapy, supportive 
therapy (Ekers et al., 2008), and pharmacotherapy, and that there are limited 
associations between effects found and possible confounding variables (Ekers et al., 
2014). Still, in 2009, the updated treatment recommendations for severe depression 
noted that the evidence for CBT and IPT was more robust than it was for behavioural 
activation (NICE, 2009). Indeed, referenced meta-analyses were underpowered and 
therefore subject to error. They often included studies considered as of low-quality, 
for reasons such as not using diagnostic interviews to determine participant inclusion, 
and not assessing treatment fidelity. In fact, removing low-quality studies from one 
meta-analysis removed the significant effect of behavioural activation over ADM 
(Ekers et al., 2014). However, NICE’s (2009) conclusion is also likely to have been 
influenced by the fact that there were less studies of behavioural activation’s efficacy 
in existence at the time. 
More recently, a higher powered (n = 440) randomised controlled non-
inferiority trial of BA concluded that BA is non-inferior to CBT, with 67% of 
depressed participants being considered treatment completers, and 64% of those 
demonstrating treatment response (50% decrease from baseline) over the twelve 
month period of the trial. The study also concluded that BA can be delivered by less 
25 
 
highly trained professionals than CBT requires (supporting the idea that it is less 
‘complex’), and that at twelve months post-treatment it is more cost-effective at 
standard willingness to pay thresholds than CBT (Richards et al., 2016). Therefore, as 
suggested by commentaries on the effects of BA, it is thought that BA can be more 
attractive to services seeking economical and flexible treatment options, reinforcing 
its amenability for dissemination and accessibility (Curry & Meyer, 2016).  
Behavioural activation is already found to be effective when disseminated 
across diverse settings and populations, including older adults, ethnic minorities and 
those with severe comorbidity (Kanter et al., 2015; Moradveisi, Huibers, Renner, 
Arasteh, & Arntz, 2013). Behavioural activation has also now been effectively 
disseminated across a wide variety of delivery formats including group (Porter, 
Spates, & Smitham, 2004) and computerised therapies (Andersson & Cuijpers, 2009). 
Regardless, in line with efforts to increase access to depression treatment, reviews of 
the existing literature have still called for continued innovation in its dissemination 
(Cuijpers, 2015; Dimidjian et al., 2011). 
Time-intensive treatment (TT) 
 
As mentioned, one option with potential for enhancing treatment access, 
choice and dissemination, is TT delivery. Currently the majority of research on TT 
has been conducted on anxiety disorders. Condensing treatment down over a shorter 
period of time, as an alternative to weekly hourly sessions, could be attractive to 
individuals who have a more immediate need or desire to recover (e.g., due to work 
and relationships being at risk), are less able to attend weekly treatment for longer 
periods of time due to their regular commitments (e.g., work, child care and travel 
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time), or have not responded to weekly treatment (Oldfield, Salkovskis, & Taylor, 
2011; Storch et al., 2007). 
Rationale for TTs has been based on early findings that avoidance can delay 
emotional processing (Rachman, 1979), and that in comparison to more traditionally 
spaced treatment, providing more frequent therapy sessions increases the rate of 
extinction of reinforcement patterns (Mackintosh, 1974, as cited in Oldfield et al., 
2011, p. 8). Indeed, some regression analyses have demonstrated that increased 
symptom change between treatment sessions (sudden gains), and faster overall 
recovery, are both significantly associated with more frequent psychological treatment 
delivery (Bohni, Spindler, Arendt, Hougaard, & Rosenberg, 2009; Ehlers et al., 2010), 
regardless of the total number of sessions attended (Erekson, Lambert, & Eggett, 
2015; Gutner, Sloan, Suvak, & Resick, 2016; Reese, Toland, & Hopkins, 2011). 
Although these regression analyses lacked experimental designs, and causality cannot 
be assumed, TT may also be associated with a decrease in total treatment durations 
deemed necessary for symptom improvement and the overall amount of time that 
individuals spend suffering. Concurrently, where empirically supported, TT could 
reduce the direct and indirect costs of depression (Kazdin & Blasé, 2011), treatment 
drop-out, and service waiting list times, which would be attractive to organisations 
(Zlomke & Davis, 2008).  
Pioneers of TTs also highlight that they provide more frequent opportunities 
for symptom monitoring and safety promotion, and that they are thought to be helpful 
to those with memory problems as they keep session material fresh (Grey et al., 
2009). Given the centrality of therapeutic alliance to psychotherapy outcomes 
(Fluckiger, Del Re, Wampold, Symonds, & Horvath, 2012), and the comparable 
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outcomes of different treatment approaches (Cuijpers, 2015), it is also conceivable, 
albeit not proven, that allowing therapeutic relationships to develop quicker could 
lead to more client motivation, and compliance, and be a non-specific therapy 
mechanism by which more rapid change occurs.  
Beyond assumptions, lived perceptions of TT in comparison to more 
traditional weekly sessions have been studied. A sample of participants with 
obsessive-compulsive disorder (OCD), considered TT to be an efficient and 
acceptable treatment adaptation in comparison to weekly sessions. Findings suggested 
that TT reduced rumination time, while enhancing the therapeutic alliance, client 
focus, momentum and motivation (Bevan, Oldfield, & Salkovskis, 2010). However, 
individual differences influenced treatment preference. Reported disadvantages of TT 
included it being “overwhelming” and “too brief”’ to enable “real change” (Bevan et 
al., 2010, p.173). Qualitative research is limited by recruiting small samples, and this 
study in particular was biased by not exploring perceptions of those who dropped out 
of the treatment, thus limiting understanding of what drives TT drop-out. 
Undoubtedly, reference to experimental RCTs is needed to establish the efficacy of 
TT, in comparison to traditional treatment delivery, in order to either support or 
disprove the findings and assumptions described above. 
Efficacy of time-intensive treatments. Yet, a lack of standardisation of 
reporting treatment session numbers, frequencies and durations makes it much more 
difficult to identify and determine studies that have used TTs, let alone their 
efficacies. In addition, inconsistent terminology is used to mean ‘time-intensive’, such 
as ‘massed’ (Öst, 1989), ‘accelerated’ (Wootton & MacGregor 2016), and ‘high-
density’ (Hahlweg, Fiegenbaum, Frank, Schroeder, & Witzleben, 2001) treatment. 
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The term ‘intensive’ alone can also be used interchangeably to mean ‘demanding’ 
where interventions are multimodal (Schramm et al., 2007), and as mentioned above, 
the terms ‘high-intensity’ and ‘low-intensity’ are currently used to denote different 
types of treatment in the stepped-care model (NICE, 2009).  
Furthermore, there is a lack of standardisation of what TTs actually entail. 
Trials of behavioural treatments for anxiety, such as exposure and response prevention 
(ERP), have historically emphasised a need for therapy sessions to be more 
continuous than once a week (Foa & Goldstein, 1978). It follows then that there have 
been more rigorous RCTs investigating the efficacy of TTs for anxiety than there 
have been for depression. Regardless, session numbers, frequencies and durations of 
treatments considered to be time-intensive have all differed considerably. This only 
confounds treatment designs, making their findings harder to interpret.   
 As examples, Öst (1989) first described an example of TT as one-session 
treatment of specific phobias, lasting up to three hours, which is now shown to be 
effective in comparison to multiple weekly sessions (Haukebo et al., 2007; Öst, Alm, 
Brandberg & Breitholtz, 2001; Zlomke & Davis, 2008). Intensive daily CBT for OCD 
has been delivered as fourteen, 90 minute sessions over three weeks, or weekly over 
14 weeks, and found to be equally as effective as weekly treatment, at reducing OCD 
symptomatology (Storch et al., 2007). More recently, time-intensive post-traumatic 
stress disorder (PTSD) treatment, consisting of 18 hours of daily therapy, delivered 
over two, 90 minute to two hour session, for five to seven working days, was also 
shown to be as effective as therapy sessions delivered weekly over three months 
(Ehlers et al., 2014).None of these studies showed evidence of enhanced negative 
effects or increased drop-out associated with TT. Rather, some studies observed 
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improvements were even maintained at long-term follow-up points (Ehlers et al., 
2014; Öst et al., 2001). However, there have not been many rigorous studies like 
these. It is conceivable that findings may not generalise to larger trials, and the studies 
themselves acknowledge that their findings could be confounded by extraneous 
variables, such as pre-treatment differences between their treatment conditions 
(Haukebo et al., 2008; Storch et al., 2007). Therefore, the findings still need to be 
considered tentatively.  
Furthermore, inconsistencies in comparative trial findings indicate uncertainty 
surrounding the short and long-term effects of TTs. Some experimental evidence 
demonstrates that TT shows superiority for immediate short-term outcomes, yet that 
improvements deteriorate over the longer-term (Bohni et al., 2009; Storch et al., 
2007). This suggests that TT may be related to undesirable outcomes such as lower 
retention of learning and higher relapse rates. Indeed, it has been suggested that 
longer spacing between sessions can impede learning, but can also provide increasing 
and diverse opportunities to practice and consolidate learned skills in different 
contexts, potentially promoting the long-term retention of progress (Abramowitz, Foa, 
& Franklin, 2003). Conversely, Haukebo et al., (2008), only found equal effects of 
time-intensive versus spaced dental phobia treatment one year post-treatment, after 
spaced treatment had initially appeared superior and change was explained by 
continued improvement of TT outcomes. It may be that without some spacing 
between sessions or practicing of skills post-treatment, progress might be lost once 
treatment ends. It has also been suggested, though following their naturalistic study, 
that the retention of more ‘complex’ treatment skills, encompassing more mechanisms 
(e.g., cognitive and behavioural mechanisms in CBT), is harder within intensive time-
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periods, than ‘simpler’ (e.g., behavioural mechanisms in behavioural activation) skills 
(Webb et al., 2015).  
Time-intensive treatment of depression 
 
Based on promising existing evidence for TT of anxiety disorders, it is 
reasonable to assume that time-intensive BA for depression could also have 
promising effects for some individuals. After all, anxiety and depression are 
interrelated. They are both theorised to be characterised by negative affect (Mineka, 
Watson, & Clark, 1998; Watson, 2005), and they commonly co-occur (Kessler et al., 
1996). Indeed, longitudinal evidence suggests that avoidance and escape behaviours 
are primary perpetuating factors of both anxiety and depression (Jacobson & 
Newman, 2014). Accordingly, treatments of anxiety and depression (e.g., CBT, ERP 
and BA) share some conceptual underpinnings, namely behaviour modification, often 
targeting avoidance (Hopko, Robertson, & Lejuez, 2006). Therefore, one might 
assume that the therapeutic effects of activation in behavioural activation (learning 
new responses to positively reinforcing stimuli) and exposure in ERP (learning new 
responses to previously feared stimuli), through extinction, are functionally similar 
(Hopko et al., 2003b). However, operant conditioning (learning via reinforcement 
interactions), tends to be used to modify affective symptoms of depression, whereas 
classical conditioning (learning via stimulus-response interactions) holds higher 
theoretical basis in anxiety disorder treatment (Neudeck & Wittchen, 2012; Ramnero 
et al., 2016). What is more, existing research on mechanisms of change underlying 
behavioural activation outcomes is still mixed and speculative, meaning that they 
have not been confirmed as the same mechanisms of change present in anxiety 
treatment (Hunnicutt-Ferguson et al., 2012; Lemmens, Muller, Arntz, & Huibers, 
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2016; Lorenzo-Luaces et al., 2016; Santos et al., 2016). Even so, RCTs investigating 
time-intensive anxiety treatments have also demonstrated transfer effects in 
depression outcomes (Ehlers et al., 2010; 2014; Storch et al., 2007), which has even 
resulted in increasing interest in integrating behavioural activation treatments for 
individuals with comorbid or mixed anxiety and depression presentations 
(Ammerman et al., 2012; Barlow & Campbell, 2000; Hopko, Lejuez, Ryba, Shorter, 
& Bell, 2016). 
Time-intensive behavioural therapy. Actually, even prior to the 
development of stand-alone behavioural activation, the efficacy of delivering 
behavioural therapy (BT) components (e.g., self-monitoring, activity scheduling, and 
problem-solving that went on to embody behavioural activation), time-intensively, 
had been demonstrated. For example, depression symptomatology measured on the 
Beck Depression Inventory (BDI; Beck, 1967) reduced at an equally effective rate 
following either randomly allocated BT or CT, when delivered in six, 40 minute 
sessions, over four weeks (Taylor & Marshall, 1977), and these findings were 
maintained at 5 week follow-up. In addition, Zeiss, Lewinsohn and Munoz (1979), 
found twelve BT sessions, delivered three times a week, over one month, to be 
equally as effective as interpersonal and cognitive approaches when reducing 
depression symptomatology on a depression behaviour checklist (Grinker, Miller, 
Sabshin, Nunn, & Nunnally, 1961). In retrospect, the authors commented that they 
considered their treatment schedule to be too time-intensive, stating that it “did not 
allow enough time for clients to practice new skills under therapist guidance” (Zeiss 
et al., 1979, p. 432). Instead, they recommended that future researchers spread the 
sessions out over a six week period. Furthermore, these study samples were subject to 
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selection bias as they were small, heterogeneous, non-clinical, opportunity samples. 
The incidence of depression was not measured using diagnostic screening tools, and 
outcomes were predominantly measured using self-report scales, reducing the validity 
of the outcomes. Study findings were also subject to experimenter bias, as either only 
one therapist delivered the treatments and rated outcome measures (Taylor & 
Marshall, 1977), or therapists had limited experience (Zeiss et al., 1979), Therefore 
the reliability and generalisability of the study findings are limited.   
Furthermore, conflicting findings for the effectiveness of time-intensive BT do 
exist. One study comparing group BT delivered either immediately (twice a week for 
two hour long sessions, over four weeks), or delayed (for four weeks of self-
monitoring followed by weekly sessions), reported that delayed treatment led to 
significantly increased activation and significantly decreased depression scores in 
comparison to the immediate treatment condition. This effect was hypothesised by the 
authors as caused by the four weeks of self-monitoring better preparing participants 
for treatment (Barrera, 1979), but was also acknowledged as potentially confounded 
by therapist experience. 
How time-intensive should behavioural activation be? When BA was 
eventually introduced as a stand-alone treatment (Martell et al., 2001) for depression, 
it was specifically intended to be delivered twice a week for the first three to four 
weeks and then once a week thereafter, making it time-intensive to begin with. 
Indeed, this mode of delivery is now recommended for consideration, particularly for 
clients experiencing moderate to severe symptoms (NICE, 2009). Martell et al., 
(2001) specifically intended such treatment delivery to promote client engagement, 
the therapeutic alliance, early improvement and the reduction of risk. A later step-by-
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step guide to BA highlighted that barriers to the practicalities of this methodology, 
such as client availability, service demands and resources, prevented the 
recommendation from being followed consistently in clinical practice (Dimidjian, 
Martell, Addis, Herman-Dunn, & Barlow, 2008).   
It may not be surprising therefore, that since the development of stand-alone 
behavioural activation interventions, this literature review found no published, gold-
standard, RCTs comparing the efficacy of time-intensive behavioural activation for 
depression to treatment as usual or control conditions. This comparison has not even 
been investigated in the wider field of depression treatments yet. In fact, the first 
study of this kind, a RCT comparing the cost-effectiveness of twice-weekly and once-
weekly IPT and CBT, is currently ongoing (Bruijniks et al., 2015).  
Therefore, it makes sense that Cuijpers, Huibers, Ebert, Koole, & Andersson, 
(2013) concluded that there is a lack of understanding of an optimal intensity of 
psychotherapy sessions for depression. Their meta-regression analysis of RCTs 
investigated the association between the effectiveness of psychological treatments for 
adult depression and a) the number of sessions, b) treatment durations and c) intensity 
of session deliveries, in order to determine how much psychotherapy is needed to treat 
depression. They defined treatment intensity as the number of sessions delivered per 
week, and included 70 trials in total. Their findings showed that the intensity of 
psychological treatments for depression ranged from 0.44 to two sessions per week, 
and that the majority of depression treatment studies delivered just one session per 
week. Six studies included in the meta-analysis investigated the efficacy of 
behavioural activation or its components (Carpenter, Smith, Aharonovich, & Nunes, 
2008; Dimidjian et al., 2006; Ekers, Richards, McMillan, Bland, & Gilbody, 2011; 
34 
 
Taylor & Marshall, 1977; Teri, Logsdon, Uomoto, & McCurry, 1997; Turner, Ward, 
& Turner, 1979). However, only two delivered treatment 1.5 times a week on average 
(Dimidjian et al., 2006; Taylor & Marshall, 1977), and one delivered treatment 1.25 
times on average (Turner et al., 1979).  
Turner et al., (1979), delivered five 50 minute sessions of activity scheduling 
over a 30-day period and found a significant reduction in depression symptoms in 
comparison to exercise, activity monitoring, and attention-control conditions that did 
not increase participant activity levels. However, similarly to Taylor and Marshall’s 
(1977) study (described above), their study was limited by sampling and experimenter 
biases. In addition, the majority of its sessions (n = 3) were delivered weekly. 
Conversely, Dimidjian et al., (2006), (also mentioned above), delivered 24, 50 minute 
sessions of stand-alone BA, over 16 weeks, (meaning that they did employ the 
recommended twice-weekly delivery of sessions for the first eight weeks) when 
demonstrating its efficacy as treatment for clinically depressed outpatients, in 
comparison to both CBT and ADM.  
Despite comparing a variety of different treatment formats, the overall finding 
of the meta-analysis was that, effectiveness of depression treatment was more 
associated with session intensity than general treatment quantity. In fact, having two 
sessions a week as opposed to one session each week increased treatment effect size 
by g = 0.45. This significant effect was still present when comparisons between 
weekly, more than weekly and less than weekly treatments, were all made separately. 
Longer treatment durations also resulted in significantly lower effect sizes, and a 
decrease of g = 0.13 with every additional week of therapy. There was also a 
significant positive relationship between treatment duration and treatment effect size. 
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However, the association between session intensity and effect size was the only 
remaining significant association when more sensitive analyses were employed that, 
for example, excluded studies where diagnostic interviews had not been used to assess 
for depression. To explain this effect, the authors referred to animal model evidence 
within neurobiology, which suggests that learning processes require neurons born 
over the past five days (Henn & Vollmayr, 2004), and therefore that TT may increase 
the survival of such neurons, and in turn accelerate the learning of therapeutic skills.  
Nevertheless, these findings cannot support an inference of causality between 
variables. Findings were based on planned treatment amounts, frequencies, and 
intensities, which may not have been representative of actual treatment delivered 
following participant drop-out and non-attendance. Findings may also be biased by 
not always accounting for the quality of treatments included in the meta-analysis, and 
not considering the impact of booster sessions on treatment effects. Furthermore, the 
studies included in the meta-analysis were acknowledged as at high risk of publication 
bias (Cuijpers et al., 2013).  
Regardless, Cuijpers et al., (2013) called for future studies, employing 
rigorous methodology (e.g., multiple baseline or RCT designs), to investigate the 
efficacy of different TTs for depression. In line with general attempts at increasing 
depression treatment access, currently the bulk of research influenced by Cuijpers et 
al.’s (2013) findings consists of investigating technology-assisted (mobile or internet-
based) therapies (e.g., Kooistra et al., 2014).  
One-session behavioural activation. The lack of understanding of optimal 
depression treatment intensity makes it less clear how time-intensive BA for 
outpatients with depression should be structured. Cuijpers et al., (2013) proposed that 
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“no one would probably consider treating depression in one week” (p. 11). Indeed, 
greater homework completion (Busch, Uebelacker, Kalibatsera, & Miller, 2010) and 
activity levels (Mazzucchelli et al., 2009) are both shown to correlate with positive 
change in behavioural activation, which supports the suggestion that retention of TT 
outcomes could require longer opportunities to practice skills gained from therapy 
(Abramowitz et al., 2003). In addition, considering that the time required to form new 
habits successfully (Lally, van Jaarsveld, Potts, & Wardle, 2010), can be longer than 
time required for habituation to anxiety (e.g., Öst et al., 1989), one might have 
anticipated that interventions for depression, where habitual learning carries weight, 
could not be effective after a single session, or that they might be less effective than 
shown for specific phobias. However, there is also evidence to suggest that the 
quantity of activity completed in behavioural activation treatment is not associated 
with change in depression outcomes (Hershenberg, Paulson, Gros & Acierno, 2014; 
Ryba et al., 2014). In addition, empirical as well as less rigorous research has 
highlighted that success and temporal aspects of depression treatments are 
heterogeneous (Manos, Kanter, & Luo, 2011; Santos et al., 2016; Stavrakakis et al., 
2015).  
In fact, some research has indicated behavioural activation’s potency when 
completed for one or two weeks, following just one treatment session. Gawrysiak, 
Nicholas and Hopko (2009) administered one 90 minute session of BATD to 30 
university students with moderate levels of depression. Following the intervention, 
participants were instructed to complete activation goals over a two week period. No 
one dropped out, and findings showed that 93% of those receiving the intervention 
experienced reliable and clinically significant improvements in their experience of 
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depression symptoms, according to BDI-II (Beck, Steer, & Brown, 1996) scores, and 
36% made reliable and clinically significant change in their anxiety levels, as 
measured by the Beck Anxiety Inventory (BAI; Beck & Steer, 1993). Only 31% of 
participants in a no-treatment control condition showed such progress on either 
measure. Despite the study making good efforts to maximise the external reliability of 
the findings (e.g., through randomisation), it had many limitations. Recruiting a 
volunteer sample of non-clinical university students, and excluding anyone who was 
taking medication or had received psychological treatment in the past two years, 
reduced the generalisability of the study findings. Participants only completed self-
report measures, and although adequate, the sample size was small, increasing the 
probability of measurement errors. Furthermore, the study did not include a follow-up 
measurement, reducing our understanding of how outcomes may or may not have 
been maintained over time. 
In 2016, the efficacy of another single session of BATD, also lasting for 90 
minutes, was investigated as a preventative depression intervention, in comparison to 
a wait-list control condition, for a community sample of 13 non-depressed carers 
(Read, Mazzucchelli, & Kane, 2016). The findings indicated that the intervention led 
to reduced stress levels in carers but that it did not lead to reliable or clinically 
significant reduction in depression or anxiety symptoms on the Depression Anxiety 
Stress Scales (Lovibond & Lovibond, 1995). The small sample size may have resulted 
in non-significant findings. In addition, the authors themselves acknowledge that 
treatment adherence of only 56% and a two week intervention period may not have 
allowed for the interventions full impact to be demonstrated. They proposed that 
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future research should include short telephone calls between the therapist and client, 
to prompt activation.  
Even more recently, 46 participants with diagnosed MDD were randomised to 
either Gawrysiak et al.’s (2009) one-session BATD intervention or a wait-list control 
condition (Nasrin, Rimes, Reinecke, Rinck, & Barnhofer, 2017). After only a one 
week intervention phase, post-treatment outcome measures indicated that participants 
made significant improvements in self-reported depression symptoms (according to 
the Patient Health Questionnaire; Kroenke, Spitzer and Williams, 2001). Still, these 
effects were only subtle, and again potentially influenced by the small sample size, 
9% of participants dropping-out, and experimenter bias, as only one therapist 
delivered the treatments. Clearly there is some evidence for the efficacy of one-
session BATD treatments, though this is limited and inconsistent.  
Multi-session time-intensive behavioural activation. Multi-session, time-
intensive behavioural activation treatment has been more commonly researched in 
inpatient settings. For inpatients, session frequency tends to be higher, as length of 
stay is reduced. 
One pilot RCT compared BATD to a supportive psychotherapy control 
condition, for 25 inpatients with depression. In the BATD condition participants were 
seen, for 20 minute sessions, three times a week, over a two week period (Hopko, 
Lejuez, Lepage, Hopko, & McNeil, 2003). According to outcomes on the BDI-II 
(Beck et al., 1996), BATD was shown to be more efficacious than the control 
condition. However, the control condition was not empirically validated, and the 
experimenters did not measure treatment adherence to either condition, threatening 
the internal validity of the findings. 
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In a separate study, 50 older adults on a geriatric inpatient unit, presenting 
with depression and cognitive impairment, were randomised to receive either eight 30 
to 60 minute sessions of BATD, over four weeks, or treatment as usual. BATD led to 
improvement in depression symptoms on the Geriatric Depression Scale Short Form 
(Sheikh & Yesavage, 1986) for 24% of depressed inpatients as opposed to only 12% 
improving in a treatment-as-usual condition (Snarski et al., 2011). However, the 
findings were biased by high attrition rates (n = 9, 36%).  
More recently, a behavioural treatment model for depression, based on the 
synthesis of BA and BATD has been developed (BA/TD: Kanter, Busch, & Rush, 
2009), maintaining emphasis on functional analysis while keeping the structure of 
treatment simple. Eight to 12 sessions of the treatment were delivered once or twice a 
week to 13 participants from Swedish inpatient settings, who were transitioning to 
outpatient services and indicated having significant depression symptoms according 
to the Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery & 
Åsberg, 1979). Comparisons between pre and post-treatment scores indicated that 
participants made significant improvements in depression symptoms. Credibility and 
acceptability of the intervention were also high, deeming the intervention feasible for 
their population. However, the mean number of sessions delivered was only three and 
a half, three participants dropped-out, and the researchers were unable to draw 
conclusions about the interventions efficacy as the study was not a randomised 
controlled trial (Folke et al., 2015a).  
Folke et al., (2015b) went on to test the efficacy of their time-intensive BA/TD 
intervention using the more rigorous methodology of multiple baseline single case 
experimental design (SCED). They recruited six participants with depression 
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(according to a score of 20 or more on the MADRS) from three different inpatient 
wards in Sweden. Participants were randomised to baseline phases lasting one to six 
days and then attended two, daily, 20 to 30 minute sessions of BA/TD, over five 
consecutive days. Depression outcomes were measured according to participants 
completing daily self-report versions of the MADRS (Svanborg & Åsberg, 1994), an 
hourly diary rating their felt level of depression, and their activation levels on the 
short Behavioural Activation for Depression Scale (Manos et al., 2011). Independent 
raters also collected clinician-rated versions of the MADRS at the beginning and end 
of baseline and intervention phases. The study findings indicated that the majority of 
participants experienced reliable change (Jacobson & Traux, 1991) in depression 
symptomatology, according to daily self-report (n = 5, 83%) and clinician-rated 
measures (n = 4, 66%). Fewer participants demonstrated clinically significant change 
in their self-report (n = 2, 33%) and clinician-rated outcomes (n = 3, 50%). However, 
feasibility measures also demonstrated that participants rated the treatment as highly 
satisfying. Even so, experimental bias may have confounded these findings as non-
random recruitment of participants was used, the first author delivered the 
intervention, and outcome raters were also members of the research team.  
Moreover, all of the studies described above, that were conducted within 
inpatient settings would benefit from having larger sample sizes, increasing statistical 
powers. None of the studies used structured clinical interviews to determine whether 
or not participants met diagnostic criteria for MDD, reducing the validity of their 
samples. In addition, all of the participants had comorbidities and were receiving 
multiple standard inpatient treatments concurrently to the behavioural activation. 
They will of course have included medicinal treatment dosages that can fluctuate 
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daily. While such a range of depression severity does enhance generalizability of the 
study findings, it also confounds them. Furthermore, none of the studies measured 
treatment fidelity, meaning the integrity of the interventions is uncertain. Given that 
stay durations on inpatient units are often short and interrupted by sudden discharge, 
the participants were often unable to even complete their behavioural activation. In 
fact, none of the inpatient studies described collected follow-up outcome measures, 
rendering the maintenance of any of their treatment effects, unknown.  
Summary. In summary, some existing research describes the merits of 
delivering both behavioural activation and TTs, in comparison to other treatment 
types or modalities. However, TT for depression using behavioural activation has not 
been investigated to the same rigorous standards as some treatments for anxiety 
disorders have been. What is more, any existing research into its effects has been 
subject to several limitations. Of note, the majority of rigorous evidence investigating 
the efficacy/effectiveness of time-intensive behavioural activation, though supportive, 
has either not been time-intensive across the total treatment duration (e.g., Dimidjian 
et al., 20006) or, where it has been, it has also been much briefer (e.g., Gawrysiak et 
al., 2009) than the current recommended behavioural activation durations for 
outpatients with depression (NICE, 2009). Therefore, time-intensive behavioural 
activation treatments for depression have not been defined in a consistent way. Also, 
it seems the majority of existing time-intensive behavioural activation, owing to 
taking place within inpatient services, has delivered BATD or BA/TD as opposed to 
BA, and has been less focused on increasing access to completing treatments but more 
focused on participants making fast progress in contexts where stay durations are 
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unpredictable and most often short (F. Folke, personal communication, February 6, 
2017).  
Currently, meta-analyses have predicted that cost-effectiveness and client 
preference will increasingly influence treatment provisions (Mazzucchelli et al., 
2009). Despite most treatment of depression occurring in adult outpatient settings, and 
there being more rigorous existing research of BA’s efficacy (Richards et al., 2016), 
as opposed to BATD’s, particularly within outpatient settings (Kanter et al., 2010), 
this review found no examples of studies investigating the effects of continuously 
delivered time-intensive BA in these settings. Therefore, there appears to be a gap in 
the literature, and given the implication that time-intensive BA for depression could 
enhance treatment access and effects; it is a gap worth filling. 
The present study 
 
Accordingly, the practical key aim of the current study was to conduct a 
preliminary examination of the effects of a time-intensive BA intervention, delivered 
to adults with depression, presenting to outpatient primary care services. The study 
aimed to answer the following research questions: 
1. In terms of recruitment rate, treatment duration, retention, and treatment 
credibility/expectancy ratings; is time-intensive BA a feasible intervention for 
adults with depression who present to outpatient primary care services? 
2. Can time-intensive BA lead to improvement on idiographic measures of 
depression symptoms? 
3. Can time-intensive BA lead to reliable and clinically significant change on 
standardised and process measures of depression and anxiety?  
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4. Are treatment gains maintained over a three week follow-up period? 
5. Do participants’ and therapists’ evaluations of the intervention indicate that it 
is considered an acceptable treatment? 
The study employed a multiple baseline single-case experimental design 
(SCED), with randomisation to baseline duration. SCEDs are a robust method for 
testing causal mechanisms of treatments. They monitor progress within individual 
participants over time by repeatedly measuring outcome variables across different 
phases (e.g., baseline and intervention), rather than making within and/or between 
group comparisons (Kazdin, 1982). This allows detailed change to be demonstrated 
within each participant (Turpin, 2001), for participants to act as their own controls, 
and for individual differences between multiple participants to be captured (Morley, 
2015a), enabling a more complete understanding of change. Thus, SCEDs are 
considered adequate starting points for guiding practice development (Morley, Linton, 
& Vlaeyen, 2015). Furthermore, SCEDs are more readily applicable to busy primary 
care settings than larger more rigorous research designs and require fewer participants 
to detect an effect. Therefore SCED was considered a more appropriate design for the 
current proof-of-concept study.  
The multiple baselines characteristic increases the experimental control of 
study findings by demonstrating the stability of outcomes, over differing durations, 
before the intervention is manipulated. Randomisation to baseline lengths controls for 
extraneous threats to validity, such as maturation, enabling outcomes to be attributed 
to the intervention as opposed to time (Kratochwill et al., 2010). 
Eight participants with a primary diagnosis of MDD were recruited from three 
IAPT outpatient adult mental health services in London, and were prospectively 
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followed during the course of their time-intensive BA. Following suggestions from 
previous research (described above), the Principal Investigator decided that the TT 
would consist of seven bi-weekly sessions (Cuijpers et al., 2013), of BA delivered 
over 22 days (Zeiss et al., 1979), with three optional additional booster sessions 
(Cuijpers et al., 2013; NICE, 2009), and regular prompting (Read et al., 2016) (see 
Methods for further rationale).   
Participants completed daily visual analogue scales measuring their mood, 
anxiety, rumination, avoidance, encapsulated beliefs and chosen idiographic 
symptoms of depression. They also completed standardised weekly measures of 
depression and anxiety symptomatology, as well as process measures of activation 
and dysfunctional attitudes. Acceptability of the intervention was determined by 
measuring client satisfaction and both therapist and client’s ratings of the 
intervention’s acceptability. 
Besides using rigorous SCED methodology, the study aimed to build on the 
existing literature by defining a novel application of time-intensive BA that was 
continuous and less brief. The study recruited outpatients, with less severe 
comorbidity, who were not engaging in any other psychological intervention 
simultaneously to the BA, but were allowed to participate if they were taking ADM or 
had received previous psychological treatment within the last two years, but not the 
last six months. The reliability of the outcomes was enhanced by collecting clinician-
rated as well as self-report measures of depression symptomatology. Treatment 
validity was also improved by using diagnostic screening criteria to select 
participants, using multiple qualified therapists to deliver the intervention (none of 
whom were the Principal Investigator), measuring the treatment fidelity and 
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considering the durability of change by monitoring symptoms for three weeks post-
treatment.  
Participants’ outcomes were explored at an individual level using visual 
analyses of graphed data. Statistical analyses were also conducted to determine the 
amount of data that differed between the study phases, and whether or not participants 
made reliable and clinically significant change. Participant and therapist’s evaluations 
of the acceptability of the intervention are also described.  
It was hypothesised that following the intervention, participants would show 
improvements in their idiographic, standardised and process measures of depression 
symptomatology, and that these effects would generalise to anxiety symptoms. 
Improvement was operationalised as making significant declines on idiographic 
measure ratings (according to Tau statistics), or reliable change (Jacobson & Traux, 
1991) on standardised and process measures. Due to the lack of existing research in 
this area, no directional hypotheses were made about whether or not progress would 
reach reliable and clinically significant change, be maintained following the short 
follow-up period, or whether or not the intervention would be viewed as acceptable 
and feasible. 
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Methods 
Participants 
 
Sample. In total eight participants (two male, six female), consented to take 
part. Participants were recruited from three primary care Improving Access to 
Psychological Therapies (IAPT) services in London. The time period for recruitment 
was September 2016 - March 2017.  
Inclusion criteria. The following inclusion criteria were used for the study: 
1. Being aged 18 or over; 
2. Meeting criteria for a primary diagnosis of MDD according to The Research 
Version of Structured Clinical Interview for MDD (First, Williams, Karg, & Spitzer, 
2015);   
3. Having sufficient command of English to comprehend instructions and measures 
without the use of an interpreter;  
4. Scoring ≥ 10 on The Patient Health Questionnaire (PHQ-9; Kroenke & Spitzer, 
2002); 
5. Scoring ≥ 25 on The Montgomery-Åsberg Depression Rating Scale (MADRS; 
Montgomery & Åsberg, 1979);  
6. If prescribed anti-depressants, being on a dose that had been stable over the past 
six weeks with future type and dosage being controlled (by their General 
Practitioners) to remain constant;  
7. Being willing and able to travel to treatment at the time-intensive rate; 
8. Having treatment goals that were suitable for receiving BA; 
9. Having no specified preference to receive CBT.  
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Clients who showed obvious presence of a comorbid diagnosis that was more 
severe (e.g., bipolar disorder, psychotic and personality disorders) and/or more 
prominent (e.g., substance dependency, panic and agoraphobia) than MDD, and 
required a different intervention, were excluded. Clients were also excluded from 
taking part in the study if they were acutely suicidal, had attempted suicide within the 
previous two months, were receiving any other form of psychological intervention 
currently, or in the preceding six months, had a long-term physical health condition 
that would prevent intensive treatment attendance (e.g., needing hospitalisation or 
being immobile), required specialist perinatal care or had a cognitive impairment due 
to an organic cause (e.g., learning disability or dementia).  
Eventually, to preserve the power of the study as much as possible, the 
exclusion criteria were relaxed to enable the recruitment of participants who had 
received psychological treatment in the last six months (given the design’s use of a 
baseline phase), or were due to receive a low-intensity depression treatment before 
being stepped-up for high-intensity treatment of a comorbid problem (e.g., social 
phobia). Broadening these criteria was deemed to represent more accurately the types 
of clients seeking depression treatment across London IAPT services.  
Eight participants completed treatment. One participant dropped out of the 
study following her assessment as she was returning to work and disclosed that 
outcome measure completion made her feel more depressed. The flow of participants 
that were approached and recruited into the study is depicted in Figure 1. 
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 Completed: N = 8 
Service 1: n = 5 
Service 2: n = 2 
Service 3: n = 1                                                                                
 
Approached: N = 60 
Service 1: n = 20    
Service 2: n = 39 
Service 3: n = 1                                         
 
Declined/excluded: N =. 32 
Unable to attend time-intensively: n = 23 
Requested CBT: n = 2 
No longer seeking treatment: n= 2 
Did not wish to take part in research: 
 n = 5 
 
Accepted information sheet:  
N = 28  
Service 1: n = 15 
Service 2: n = 12 
Service 3: n = 1                                            
 
Declined/excluded: N = 5  
Unable to attend time-intensively: n = 3 
Requested CBT: n = 2 
Unable to contact: n = 1 
                                          
 
Excluded: N = 14 
Currently in treatment: n = 1 
Severe comorbidity: n = 4  
Primary anxiety: n = 2 
Below MADRS cut-off: n = 1  
Requested CBT: n = 4  
Did not meet MDD criteria: n = 1 
Unable to attend: n = 1 
                                           
 
Appropriate and assessed: N = 9                                           
Service 1: n = 5 
Service 2: n = 3 
Service 3: n = 1                                        
Participants who dropped out: N = 0                                            
 
Consented and randomised to 
baseline lengths: N = 8                                         
Service 1: n = 5 
Service 2: n = 2 
Service 3: n = 1                                        
Dropped out: N = 1                                             
Did not wish to complete measures. 
 
Interested and screened: N = 23 
Service 1: n = 12 
Service 2: n = 10 
Service 3: n = 1                                            
 
Figure 1. Flow of recruitment and participation 
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Recruitment. Initially, six services were approached and asked to be involved 
in the research study. The three sites that declined involvement did so due to either 
already being involved in other depression research or not having therapists whose 
hours would have enabled them to see participants time-intensively.   
At participating services, the Principal Investigator and Psychological 
Wellbeing Practitioners/Assistant Psychologists were responsible for recruitment. 
Potential participants were initially identified from consecutive referrals on service 
waiting lists, as those who were being offered BA, and whose initial assessment 
suggested that they might be eligible to participate in the study. The study was then 
briefly introduced to clients when feeding back their treatment options to them. Those 
who were interested in participating in the study were sent a participant information 
sheet (Appendix 2). After reading the information sheet, those who were still 
interested in taking part were screened by the Principal Investigator to see if they met 
the study inclusion criteria. Participant eligibility was always checked with at least 
one other member of the research or clinical team (the Principal Investigator, 
supervisors, therapists and service leads). Those that were deemed eligible to be 
included in the study, and were still interested in taking part were then booked in for 
an assessment session with a therapist. Participants were not offered any 
compensation for taking part in the study.  
Power. Systematic procedures for performing power analyses for SCEDs are 
under-developed (Arntz, Sofi, & van Breukelenm, 2013). Still, to increase external 
validity of study findings, and to compensate for low statistical power that is normally 
associated with small-N samples (Turpin, 2001), it is recommended that SCEDs be 
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replicated across more than one participant (Hayes, Barlow, & Nelson-Gray, 1999). A 
‘three point guideline’ has been recommended for determining experimental control 
of study designs (Lanovaz & Rapp, 2015). Indeed, existing SCEDs have recruited a 
median of three participants (Shadish & Sullivan, 2011). However, it was later 
reported that multiple baseline design power only exceeds the desirable 0.8 when the 
number of time points per phase is 12 and the number of cases is nine (Shadish, 
Hedges, & Pustejovsky, 2014). In an attempt to consider these recommendations, to 
improve upon sample sizes of existing studies with similar designs (e.g., Folke et al., 
2015b), to account for potential participant attrition, and to aim to recruit a feasible 
sample size within the study time-frame, this study inflated a desired sample size of 
nine by 25% and aimed to recruit 11 participants.    
Therapists. Therapists involved in the study were either Clinical 
Psychologists and/or High-Intensity Cognitive Behavioural Therapists. Therapists 
were only considered eligible to take part in the study if they had completed their 
qualification and had accreditation with The British Association of Behavioural and 
Cognitive Psychotherapies (BABCP). Therapists received training in BA as part of 
their qualifications but were also required to attend a half-day training session on BA 
in order to take part in the study. The training session was delivered by experts in the 
field and included a PowerPoint presentation summarising the background to the 
study, the main research questions and teaching on the principles and mechanisms of 
BA. Therapists then needed to demonstrate self-reported competence in delivering 
BA, using an adapted version of the Quality of Behavioural Activation Scale 
(QoBAS; Dimidjian, Hubley, Martell & Herman, 2016) (see Measures and Appendix 
3).  
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Therapists were not paid extra for their involvement in the study. Motivations 
to participate included work variety, and potential for authorship should the current 
study findings be published. In total, six therapists took part in the study, three from 
Service 1, two from Service 2 and one from Service 3. All included therapists 
achieved a mean adapted QoBAS score of 66% (55.8/84), and their mean duration of 
time post-qualification was 3.37 years (three years and four months, SD = 43.80, 
range = six months - nine years). 
Ethics. The study was reviewed and approved by Royal Holloway University 
of London Research Committee (Appendix 4). The UK Central London Research 
Ethics Committee gave approval for the study (16/LO/0485) on 13/04/2016. Approval 
was subsequently given by the NHS Health Research Authority (HRA), relevant local 
Research and Development (R&D) teams, and The Royal Holloway University 
Department Ethics Committee self-certification was obtained. Service 3 was not 
initially part of the study’s ethical approval. No amendment was necessary when it 
was added because it was part of the same NHS Foundation Trust/R&D team as 
Service 2. Approval documentation front sheets can be seen in Appendices 5 to 8. 
Service user consultation. The participant information sheet, research 
protocol and treatment delivery design were reviewed by a service user and carer 
group at a London university with research connections to Service 2. The group was 
asked to comment on the acceptability of participant resources and the feasibility of 
the design of treatment delivery. The group reported thinking that the study was 
investigating a worthwhile intervention but that it would be very time-consuming for 
participants to complete the necessary outcome measures. They also wondered if 
participants would receive feedback on their outcome measure scores. They were 
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supportive of the intervention including session breaks and clinician prompting. 
Materials and procedures were adapted to consider the views of the service users.  
Design  
 
The study employed an A1BA2 single-case experimental design (SCED) with 
multiple baselines, and a symptom monitoring follow-up period. The A1
 
phase was 
the non-concurrent multiple baseline phase, systematically randomising participants 
to collect outcome measures for seven, 14 or 21 days prior to starting phase B. Phase 
B was the intervention phase, lasting a minimum of 22 days and a maximum of 52 
days, comprising of seven face-to-face sessions and three optional booster sessions. 
The A2 phase represents a period when outcomes were monitored again, for up to 
three weeks, after the withdrawal of the treatment. An AB design was used when 
follow-up scores were not obtainable.  
The manipulated intervention was time-intensive BA for depression, based on 
Martell et al.’s (2013) clinicians’ guide, which is the same intervention that was 
delivered in previous trials (Dimidjian et al., 2006; Dobson et al., 2008) and is 
described in more detail below (see Intervention). Time-intensive was operationalised 
as treatment that is not delivered in the traditional weekly 50 minute/ hourly sessions, 
but is concentrated and delivered at a higher level, over a shorter period of time 
(Oldfield et al., 2011). The dependent variables were depression and anxiety 
symptomatology, indicated by quantitative scores on outcome measures, and the 
intervention’s acceptability, as indicated by recruitment and retention rates as well as 
participant and therapists’ acceptability ratings.  Figure 2 shows a visual 
representation of the design and procedures.  
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Figure 2. Diagram of the study design and procedures 
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Measures 
 
Five types of outcome measures were collected during the study: screening, 
idiographic, standardised, process, and ending measures.  Of note, the specific 
constructs of depression and anxiety were measured using multiple types of measures. 
Depression was measured using an idiographic visual analogue scale (see Idiographic 
measures below), a clinician rated scale (see The Montgomery-Asbery Depression 
Rating Scale below), and a standardised self-report scale (see The Patient Health 
Questionnaire below).  Anxiety was measured using an idiographic visual analogue 
scale (see Idiographic measures below) and a standardised self-report scale (see The 
Generalized Anxiety Disorder Scale below). Repeated measurement of the same 
overlapping constructs was used because idiographic measures consider 
individualised meanings of constructs and are highly sensitive to change within 
individual subjects, enabling more detailed understanding of where subtle change 
occurs, whereas standardised measures are less sensitive to change but, given that 
they are based on population norms, they can provide global context to idiographic 
findings. Both clinician and self-report rated standardised measures of depression 
were collected to enhance the reliability of the findings, given that research suggests 
that they each provide unique information, of relevance to clinical outcomes 
(Cuijpers, Li, Hofmann, & Andersson, 2010; Uher et al., 2012).  
All measures were completed using electronic or paper copies.   
Screening measures. Some measures were completed solely during the 
screening process when determining whether or not referrals met criteria to participate 
in the study. They were completed by the Principal Investigator, over the telephone. 
Completion of the screening process took approximately one hour. 
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The Research Version of the Structured Clinical Interview for Major 
Depressive Episode (SCID-5-RV; First, Williams, Karg, & Spitzer, 2015). The 
SCID-5-RV is a clinician led semi-structured interview guide and was used for 
making a diagnosis of MDD, based on DSM-5 criteria.  
Demographic Variable Questionnaire. A Demographic Variable 
Questionnaire (Appendix 9) was created by the Principal Investigator and completed 
by participants in order to consider the differences between participants and the 
existence of potential confounding variables that might have influenced their 
treatment outcomes. Variables assessed included age, sex, gender, ethnicity, duration 
of the problem, previous treatment, comorbidity and significant life events.  
The Patient Diagnostic Screening Questionnaire (PDSQ; Zimmerman & 
Mattia, 2001). The PDSQ (see Appendix 10) was routinely completed by clients at 
their referral, to assess whether or not they might have had difficulties comorbid to 
their depression. The PDSQ is a 126-item self-report questionnaire that screens for 13 
DSM-IV Axis-I disorders most commonly seen in adult outpatients (e.g., PTSD and 
OCD). The measure acts as a diagnostic aid to facilitate making diagnoses and has 
been found to show sufficient internal reliability (α = .68 - .96), 99.6% sensitivity, 
69.5% specificity, and 98.8% negative predictive value (Galvez, Fernandez, 
Manzanaro, & Valenzuela, 2010). Where the PDSQ indicated the presence of 
disorder, the relevant SCID (First, Williams, Karg, & Spitzer, 2015) was then 
completed.  
The Credibility/Expectancy Questionnaire (CEQ; Devilly & Borkovec, 
2000). The CEQ (see Appendix 11) was completed at the end of Session One, once 
participants had been oriented to BA, to assess the strength of participants’ thoughts 
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and feelings, about the credibility and expectancy of their treatment. The 
questionnaire consists of six items. Four of the items are measured on a nine point 
scale ranging from 1 (“not at all” or “none”) to 9 (“very”). Two of the items are 
measured on an 11 point scale ranging from 0% to 100%. The measure score is 
summed and ranges from 3 to 27. Higher scores indicate participants having higher 
credibility or expectation for improvement as a result of the treatment. The 
expectancy factor is shown to have a standardised Cronbach’s α of .90, and the 
credibility factor has an α of .86, demonstrating the measure’s internal reliability. 
Expectancy scores are found to be significantly positively correlated with change 
scores on the Depression Anxiety Stress Scale (r = 0.20, Lovibond & Lovibond, 
1995) and the Impact of Events Scale (r = 0.26, Horowitz, Wilner, & Alvarez, 1979), 
suggesting their convergent validity. 
 To reduce time pressure on participants and screeners, no diagnostic tools 
were used to screen for personality disorders. It was thought that personality disorder 
symptoms would have been evident following participants initial service triage, and 
indeed such referrals would not have been suitable for the recruitment services intake.  
 Idiographic measures. Idiographic measures were the primary outcome 
measures for this study (see Appendix 12). Idiographic measures are a crucial 
component to SCEDs as they allow for the repeated collection of data, visual analysis 
(Morley, 2015d) and analyses of phase non-overlap. Idiographic measures were 
administered daily (see Table 1) across the course of the study and consisted of six 
non-standardised self-report Visual Analogue Scales (VASs) that took approximately 
one minute each to complete. Despite these measures not being validated, VASs in 
general are considered reliable and suitable for SCEDs due to their simplicity, and 
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known sensitivity to change within individual subjects, and across short periods of 
time (McCormack, Horne, & Sheather, 1988). They are also considered valid if they 
are carefully defined (Morley, 2015d).  
The VASs were designed by the Principal Investigator and measured levels of 
depression, anxiety, rumination, avoidance, an encapsulated belief, and a chosen 
idiographic symptom. The encapsulated belief consisted of a statement that 
summarised the meaning of the participants’ experience of depression. The chosen 
idiographic symptom was whichever symptom participants noticed most or most 
wanted to monitor. It was hoped that enabling participants to choose two of their 
outcome measures might encourage them to stay engaged in outcome measure 
completion, and to have agency over witnessing change, potentially enhancing their 
motivation to complete the study measures. VAS scores ranged from 0 to 100, where 
higher scores indicated higher symptomatology, frequency or belief.  
Standardised measures. Standardised measures (Appendix 13 to 15) were 
collected weekly during baseline, intervention and follow-up phases (see Table 1) in 
order to determine which participants had made reliable and clinically significant 
change (Jacobson & Traux, 1991) after receiving the intervention (Morley, 2015b), 
and to provide context to idiographic outcomes. Participants were asked to rate these 
measures referring to their past week, which required altering the measure instructions 
in some cases (for the PHQ-9 and GAD-7). Standardised measures are less sensitive 
to change than idiographic measures because they are developed to measure 
constructs between people, based on known population norms (Morley, 2015b).  
The Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery 
& Åsberg, 1979). The MADRS is a 10-item clinician-rated scale and was used to 
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measure symptoms of depression. Each item is rated on a seven point Likert scale 
from 0 (indicating ‘normal’ or ‘no difficulties’) to 6, and the scale takes 10 to 15 
minutes to complete. The summed score range is 0–60, and higher scores reflect 
greater symptomatology. Total scores of 7 to 19, 20 to 34, and 35 or more represent 
mild, moderate and severe depression respectively. The measure has shown inter-rater 
reliability between .89 and .97 as well as significant correlation with the Hamilton 
Rating Scale (Hamilton, 1960), indicating its convergent validity (Montgomery & 
Åsberg, 1979). The Beck Depression Inventory (BDI; Beck, Ward, Mendelson, Mock, 
& Erbaugh, 1961) is considered a gold-standard self-report measurement of 
depression (Cusin, Yang, Yeung & Fava, 2010). The MADRS was chosen over the 
BDI because it is clinician-rated, improving the study’s reliability. It also corresponds 
closely to the diagnostic criteria for MDD and was available to the Principal 
Investigator for no monetary cost.  
The following standardised measures were completed as part of routine 
outcome measure collection within IAPT services. They take approximately 10 
minutes to complete together: 
The Patient Health Questionnaire (PHQ-9; Kroenke & Spitzer, 2002). The 
PHQ-9 is a 9-item self-report measure of depression symptoms, usually over the past 
two weeks. Each item is scored from 0 (‘not at all’) to 3 (‘nearly every day’), and the 
summed total score ranges from 0 to 27, with higher scores reflecting greater 
symptomatology. Total scores of 5, 10, 15 and 20 represent mild, moderate, 
moderately severe and severe depression, respectively. Cronbach’s α for the scale is 
.89 and it has significant correlation with a number of health measures, implying its 
convergent validity (Kroenke et al., 2001). The PHQ-9 has the advantage of being 
59 
 
shorter than the BDI (Titov, Dear, McMillan, Anderson, Zou, & Sunderland, 2011), 
and having superior criterion validity in comparison to the Hospital Anxiety and 
Depression Scale (Löwe et al., 2004).  
The Generalized Anxiety Disorder Scale (GAD-7; Spitzer, Kroenke, 
Williams, & Löwe, 2006). The GAD-7 is a 7-item self-report measure for symptoms 
of generalized anxiety, usually over the past two weeks. Each item is rated from 0 
(‘not at all’) to 3 (‘nearly every day’). The total score ranges from 0 to 21, with higher 
scores reflecting greater symptomatology. Scores of 5, 10 and 15 represent mild, 
moderate and severe anxiety respectively. The GAD-7 has excellent internal 
consistency (Cronbach’s α = .92) and test-retest reliability (Intra-class Correlation 
[ICC] = .83) and relates strongly to scores on the Beck Anxiety Inventory (Beck, 
Epstein, Brown, & Steer, 1988) demonstrating its convergent validity (r = 0.74; 
Spitzer et al., 2006). 
Process measures. Process measures (Appendix 16 and 17) were collected to 
measure whether or not components of the treatment were having their intended effect 
(Morley, 2015a). These were collected weekly during the baseline and intervention 
phases (see Table 1) and took approximately 10 minutes to complete together. 
Participants were asked to complete them referring to their past week. 
The Behavioural Activation for Depression Scale - Short Form (BADS-SF; 
Manos et al., 2011). The BADS-SF is a 9-item self-report scale measuring activation 
and avoidance over the past week, and is generally used over the course of BA. Items 
are rated from 0 (“not at all”) to 6 (“completely”), though some items are reverse 
scored. Total scores range from 0 to 54. Higher scores represent more activation and 
less avoidance. Activation (6 items) and avoidance (3 items) subscale scores can also 
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be calculated, with higher scores indicating doing more of each area of interest. The 
scale is shown to have strong internal consistency (Cronbach’s α = .82) and its 
construct validity is as good as if not better than the original BADS measure. For 
example it demonstrates significant negative correlation (r = -.49) with Beck Anxiety 
Inventory (1988) scores (Manos et al., 2011).  
The Dysfunctional Attitudes Scale - Short Form (DAS-SF; Beevers, Strong, 
Meyer, Pilkonis, & Miller, 2007). The DAS-SF is a 9-item scale measuring 
dysfunctional cognition (thought to reflect negative self-evaluation) relating to 
depression. Items are rated from 1 (“totally agree”) to 4 (“totally disagree”) and 
measure strength of dysfunctional attitudes. Total scores are summed to range from 9 
to 36, and all items are reverse coded by subtracting each item score from 5. Higher 
total scores indicate greater dysfunctional attitudes. Cronbach’s αs for the DAS-SF1 
(the version used herein) is .84, demonstrating its strong internal consistency. The 
scale also strongly correlates with outcomes from the original DAS (r = .92). The 
scale has good convergent validity as it moderately correlates with The Cognitive 
Bias Questionnaire (Krantz & Hammen, 1979) (r = .52) and Hopelessness Scale 
(Beck, Weissman, Lester, & Trexler, 1974) (r = .28) scores (Beevers et al., 2007).  
Ending measures. The following measures were completed after participants 
finished their seventh treatment session, in case participants chose not to attend their 
optional booster sessions. They took approximately 15 minutes to complete. 
A briefer version of the Demographic Variable Questionnaire was completed 
post-treatment to determine whether or not participants experienced any outcome-
related changes during the course of their treatment.  
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The Client Satisfaction Questionnaire (CSQ; Larsen, Attkisson, Hargreaves, 
& Nguyen., 1979). The CSQ (see Appendix 18) is an 8-item self-report measure of 
clients’ perspectives of the value of services, and was used here as a quantitative 
measure of treatment acceptability. All items are rated on different four point Likert 
scales. Item scores are summed to give a total score ranging from 8 to 32, with higher 
scores indicating greater satisfaction. Cronbach’s α values for the scale have been 
found to range from .83 to .93, indicating excellent internal reliability. The scale 
scores are also found to positively correlate with symptom reduction scores, 
indicating its convergent validity (Attkisson, 2012).  
The Client Feedback Form. Participants were asked to rate how acceptable 
they had found their treatment on a visual analogue scale of 0 (“not at all”) to 
100 (“completely”) (Appendix 19). 
The Therapist Feedback Form. Therapists were also asked to rate the 
acceptability and utility of the intervention, their confidence delivering it, and 
their intention to use it in future, all on visual analogue scales ranging from 0 
(“not at all”) to 100 (“completely”) (Appendix 20).  
The Quality of Behavioural Activation Scale (QoBAS; Dimidjian et al., 
2016). The QoBAS (see Appendix 21) measures the quality with which BA 
techniques are applied. A self-report version of the measure (see Appendix 3), created 
by the Principal Investigator, was used here to determine therapist self-rated 
competence in BA following their BA training. The original version of the measure 
(Appendix 21) was used to assess the treatment fidelity of BA therapists post-
treatment. The measure is split into three parts. Part one consists of rating seven items 
measuring structural and stylistic strategies (e.g., following an agenda). Part two 
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consists of seven items measuring conceptualisation, strategy and application (e.g., 
use of the BA model). Items from part one and two are rated on a seven point Likert 
Scale from 0 (“poor”) to 6 (“excellent”), with a score of 3 indicating satisfactory BA 
skill quality. Higher scores indicate greater quality of the treatment delivered. Part 
three allows raters to make additional considerations and comments. The measure is 
not yet validated, but it is the primary measure of quality of BA in use, and was 
shared with the Principal Investigator under the agreement that the current study’s 
QoBAS data could then be shared with S.Dimidjian, for validating the scale. 
Procedure 
 
The TT used in this study was new and exploratory. It was designed in 
collaboration with experts in the field of BA and TT, as well as IAPT service 
managers. As participants act as their own control within SCEDs, they are 
intentionally flexible and adaptive (Kratochwill et al., 2010). Therefore, it was 
anticipated that in order to be flexible to participant needs, procedures might differ 
slightly for each participant.  
 Randomisation. After being screened and found eligible to take part in the 
study, the Principal Investigator randomly allocated participants to an intervention 
start time using a random number generating command on Microsoft Excel. Baseline 
durations were then communicated to study therapists before participants attended a 
two hour long introduction/assessment session. Baseline durations of seven, 14 or 21 
days long were considered acceptable and ethical as baseline phases were 
incorporated into service wait times, which on average were six weeks.  
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Introduction/assessment session. Written informed consent was obtained by 
the therapists at the start of the session (Appendix 22). Participants understood that 
they were free to withdraw from the study at any point. The therapist and participant 
then worked collaboratively to build a functional analysis of the problem. Participants 
had the option to bring a significant other to the session, in order to enhance the 
formulation. Encapsulated beliefs were identified using downward arrow techniques 
(e.g., what does it mean about you as a person?), idiographic symptoms to measure 
were chosen, and all VASs were completed. Therapists also oriented participants to 
the aims and content of BA. Treatment start times (according to randomisation and 
availability) were discussed, and Participant Orientation Forms were completed 
(Appendix 23) to summarise when participants would need to attend sessions, and 
how they might need to reorganise their diaries in order to maximise their attendance. 
Finally, therapists introduced participants to outcome measures that they would need 
to complete throughout the study duration. They were then given relevant baseline 
measures to take home with them and return to their first treatment session.  
Baseline phase. During the baseline phase, participants were instructed to 
complete daily VASs. They also completed standardised and process measures once a 
week. The MADRS was completed over the telephone by their therapist. Depending 
on whether participants were randomised to a 7, 14 or 21 day baseline period, 
participants had a minimum number of seven baseline data points and a maximum of 
21. These baseline durations were considered acceptable as baseline ranges most often 
include between three and 10 data collection points (Turpin, 2001), and it would have 
been impractical to ensure that baseline data were stable before starting treatment. 
Participants did not receive any treatment during their baseline period and 
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communication via the telephone did not contain therapeutic manipulation, making 
stable baseline outcomes more likely. 
 Intervention phase. BA began directly after baseline periods. Overall, the 
core goals of the intervention were to: 
1. Orient participants to understanding what BA is, and to socialise them to the 
behavioural model of depression; 
2. Conduct an idiographic functional analysis of participants’ (overt and covert) 
avoidance and excessive behaviours, as well as the contextual contingencies of 
reinforcement maintaining them; 
3. Collaboratively develop treatment goals; 
4. Monitor participants’ daily activity levels, links between activities and their sense 
of pleasure and mastery; 
5. Review participant activity levels in order to develop their conceptualisation; 
6. Make changes by gradually structuring and scheduling relevant goal-oriented 
activities for participants; 
7. Review activity scheduling, providing regular feedback on areas of progress and 
areas for improvement, before developing the activity schedule; 
8. Repeatedly practice problem solving and troubleshooting to reduce the likelihood 
of barriers to completing scheduled activities; 
9. Address relapse prevention (Martell et al., 2013).  
Participants were asked to arrive early for their sessions so that they could 
complete idiographic, standardised and process measures in service waiting rooms 
before their sessions began. If consent was given, sessions began by starting audio 
recording for later rating. All core techniques referred to in Martell et al.’s (2013) 
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clinicians’ guide were available for use, as therapists had access to the guide. 
However, given that BA is not strictly protocol driven (Dimidjian et al., 2008), weight 
given to techniques varied depending on individual participant formulations. Table 1 
below shows an example of how our time-intensive BA might have progressed 
(assuming here that participants were seen on Mondays and Fridays), as well as when 
outcome measures were completed. In summary, all sessions tended to consist of 
completing clinician-rated outcome measures, reviewing progress, assessing risk, 
developing a shared agenda, summarising the session, eliciting feedback, setting 
homework activities, discussing which outcome measures needed completing and 
returning for the next session, what the focus of the next session would be, and 
discussing treatment endings. To reduce therapist burden while ensuring that all 
outcome measures were completed at the right time, therapists were given folders 
indicating how BA might be delivered time-intensively, when to administer outcome 
measures, a space to store them, and finally details of practical issues to consider 
when providing intensive treatment (Appendix 24). Examples of practical 
considerations included: 
1. Advanced organisation of case-loads, session times and time to prepare for 
sessions; 
2. The possibility to be made exempt from some service responsibilities (e.g., all-
staff meetings) in order to implement intensive treatment while reducing burn-out; 
3. Deciding clear attendance boundaries with participants, in order to promote 
attendance; 
4. Devising creative solutions to achieving goals of any unavoidably missed sessions 
(e.g., extending subsequent sessions, and offering telephone sessions); 
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5. Managing the continuation outcome collection when sessions were missed; 
6. Managing minimal discussion of inadvertent events to keep sessions focused on 
activation; 
7. The application of therapeutic boundaries during breaks; 
8. Employing ways to reduce cognitive functioning difficulties (e.g., reducing 
distractions and providing session summary sheets); 
9. Remaining aware of goals needing to be realistic within TT periods, and 
collaboratively setting meaningful activation tasks that maximised the possibility 
for reinforcement. 
Table 1 An example of how BA techniques and outcome measures may have been 
delivered time-intensively. 
Intervention 
phase day 
Example content Recommended 
contact 
duration 
Outcome 
measures 
completed 
1 
(e.g., 
Monday) 
Treatment Session 1: 
Further assessment 
Goal setting 
Functional analysis  
Orientation to treatment  
Introduction to activity monitoring 
2 hours Standardised 
measures 
Idiographic 
measures 
Process 
measures 
2 Activity monitoring and prompting Up to 10 
minutes 
Idiographic 
measures 
3 Activity monitoring and prompting Up to 10 
minutes 
Idiographic 
measures 
4 Activity monitoring and prompting Up to 10 
minutes 
Idiographic 
measures 
5 Treatment Session 2:  
Review activity monitoring 
Problem-solve 
Add to functional analysis 
2 hours Idiographic 
measures 
6 Activity monitoring  Idiographic 
measures 
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7 Activity monitoring  Idiographic 
measures 
8 Treatment Session 3: 
Review activity monitoring 
Troubleshoot 
Add to functional analysis 
Activity scheduling 
Problem-solve barriers 
2 hours Standardised 
measures 
Idiographic 
measures 
Process 
measures 
9 Activation and prompting Up to 10 
minutes 
Idiographic 
measures 
10 Activation and prompting Up to 10 
minutes 
Idiographic 
measures 
11 Activation and prompting 
 
 
Up to 10 
minutes 
Idiographic 
measures 
12 Treatment Session 4: 
Review activity schedule 
Troubleshoot 
Activity scheduling 
Problem-solve barriers 
1 hour Idiographic 
measures 
13 Activation  Idiographic 
measures 
14 Activation  Idiographic 
measures 
15 Treatment Session 5: 
Review activity schedule 
Troubleshoot 
Activity scheduling 
Problem-solve barriers 
1 hour Standardised 
measures 
Idiographic 
measures 
Process 
measures 
16 Activation and prompting Up to 10 
minutes 
Idiographic 
measures 
17 Activation and prompting Up to 10 
minutes 
Idiographic 
measures 
18 Activation and prompting Up to 10 
minutes 
Idiographic 
measures 
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19 Treatment Session 6: 
Review activity schedule 
Troubleshoot 
Activity scheduling 
Problem-solve barriers 
1 hour Idiographic 
measures 
20 Activation  Idiographic 
measures 
21 Activation  Idiographic 
measures 
22 Treatment Session 7: 
Review activity schedule 
Troubleshoot 
Plan for the future 
Review goals and progress 
Relapse prevention 
1 hour Standardised 
measures 
Idiographic 
measures 
Process 
measures 
Ending 
measures 
23 Activation and prompting Up to 10 
minutes 
Idiographic 
measures 
24 Activation and prompting Up to 10 
minutes 
Idiographic 
measures 
25 Activation and prompting Up to 10 
minutes 
Idiographic 
measures 
26 Activation and prompting Up to 10 
minutes 
Idiographic 
measures 
27 Activation   Idiographic 
measures 
28 Activation   Idiographic 
measures 
29 Optional Booster Session 1: 
Review activity schedule 
Troubleshoot 
Plan for the future 
1 hour Standardised 
measures 
Idiographic 
measures 
Process 
measures 
36 Optional Booster Session 2: 
Review activity schedule 
Troubleshoot 
Plan for the future 
1 hour Standardised 
measures 
Idiographic 
measures 
Process 
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measures 
50 Optional Booster Session 3: 
Review activity schedule 
Troubleshoot 
Plan for the future 
1 hour Standardised 
measures 
Idiographic 
measures 
Process 
measures 
 
Participants received a minimum of 10 and maximum of 13 hours of face-to-
face treatment, consisting of seven initial sessions and three optional booster sessions. 
As a rule, face-to-face sessions were always between two and three days apart, as 
opposed to daily. Therefore, participants were seen twice-weekly. This was intended 
to allow participants to complete activity monitoring for five days, and to have 
enough time to implement activation and consolidate learning, while still rapidly 
promoting engagement and the therapeutic relationship (Martell et al., 2001). Longer 
spacing between sessions was not used, influenced by findings to suggest that there 
can be negative associations between hours of treatment per week and effect size 
(Jonsson, Kristensen, & Arendt, 2015), and in case of manifesting avoidance 
increasing the likelihood of participant non-attendance. From Table 1 it is possible to 
imagine how within this rule, five out of seven face-to-face treatment sessions could 
also have been scheduled more flexibly.  
The initial three treatment sessions were recommended to last for two hours, 
and the last four were recommended to be one hour long, though all contact time was 
recorded and expected to fluctuate. Considering existing research to suggest that BA 
sessions are more efficacious when lasting less than 90 minutes (Braun, Gregor, & 
Traun, 2013), and to promote concentration and activation, therapists and participants 
were advised to include a break in longer sessions, and were instructed to record what 
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they did during any breaks. Homework was set each session and tended to be 
following activity schedules, listening to audio recordings of treatment sessions, and 
completing daily VASs. 
To enable the treatment to end gradually, and to potentially enhance progress 
over time (Gearing, Schwalbe, Lee, & Hoagwood, 2013; Storch et al., 2007), three 
optional face-to-face booster sessions were offered after participants’ seventh 
sessions. Boosters were kept as optional following evidence to suggest that frequency 
rather than the amount of therapy governs speed of recovery (Cuijpers et al., 2013; 
Erekson et al., 2015). Boosters were recommended to take place at one, two and four 
weeks after Session Seven. With the inclusion of booster sessions, it was expected 
that participants could complete a maximum of 52 idiographic data points, and 10 
standardised and process measure data points, during the intervention period. 
To enhance attendance, participants received automatic text message 
reminders about their next session. On weekdays, in-between face-to-face sessions, 
and up until booster sessions began, therapists (from Service 1 and 3) and an Assistant 
Psychologist (from Service 2) telephoned, texted, or emailed participants for short 
‘prompting’ conversations. Prompting was intended as a method of contingency 
management, to demonstrate therapists’ dedication to participants, to validate 
participants’ experiences, and to positively reinforce progress, motivation, treatment 
compliance and the therapeutic relationship. Participants could send text messages or 
emails to their therapist whenever they wanted to, though no communication occurred 
over weekends, and participants understood that therapists would try to respond to 
them within 24 hours. The frequency of prompts was not predefined, and was 
dependent on need and feasibility. However, therapists followed some ‘prompting 
71 
 
guidelines’, such as leaving a message if they could not get through to a participant on 
the telephone, and logging all prompting attempts, so that time spent prompting 
participants was included in treatment duration calculations.  
Therapists received supervision, whenever necessary. Clinical supervision was 
provided by senior NHS clinicians trained in delivering BA, and was overseen by 
research experts where requested. Research supervision was also provided by the 
Principal Investigator whenever requested.  
Participants who received eight hours of clinician contact were deemed to 
have completed enough BA (Barkham et al., 1996; Richards, 2016). At the end of 
treatment, participants and therapists were asked to complete ending measures. All 
participants were offered a clinical review to see if they required further psychological 
or medical treatment. Those that did require further treatment went back on their 
service waiting list for treatment delivered at the usual frequency. However, if 
immediate treatment was deemed necessary, they were offered to continue sessions 
with their existing therapist.  
Treatment fidelity. To reduce threats to the study’s validity, therapists’ 
competency in BA was measured. Once all treatments were completed, three 
Assistant Psychologists who had attended the BA training and were independent to 
the research team, used the Quality of Behavioural Activation Scale (Dimidjian et al., 
2016) to assess one randomly selected (determined by a random number generating 
computer program) audio recording from each consenting participant’s sessions. 
Follow-up phase. Where possible, participants continued to complete 
outcome measures after their last treatment session. Participants were asked to 
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continue to complete idiographic VASs daily and standardised measures weekly, for 
three weeks. Completing follow-up measures enabled the trend of outcome measures 
to be assessed beyond the completion of all attended sessions. Follow-up data were 
sent back to services via email or post.  
Therapists stored all completed outcome measures in a folder. The data were 
collected and entered by the Principal Investigator. Data were stored under lock and 
key at recruitment services, and under password protection electronically. 
Demographic information and consent forms were stored separately to outcome data. 
All participants were given the option to receive a summary of the study findings once 
the study was completed.  
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Results 
Descriptions of recruited participants, treatment delivered, treatment retention, 
treatment credibility/expectancy and treatment fidelity are presented first, in order to 
consider the treatment feasibility. In order to answer how effective the intervention 
was, individual graphical and statistical analyses of idiographic measures are then 
presented, followed by more general conclusions across participants. This is followed 
by analyses of whether or not participants made reliable and clinically significant 
change on standardised and process measures or not. Finally, the acceptability of the 
treatment is considered with descriptions of findings from ending measures. 
Throughout this section, percentages are reported rounded to the nearest percentage. 
Means (M), standard deviations (SD), Tau values and p values are reported to two 
decimal places, unless to indicate p <.001. 
Is time-intensive BA a feasible intervention for adults with depression who 
present to outpatient primary care services? 
Treatment recruitment rate. Eight participants were recruited between 
September 2016 and March 2017; one participant every 23 days. From the sample 
approached (n = 60), only 13% (n = 8) went on to take part in the study. However, of 
those screened who qualified for being included in the study (n = 9) 89% did then 
consent to take part (n = 8), indicating high uptake of suitable participants. The main 
reason for declining participation was being unable to attend sessions time-intensively 
(n = 23). The main reasons for exclusion from participation post-screening were 
experiencing severe comorbidity (e.g., personality disorder) or requesting treatment 
that would address the content of negative thoughts (CBT) (n = 4; see Figure 1 in 
Methods).  
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The six therapists to take part in the study were only 26% of the number of 
therapists who attended the BA training (n = 23), indicating that therapist recruitment 
into the study was low. Reasons for not taking part in the study were working part-
time (n = 4), having a full case-load (n =10), and not yet being fully qualified (n = 3). 
Due to the ratio of participants to therapists, the majority of therapists treated one 
participant. Two therapists treated two participants, though not concurrently. 
Participants’ demographic and clinical information. The demographic and 
clinical characteristics of participants recruited into the study can be seen in Table 2, 
though some details have been changed, to protect participant anonymity. The sample 
was heterogeneous. The mean age was 39 years (SD =14.57, range = 21 - 60), and 
participants were from a range of ethnic backgrounds. The mean duration of 
depressive episodes was 11 months (SD = 14.27, range = 2 months - 4 years). All 
participants self-reported experiencing multiple previous episodes of depression (M = 
3.00, SD = 0.83). All but one participant had experienced a previous trial of treatment 
for previous depressive episodes, though no one reporting three or more previous 
episodes had previously received MBCT. Of note, previous treatments seemed brief 
for the majority, except PB, PD and PG. Five participants were taking antidepressant 
medication, four met criteria for a comorbid diagnosis of generalized anxiety disorder 
(GAD), and four also had a long-term physical health condition (LTC). The majority 
of participants were not in a relationship and no one was in full-time employment. All 
participants had completed O-Levels or gone on to higher education.  
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Table 2 Participants’ demographic and clinical information. 
P Service Sex Age Ethnicity Marital 
status 
Education 
level 
Employment 
status  
Duration 
of  
problem 
Previous 
episodes  
Previous treatment 
(duration, year) 
 
Current 
medication 
(dose, 
duration)  
Comorbidity 
 
A 
(PA) 
1 F 37 White 
Portuguese 
Single Undergraduate 
degree 
Unemployed  2 
months 
2 1.CBT for anxiety  
(7 sessions in 2015) 
None GAD 
LTC 
B 
(PB) 
1 F 60 White 
British 
Divorced O-Levels Retired 10 
months 
3 1. Psychiatric 
hospitalisation for 
depression (duration 
unknown, 1981) 
2. Counselling  
(1 year, 1990) 
3. Rehab 
 (6 months, 2001) 
Citalopram 
(20 mg, 12 
months) 
LTC 
C 
(PC) 
2 F 49 White 
Mixed 
European 
Separated Undergraduate 
degree 
Unemployed 4 years 4 1.CBT for low mood 
(8 sessions in 2015) 
Citalopram 
(20 mg, 9 
months) 
GAD 
LTC 
D 
(PD) 
2 F 31 Black 
British / 
Caribbean 
In a 
Relationship 
NVQ Long-term 
Sick Leave 
4 
months 
4 1.CBT for low mood 
(16 sessions in 2011) 
Fluoxetine 
(20 mg, 10 
weeks)  
Secondary 
anxiety and 
panic attacks 
E 
(PE) 
1 M 21 White 
British 
 
Single A-levels Unemployed 2 
months 
3 1.CBT for depression 
(6 sessions in 2014; 1 
session in 2015) 
Citalopram 
(10 mg, 8 
weeks) 
None 
F 
(PF) 
1 F 27 White 
European 
Single Undergraduate 
degree 
Student  6 
months 
2 None None Secondary 
anxiety 
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G 
(PG) 
 
3 F 28 White 
British 
Cohabiting 
with Partner 
Postgraduate 
degree 
Student 1 year 3  1.Counselling for 
bereavement  
(10 sessions in 2014) 
None GAD 
H 
(PH) 
1 M 56 White 
British 
In a 
Relationship 
A-levels Unemployed 6 
months 
2 1.Counselling  
(6 sessions in 1992) 
2.Counselling (2 
sessions in 2008) 
3. Counselling (3 
sessions in 2016) 
Fluoxetine 
(40 mg, 5 
months) 
GAD 
LTC 
Note. GAD = generalized anxiety disorder; LTC = long-term condition; NVQ = National Vocational Qualification; P = participant.
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Treatment credibility/expectancy. The mean credibility score of participants 
who completed the CEQ was 22 (SD =3.64), and their mean expectancy score was 20 
(SD =3.39), out of possible subscale totals of 27. This indicates that once participants 
had an understanding of the treatment rationale they showed high credibility and 
expectancy for change (see Table 3).  
Table 3 Treatment credibility/expectancy scores. 
Participant  Credibility score  Expectancy score  
A 19 18 
B 27 24 
C 21 17 
D 25 25 
E Missing Missing  
F 21 20 
G 22 18 
H 16 Missing  
 
Treatment duration and retention. All eight participants who consented to 
take part in the research study received eight or more hours of therapist contact and 
thus were considered treatment completers. In total 76 sessions were offered, and 68 
sessions were attended (89%), indicating high treatment retention. Variation in 
prompting frequencies and attendance resulted in variations in treatment durations 
across participants (see Table 4). Two participants (PA & PB) were offered fewer 
booster sessions than others, due to Service 1 closing over the Christmas holiday 
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period. Another participant (PF) was offered one fewer booster session following 
therapist illness. Reasons for participants missing sessions included attending too late 
(n = 1, PE), being unwell (n = 2, PD) and having to attend work (n = 4, PH) or 
tribunal meetings (n = 1, PA).  
 On average participants received nine sessions (SD = 1.41), or 11 hours and 
20 minutes of therapist contact (SD = 1.62). During longer treatment sessions, all but 
one therapist (for PB and PF) opted to have a short 10 to 15 minute break half way 
through. During breaks, participants most often went for a walk and bought a drink.  
All participants received different types and frequencies of prompting, though 
two therapists reported fading prompting over time. All participants demonstrated 
replying to prompts at some point during their treatment, and the majority of 
participants (n = 6) were also prompted by an external cheerleader.
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Table 4 Treatment sequences completed by participants. 
Participant Number 
of 
sessions 
offered  
Number 
of 
sessions 
attended  
Session(s) 
missed 
Total 
duration 
of 
sessions 
Chosen 
method of 
prompting 
Prompter  Average number 
of prompts 
received  
Replied to 
prompts? 
Other 
“cheerleader” 
involvement? 
A 8 7 
 
Session 3 9 hours 
10 
minutes  
Text  Therapist 3 Yes - and 
often initiated 
texting. 
No 
B 9 9 n/a 13 
hours 5 
minutes  
Calls and 
texts 
Therapist Week 1: 1 text 
Remaining 
weeks: 1 call  
(5-10mins long) 
Yes  Yes - one close 
friend would 
suggest activities 
for them to do 
together. 
C 10 10 n/a 12 
hours  
Email Assistant 
Psychologist 
2 Yes  Yes - her ex-
partner would 
escort her to 
sessions and 
support child care.  
D 10 8 Sessions 
4 and 5 
11 
hours 
50 
minutes  
 
 
Calls and 
voicemails 
Assistant 
Psychologist 
1 Yes - to calls. Yes - her sister. 
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E 10 9 Session 2 11 
hours  
Calls and 
texts 
Therapist Week 1: 1 call 
(10-20minutes) 
Remaining 
weeks: 
Unknown but 
limited number 
of texts. 
Yes 
 
 
Yes - his cousin 
encouraged him to 
leave the house 
more often.  
F 9 9 n/a 12 
hours  
Calls Therapist Week 1 and 2:  
1 call  
Remaining 
weeks: Seldom 
prompted. 
Yes No 
G 10 10 n/a 13 
hours 
Text Therapist 1 call (one day 
per week) 
3 texts (2 days 
per week) 
Yes Yes- her brother 
and mother.  
H 10 6 Session 7 
onwards 
8 hours 
45 
minutes  
Calls and 
texts 
Therapist 3 (though only 
one day per 
week) 
Yes - Though 
only during 
week 1 
Yes - his partner. 
Note. Prompting took place on weekdays in-between face-to-face sessions and up until Booster Session 1; ‘cheerleaders’ = members of 
clients support networks who provided external prompting (see Martell et al., 2001).
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Treatment fidelity. Only five participants consented to having their sessions 
recorded. Therefore, five sessions were rated. Acceptable competency standards were 
demonstrated as the mean QoBAS score was 3.74 (SD = 0.75,), which exceeds the 
satisfactory threshold. Reliability between the three assistants’ ratings was also 
acceptable, with an ICC of .83.   
Summary. Overall, recruitment of participants was slow, and few therapists 
were able to take part in the research study. However, high uptake of the treatment by 
suitable participants, high treatment retention, high credibility/expectancy scores and 
satisfactory fidelity scores for rated sessions implicate that time-intensive BA may be 
a feasible treatment option for depression.   
Can time-intensive BA lead to improvement on idiographic measures of 
depression symptoms, and are treatment gains maintained over a three week 
follow-up period?  
This section of the results describes individual visual and statistical analyses 
of idiographic measure data, followed by a summary of the findings across 
participants. Additional background information is provided for each participant, 
though again, some has been disguised to protect confidentiality.  
Visual analyses were conducted to consider the pattern of individual 
participants’ idiographic data over the duration of their involvement in the study. 
Although often considered an insensitive method, visual analysis of data more clearly 
enables the identification of effective interventions (Kazdin, 1998). Guidelines for 
visual analysis were followed (Kratochwill et al., 2010), including that baselines can 
be considered stable enough to determine intervention effects when 80% of baseline 
phase data fall within a 20% range of the median (Gast & Spriggs, 2010). Idiographic 
82 
 
data were graphed on x-y plots using Microsoft Excel, according to standard 
presentation of multiple baseline SCEDs, and can be seen in Figures PA1 to PH6. 
Raw data were graphed using solid lines and black square markers. Session days are 
indicated using circular markers, and significant events are indicated using a “*”, 
where specific dates were known. Study phases have been separated by dashed 
vertical lines.  
In order to assess change within and between study phases, changes in the 
central tendency, trend and variability of all idiographic measure data were 
investigated. Different calculations of central tendency, trend and variability plots 
were chosen according to Morley’s guidelines (Morley, 2015d). Definitions of key 
terms used within this section, and when they were calculated are given below (see 
Table 5).  
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Table 5 Explanation of key terms calculated within visual analysis. 
Type of 
measure  
Key term Explanation Phase length 
used for  
(data points) 
 
Depicted 
graphically 
by 
Central 
Tendency 
or Level 
Median The middle value of rank 
ordered data or the average of 
two middle data values when 
there is an even number of 
data points in a set.  
2 - 4  Dashed 
horizontal 
line 
Central 
Tendency 
or Level 
Broadened 
Median 
(BMED) 
The average of three middle 
values when ranked in order 
of magnitude. 
> 5 Dashed 
horizontal 
line 
Trend Running 
Median of 
2 (RM2) 
The average of successive 
sets of 2 data points 
throughout a phase, used to 
investigate systematic shift in 
central location over time, 
when data are highly 
variable. 
3  Dotted line 
Trend Running 
Median of 
3 (RM3) 
The average of successive 
sets of 3 data points 
throughout a phase, used to 
investigate systematic shift in 
central location over time, 
when data are highly 
variable. 
< 10  Dotted line 
Trend Running 
Median of 
5 (RM5) 
The average of successive 
sets of 5 data points 
throughout a phase, used to 
investigate systematic shift in 
central location over time, 
when data are highly 
variable. 
10+  Dotted line 
Variability  Trended 
Range 
(TR) 
Lines connecting the 
minimum and maximum data 
values in each half of a phase, 
indicating fluctuation of data 
over time. 
 
3+ Solid 
black line 
with 
diamond 
marker 
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It is important to note that the running medians and broadened medians are 
sometimes not visible on graphs, where they are the same as raw data values. At other 
times they are not visible at all because they coincide with the x-axis of graphs 
(indicating values of 0). Graphs depicting trended range can be found in Appendices 
25 to 32.  
Statistical analyses of idiographic data were conducted using Tau-U 
calculators (www.singlecaseresearch.org/calculators/tau-u), to determine whether or 
not the visual analyses were supported. Statistical analyses were deemed important as 
visual analyses only enable us to draw tentative conclusions about data (Morley, 
2015c). More conventional statistical analyses were not used as SCED data often 
violate their necessary assumption that error terms from successive observations are 
independent (Morley, 2015c). Therefore, to use them would have been considered a 
threat to the validity of results (Shadish, Rindskopf, Hedges, & Sullivan, 2013).  
Tau-U tests were especially designed for use in single-case experimental 
research. Tau-U is a combination of Mann-Whitney U (between groups) and Kendall’s 
Tau (rank correlation). Therefore, the Tau statistic merges measuring the percentage 
of non-overlap and trend between data points across pairs of phases (e.g., baseline and 
intervention). Negative trends are indicated by “-”, so for example a Tau of -0.50 
indicates that 50% of the data in one phase are lower than in its comparative phase. 
Tau-U was chosen as it draws comparisons between phases while controlling for trend 
in baseline data, which reduces the risk of drawing erroneous conclusions about the 
cause of change (Parker, Vannest, Davis, & Sauber, 2011). An unresolved issue in the 
Tau-U literature is whether or not to allow contrasts for non-adjacent phases, though 
taking caution is recommended (Parker & Vannest, 2012). Therefore, comparisons 
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were made between baseline and intervention phase data (A x B) to determine 
whether or not participants made improvements on their idiographic measures, 
following the onset of the intervention. Comparisons between the intervention and 
follow-up phase (B x C) were made to determine whether or not changes observed at 
B were maintained over the follow-up period, or changed as a result of the withdrawal 
of the intervention. Comparisons between phases A and C were not drawn because in 
this design, effects of C will always have been contaminated by effects of B (Parker & 
Vannest, 2012). Comparisons between baseline scores and the intervention and 
follow-up phase combined (A x [B+C]) were also made to determine what the overall 
impact of receiving the intervention was, in comparison to baseline (Parker & 
Vannest, 2012). As well as Tau statistics, p values are reported to demonstrate 
whether or not comparisons between phases reached significance. Confidence 
intervals defining ranges of values, and the specified probability that Tau statistics fell 
within them, have also been provided. Comparisons that resulted in significant decline 
in symptoms were considered to demonstrate improvement. After considering each 
participant individually, weighted averages were calculated to form single omnibus 
Tau-U effect sizes that reflected the proportion of non-overlap across all participants 
on each idiographic measure.  
Participant A (PA). Participant A spoke Portuguese as a first language and 
was fluent in English. She lived in a house with four other friends. She reported that 
the onset of her current episode of depression coincided with being dismissed from 
her job. During her treatment she reported no suicidal ideation. PA attended sessions 
on Mondays and Fridays. She attended six TT sessions and one booster session, one 
week later.   
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PA provided seven baseline data points, 29 intervention points, and 21 follow-
up points. She rated “I am a failure” as her encapsulated belief and “procrastination” 
as her chosen symptom. Figures PA1 to PA6 display PA’s outcomes and Tau-U 
analyses of her data are displayed in Table 6. Her anxiety and avoidance data did not 
demonstrate baseline stability. 
 
 
 
 
 
 
 
 
 
87 
 
 
 Figure PA1. Depression VAS: raw data (       ), central tendency (         ) and trend (       ).  
 
 
 Figure PA2. Anxiety VAS: raw data (        ), central tendency (         ) and trend (        ).  
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Figure PA3. Rumination VAS: raw data (        ), central tendency (        ) and trend (     ). 
 
Figure PA4. Avoidance VAS: raw data (        ), central tendency (         ) and trend (       ). 
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Figure PA5. Belief VAS: raw data (        ), central tendency (         ) and trend (       ). 
   
Figure PA6. Procrastination VAS: raw data (       ), central tendency (         ) and trend (        ).  
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 At baseline all of PA’s symptom levels were at or above 50% on her VASs. 
Her depression showed slight upward trend at baseline, and her avoidance showed 
slight downward trend, which could be attributed to baseline instability of her 
avoidance scores, and increasing variability of both. PA’s anxiety scores showed 
extreme variability at baseline, demonstrated by complete reversal in slope. Lines of 
central tendency indicate that all of PA’s symptoms, apart from anxiety (where an 
increase was observed), showed clear decreases from baseline to intervention, that 
were maintained at follow-up. PA’s level of anxiety decreased between the 
intervention and follow-up phases but remained higher than found at baseline. There 
were few suggestions of linear trends in PA’s data. The majority of her measures 
demonstrated high variability in scores, across all phases, limiting the conclusions that 
can be drawn from her graphs. Of note, variability in her scores, and increases in 
anxiety are likely to be related to her reported experiences of a family member being 
newly diagnosed with cancer and her employment tribunal claim.  
 Non-overlap analyses confirm visual analyses. PA showed significant 
reductions in her depression, rumination, encapsulated belief, and procrastination 
levels between baseline and intervention phases, and although proportions of non-
overlap reduced, these changes were maintained at follow-up. Her greatest 
improvement was for her encapsulated belief ratings. However, non-overlap between 
phases did not reach significance for PA’s avoidance levels, and her anxiety showed 
marked but not significant increase. Her anxiety only decreased significantly 
following withdrawal of the intervention but this effect was lost when combining the 
intervention and follow-up phase. Overall, statistical analyses support that time-
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intensive BA appeared to have a positive and sustained effect on the majority of PA’s 
idiographic measures.  
Table 6 Summary of tau analyses comparing PA’s idiographic outcome measures 
across the study phases. 
Measure  Comparison Tau SD Tau p value 90% CI  
Depression  A x B -0.51 0.25 .04* [-0.91, -0.10] 
B x C  -0.18 0.17 .28 [-0.46, 0.09] 
A x (B+C) -0.55 0.24 .02* [-0.94, -0.16] 
Anxiety A x B 0.40 0.25 .11 [-0.01, 0.80] 
B x C -0.45 0.17 <.01** [-0.57, -0.02] 
A x (B+C) 0.36 0.24 .13 [-0.03, 0.75] 
Rumination A x B -0.59 0.25 .02* [-0.99, -0.18] 
B x C -0.00 0.17 .98 [-0.28, 0.27] 
A x (B+C) -0.59 0.24 .02* [-0.98, -0.20] 
Avoidance A x B -0.32 0.25 .19 [-0.73, 0.09] 
B x C -0.11 0.17 .53 [-0.38, 0.17] 
A x (B+C) -0.39 0.24 .06 [-0.79, -0.01] 
Encapsulated 
belief 
A x B -0.92 0.25 <.001*** [-1.00, -0.51] 
B x C -0.25 0.17 .13 [-0.53, 0.02] 
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A x (B+C) -0.95 0.24 <.001*** [-1.00, -0.57] 
Procrastination A x B -0.68 0.25 <.01** [-1.00, -0.28] 
B x C -0.16 0.17 .33 [-0.44, 0.11] 
A x (B+C) -0.75 0.24 <.01** [-1.00, -0.37] 
Note. A = Baseline phase; B = Intervention phase; C = Follow-up phase; CI = 
confidence interval; SD = standard deviation; * = p <.05; ** = p <.01; *** = p <.001 
 
Participant B (PB). Participant B spoke English as a first language. The onset 
of her current depressive episode coincided with a combination of events, including 
bereavement, ongoing relationship difficulties with her daughter, and becoming the 
legal guardian to her grandchildren. PB experienced passive suicidal ideation but no 
intent to act on her thoughts. PB attended sessions on Mondays and Fridays. She 
attended seven time-intensive sessions and two booster sessions, falling one and four 
weeks after her seventh session.   
 PB provided seven baseline data points, 50 intervention points, and 21 follow-
up points. She rated “I am letting the kids down” as her encapsulated belief and 
“guilt” as her chosen symptom. PB’s idiographic measures are displayed in Figures 
PB1 to PB6. Rumination was her only idiographic measure to demonstrate baseline 
stability. Completed Tau-U analyses of her data are displayed in Table 7.  
 At baseline, all of PB’s idiographic symptom ratings were above 50% on her 
VASs. Her depression, anxiety and rumination ratings showed upward trajectories in 
trend across the baseline phase, and her encapsulated belief and guilt ratings showed 
reversal in trend, indicating that these symptoms were getting worse. In part, this may 
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be attributed to instability in the majority of PB’s measures at baseline. Also, at this 
time PB had received some distressing news. Within the intervention phase, clear 
downward trends and reduction in central tendencies were observed for all of PB’s 
idiographic symptoms, with pronounced change in slope during her first week of 
treatment, indicating rapid change. The majority of her symptoms had also diminished 
before her booster sessions began. Overall variability of her scores decreased for all 
measures, increasing confidence in the analyses. All progress was maintained at 
follow-up. Indeed, on almost all measures, PB’s follow-up ratings were at 0 every 
day. However, the significant baseline variability makes it hard to draw concrete 
conclusions from PB’s visual analyses.   
 Non-overlap analyses confirm that all of PB’s idiographic symptoms 
significantly decreased between her baseline and intervention phase. Tau values 
between phase B and C suggest that the effects of the intervention were reduced but 
not lost after its withdrawal, which supports the graphical suggestion that her 
improvements were maintained at follow-up. Her most consistent improvement was 
in her rumination ratings. Therefore, time-intensive BA appeared to have a positive 
and sustained effect on all of PB’s idiographic measures.  
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Figure PB1. Depression VAS: raw data (       ), central tendency (        ) and trend (        ). 
Figure PB2. Anxiety VAS: raw data (        ), central tendency (         ) and trend (       ). 
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Figure PB3. Rumination VAS: raw data (        ), central tendency (        ) and trend (       ).
Figure PB4. Avoidance VAS: raw data (        ), central tendency (          ) and trend (       ). 
96 
 
 
Figure PB5. Belief VAS: raw data (        ), central tendency (       ) and trend (       ).
Figure PB6. Guilt VAS: raw data (       ), central tendency (         ) and trend (      ). 
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Table 7 Summary of tau analyses comparing PB’s idiographic outcome measures 
across the study phases. 
Measure  Comparison Tau SD Tau p value 90% CI  
Depression  A x B -0.94 0.24 <.001*** [-1.00, -0.55] 
B x C  0.25 0.15 .10 [0.00, 0.50] 
A x (B+C) -0.96 0.23 <.001*** [-1.00, -0.58] 
Anxiety A x B -0.93 0.24 <.001*** [-1.00, -0.55] 
B x C 0.02 0.15 .91 [-0.23, 0.27] 
A x (B+C) -0.95 0.23 <.001*** [-1.00, -0.58] 
Rumination A x B -0.97 0.24 <.001*** [-1.00, -0.59] 
B x C 0.23 0.15 .13 [-0.02, 0.487] 
A x (B+C) -0.98 0.23 <.001*** [-1.00, -0.60] 
Avoidance A x B -0.94 0.24 <.001*** [-1.00, -0.55] 
B x C 0.22 0.15 .15 [-0.03, 0.47]] 
A x (B+C) -0.96 0.23 <.001*** [-1.00, -0.58] 
Encapsulated 
belief 
A x B -0.90 0.24 <.001*** [-1.00, -0.52] 
B x C 0.11 0.15 .45 [-0.13, 0.36] 
A x (B+C) -0.93 0.23 <.001*** [-1.00, -0.55] 
Guilt A x B -0.91 0.24 <.001*** [-1.00, -0.53] 
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B x C -0.30 0.15 .05 [-0.55, -0.05] 
A x (B+C) -0.94 0.23 <.001*** [-1.00, -0.56] 
Note. A = Baseline phase; B = Intervention phase; C = Follow-up phase; CI = 
confidence interval; SD = standard deviation; *** = p <.001 
 
Participant C (PC). Participant C spoke Italian as a first language but was 
fluent in English. At the time of her treatment she lived at home with her two 
children. Her current depressive episode coincided with leaving her job. PC 
experienced suicidal thoughts but no intent. PC attended sessions on Mondays and 
Thursdays, consisting of seven time-intensive sessions and two booster sessions, at 
two and four weeks after her seventh session.   
PC provided seven baseline data points, 52 intervention data points, and 21 
follow-up data points. PC rated “I cannot trust anyone” as her encapsulated belief and 
“crying” as her idiographic symptom of depression. Her idiographic outcomes are 
displayed in Figures PC1 to PC6. All of her ratings, apart from crying, demonstrated 
baseline stability. Completed Tau-U analyses of her data are displayed in Table 8.  
At baseline, central tendencies of PC’s scores indicated that her idiographic 
symptoms were all consistently rated within the 50% to 100% range on her VASs. 
Increasing variability in the majority of her scores limits conclusions that can be 
drawn about her baseline trends. With the onset of the intervention phase, all of PC’s 
measures, apart from avoidance and crying, showed immediate decline. However, 
central tendencies indicate that between baseline and intervention phases PC did not 
show clear change in her depression, avoidance or crying ratings, and very minimal 
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decline in her other symptoms. Indeed there were no clear trends in the majority of 
her data. All of PC’s symptoms, besides crying, showed immediate initial decline 
between the intervention and follow-up phases. However, declines in central 
tendencies were very minimal, and her rumination and crying levels increased. This 
meant that by the end of her treatment, all of her symptoms were still rated within the 
above average to maximum range.  
Despite the variability of intervention and follow-up data mainly remaining 
stable or decreasing, variances were all large, particularly for crying and rumination, 
making it difficult to draw conclusions from PC’s visual analyses. For crying, this is 
likely to have been influenced by PC using only three ratings (0, 50 and 100).  
Non-overlap analyses indicate that while some proportions of PC’s 
idiographic symptoms decreased between her baseline and intervention phase, none of 
the non-overlap reached significance. Between the intervention and follow-up phases, 
graphical comparisons between intervention and follow-up phases were supported, 
with the reduction in her avoidance scores reaching significance. When her 
idiographic symptom data from the intervention and follow-up phase were combined, 
PC’s overall improvements were significant for anxiety and rumination. Therefore, 
for the majority of PC’s idiographic symptoms, she did not demonstrate significant 
change associated with her treatment.  
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Figure PC1. Depression VAS: raw data (       ), central tendency (       ) and trend (       ).  
 
Figure PC2. Anxiety VAS: raw data (        ), central tendency (         ) and trend (        ). 
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Figure PC3. Rumination VAS: raw data (        ), central tendency (         ) and trend (       ). 
Figure PC4. Avoidance VAS: raw data (        ), central tendency (         ) and trend (         ). 
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Figure PC5. Belief VAS: raw data (       ), central tendency (         ) and trend (        ). 
Figure PC6. Crying VAS: raw data (         ), central tendency (         ) and trend (        ). 
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Table 8 Summary of tau analyses comparing PC’s idiographic outcome measures 
across the study phases. 
Measure  Comparison Tau SD Tau p value 90% CI  
Depression  A x B -0.31 0.23 .19 [-0.70, 0.08] 
B x C  -0.14 0.15 .36 [-0.39, 0.11] 
A x (B+C) -0.36 0.23 .11 [-0.74, 0.01] 
Anxiety A x B -0.46 0.23 .05 [-0.85, -0.08] 
B x C -0.09 0.15 .56 [-0.33, 0.16] 
A x (B+C) -0.50 0.23 .03* [-0.88, -0.12] 
Rumination A x B -0.45 0.23 .06 [-0.83, -0.06] 
B x C 0.10 0.15 .52 [-0.15, 0.34] 
A x (B+C) -0.46 0.23 .04* [-0.84, -0.09] 
Avoidance A x B -0.22 0.23 .35 [-0.61, 0.17] 
B x C -0.42 0.15 .01* [-0.67, -0.17] 
A x (B+C) -0.31 0.23 .18 [-0.67, 0.07] 
Encapsulated 
belief 
A x B -0.30 0.23 .21 [-0.68, 0.09] 
B x C -0.19 0.15 .20 [-0.44, 0.06] 
A x (B+C) -0.32 0.23 .16 [-0.70, 0.06] 
Crying A x B -0.09 0.23 .70 [-0.48, 0.30] 
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B x C 0.09 0.15 .51 [-0.15, 0.35] 
 A x (B+C) -0.04 0.23 .87 [-0.42, 0.34] 
Note. A = Baseline phase; B = Intervention phase; C = Follow-up phase; CI = 
confidence interval; SD = standard deviation; * = p <.05 
  
 Participant D (PD). Participant D spoke English as a first language. She lived 
at home with her four children. Her current depressive episode coincided with being 
unhappy with a restructuring at her work place, and relationship difficulties with her 
partner. PD attended sessions on Mondays and Fridays. She attended five time-
intensive sessions, had another 45 minute intensive session over the phone, and 
attended three booster sessions at one, two and four weeks after her final intensive 
session.  
PD provided 14 baseline data points, 51 intervention data points, and 21 
follow-up data points. She rated “I am a fuck up” as her encapsulated belief and how 
“withdrawn” she was as her chosen symptom. Her idiographic measures are displayed 
in Figures PD1 to PD6. Only PD’s depression and encapsulated belief ratings met 
baseline stability. Completed Tau-U analyses of her data are displayed in Table 9.  
At baseline, lines of central tendency indicate that the majority of PD’s scores 
fell above 50% on her VASs, though her anxiety appeared low. Downward 
trajectories in trend were clearly present for her rumination scores, and slight for her 
depression scores, though these may have been influenced by high variability in 
scores and the fact that she collected her measures over the Christmas holidays.  
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During the intervention phase, lines of central tendency indicate that all of 
PD’s symptoms, apart from anxiety (where an increase was observed), showed clear 
but non-immediate reductions. Trend lines indicate that PD’s scores tended to either 
increase or remain stable across her first four sessions and then decreased or remained 
stable between days 24 and 48 (approximately). These downward trends appeared 
more pronounced and immediate than they did at baseline, but were incongruent with 
PD’s report of self-harm and heightened suicidal ideation at her fifth session. Over the 
last two weeks of her treatment, reverse upward trajectories in her idiographic 
symptoms were observed, and these were either stable or continued to increase at 
follow-up, where all central tendencies of her symptoms increased. It is thought this 
deterioration in her symptoms was influenced by her experience of a traumatic event, 
or it could also represent a cyclical nature to PD’s depression. Indeed, variability in 
PD’s scores was pronounced during the intervention phase, and although variability 
reduced by follow-up, her visual analyses bears interpreting with caution.  
Non-overlap analyses confirm that between her baseline and intervention 
phases PD made significant improvement in all of her idiographic symptoms, except 
anxiety, but that the withdrawal of the intervention was associated with significant 
increases in all of her idiographic symptoms, indicating that her progress was lost and 
reversed. Comparisons between the baseline phase and the combined intervention and 
follow-up phases, show that overall PD only made significant improvements on her 
encapsulated belief ratings, and that her anxiety significantly increased over the total 
course of the study. 
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Figure PD1. Depression VAS: raw data (         ), central tendency (         ) and trend (        ).  
Figure PD2. Anxiety VAS: raw data (       ), central tendency (         ) and trend (       ). 
 
107 
 
 
Figure PD3. Rumination VAS: raw data (        ), central tendency (         ) and trend (       ). 
Figure PD4. Avoidance VAS: raw data (        ), central tendency (         ) and trend (        ). 
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Figure PD5. Belief VAS: raw data (       ), central tendency (         ) and trend (       ). 
Figure PD6. Withdrawal VAS: raw data (        ), central tendency (         ) and trend (       ). 
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Table 9 Summary of tau analyses comparing PD’s idiographic outcome measures 
across the study phases. 
Measure  Comparison Tau SD Tau p value 90% CI  
Depression A x B -0.55 0.18 <.01** [-0.84, -0.26] 
B x C  0.80 0.15 <.001*** [0.55, 1.00] 
A x (B+C) -0.21 0.17 .21 [-0.49, 0.07] 
Anxiety A x B 0.18 0.18 .32 [-0.11, 0.47] 
B x C 0.54 0.15 <.001*** [0.55, 1.00] 
A x (B+C) 0.40 0.17 .02* [0.13, 0.68] 
Rumination A x B -0.43 0.18 .01* [-0.72, -0.15] 
B x C 0.53 0.15 <.001*** [0.28, 0.77] 
A x (B+C) -0.29 0.17 .09 [-0.57, -0.01] 
Avoidance A x B -0.37 0.18 .04* [-0.66, -0.08] 
B x C 0.82 0.15 <.001*** [0.57, 1.00] 
A x (B+C) -0.05 0.17 .75 [-0.37, 0.20] 
Encapsulated 
belief 
A x B -0.73 0.18 <.001*** [-1.00,-0.44] 
B x C 0.84 0.15 <.001*** [0.59, 1.00] 
A x (B+C) -0.37 0.17 .03* [-0.65, -0.10] 
Withdrawn A x B -0.46 0.18 <.01** [-0.75, -0.17] 
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B x C 0.82 0.15 <.001*** [0.57, 1.00] 
A x (B+C) -0.11 0.17 .51 [-0.39, 0.17] 
Note. A = Baseline phase; B = Intervention phase; C = Follow-up phase; CI = 
confidence interval; SD = standard deviation; * = p <.05; ** = p <.01; *** = p <.001 
 
Participant E (PE). Participant E spoke English as a first language. He lived 
at home with his mother. The onset of PE’s current depressive episode coincided with 
him being unemployed and feeling unsure of his life direction. PE attended sessions 
on Mondays and Fridays. PE experienced regular suicidal ideation but nil suicidal 
intent. He attended six time-intensive sessions and three booster sessions, one, two 
and three weeks after his sixth session.   
PE provided seven baseline data points and 39 intervention data points, but did 
not consent to collecting follow-up measures, stating that outcome measure 
completion caused him to ruminate more. Of note, after missing his second treatment 
session PE misplaced four days’ worth of idiographic measures. He rated “There is 
something fundamentally wrong with me” as his encapsulated belief and “apathy” as 
his chosen symptom. His idiographic measures are displayed in Figures PE1 to PE6. 
Only his depression and avoidance measures were stable at baseline. Completed Tau-
U analyses of his data are displayed in Table 10.  
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FigurePE1. Depression VAS: raw data (        ), central tendency (           ) and trend (       ). 
Figure PE2. Anxiety VAS: raw data (       ), central tendency (         ) and trend (       ). 
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Figure PE3. Rumination VAS: raw data (       ), central tendency (         ) and trend (       ). 
 
Figure PE4. Avoidance VAS: raw data (       ), central tendency (          ) and trend (       ). 
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Figure PE5. Belief VAS: raw data (       ), central tendency (          ) and trend (       ). 
Figure PE6. Apathy VAS: raw data (       ), central tendency (        ) and trend (       ). 
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At baseline, lines of central tendency indicate that PE’s idiographic symptom 
ratings most often fell above 50% on his VASs. There were upward trajectories in 
trends for all of his symptoms except anxiety, indicating deterioration in these 
symptoms. However, all of PE’s measures showed an obvious increase in variability 
across the baseline phase, which might have been attributable to instability in the 
majority of his measures at baseline, but reduces confidence in trends. Within the 
intervention phase, clear decreases in central tendency and trend were observed for all 
of PE’s idiographic symptoms, except anxiety. Most pronounced declines in PE’s 
score trends appeared to occur before his booster sessions. Of note, trends in PE’s 
scores did fluctuate, for example during the final two weeks of his treatment (for 
anxiety, rumination and avoidance) and in particular after losing a friend to suicide 
(see *). PE reported that his bereavement initially lowered his mood but eventually 
challenged his encapsulated belief as a man that he admired had also “suffered”. This 
is evident where his scores increased following the bereavement and then showed a 
stepped decline. Alongside baseline instabilities and high variability in data across 
both of his study phases, caution must be applied to the visual analyses, and it is not 
possible to conclude whether or not his progress was maintained over time.   
 Non-overlap analyses support that PE idiographic symptoms showed 
significant proportions of decline between the intervention and baseline phases for his 
depression, avoidance, encapsulated belief and apathy ratings, and were most 
pronounced for his avoidance. Proportions of decline in his anxiety and rumination 
scores did not reach significance. Therefore, time-intensive BA appears to have had a 
significant positive effect on the majority of PE’s idiographic symptoms.  
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Table 10 Summary of tau analyses comparing PE’s idiographic outcome measures 
across the study phases. 
Measure  Comparison Tau SD 
Tau 
p value 90% CI  
Depression  A x B -0.66 0.24 <.01** [-1.00, -0.26] 
Anxiety A x B -0.06 0.24 .80 [-0.46, 0.33] 
Rumination A x B -0.45 0.24 .06 [-0.85, -0.06] 
Avoidance A x B -0.98 0.24 <.001*** [-1.00, -0.58] 
Encapsulated belief A x B -0.64 0.24 <.01** [-1.00, -0.24] 
Apathy A x B -0.69 0.24 <.01** [-1.00, -0.31] 
Note. A = Baseline phase; B = Intervention phase; C = Follow-up phase; CI = 
confidence interval; SD = standard deviation; * = p <.05; ** = p <.01; *** = p <.001 
 
Participant F (PF). Participant F spoke Portuguese as a first language but was 
fluent in English. At the time of her treatment she was living with four friends. Her 
current depressive episode followed a difficult relationship break-up. PF attended 
sessions on Mondays and Fridays. She attended seven core sessions and two optional 
booster sessions. Due to therapist illness, her seventh session took place four days 
after her sixth session and booster sessions fell one and three weeks after her seventh 
session.  
PF provided 14 baseline data points, 47 intervention data points, and only 14 
follow-up data points. PF rated “I am not good enough” as her encapsulated belief and 
“lack of energy” as her chosen symptom. PF’s idiographic measures are displayed in 
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Figures PF1 to PF6. Only her depression and encapsulated belief ratings demonstrated 
baseline stability. Completed Tau-U analyses of her data are displayed in Table 11. 
At baseline, lines of central tendency indicate that the majority of PF’s 
idiographic symptoms scores fell close to 50% on her VASs. There were clear upward 
trajectories in her baseline trends for rumination and avoidance, indicating 
deterioration in these symptoms. Lines of trend and central tendency indicate that 
clear gradual declines in all of PF’s idiographic symptoms, except avoidance, were 
associated with the intervention onset. Central tendencies showed further 
improvement at follow-up, and trends either continued to decline or remained stable. 
The highest levels of improvement occurred in the first and last weeks of PF’s 
treatment, but during the last week this improvement occurred following 
deterioration. Variability of all of PF’s scores increased over both the intervention and 
follow-up phases. This, in addition to baseline variability makes it difficult to draw 
concrete conclusions about PF’s lasting progress from visual analyses. During the 
second week of her treatment, PF returned to university following the Christmas 
holidays, and over the course of her treatment she reported being subjected to 
stalking. Though not clear, these events might have influenced the variability in her 
scores. 
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FigurePF1. Depression VAS: raw data (        ), central tendency (         ) and trend (        ).
 
Figure PF2. Anxiety VAS: raw data (       ), central tendency (          ) and trend (       ). 
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Figure PF3. Rumination VAS: raw data (       ), central tendency (          ) and trend (        ). 
 
Figure PF4. Avoidance VAS: raw data (       ), central tendency (          ) and trend (         ). 
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Figure PF5. Belief VAS: raw data (        ), central tendency (         ) and trend (       ).
 
Figure PF6. Lack of Energy VAS: raw data (       ), central tendency (         ) and trend (        ). 
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 Non-overlap analyses support that between PF’s baseline and intervention 
phases she showed significant reductions in all of her idiographic symptoms, except 
avoidance. Her greatest improvement was in her encapsulated belief ratings. Though a 
proportion of her depression and anxiety scores were higher after the withdrawal of 
the intervention, indicating a reduction in the effect of the intervention following its 
end, this did not reach significant levels and so, as suggested by the visual analysis, 
the effects of the intervention were not lost. PF’s ratings of rumination, avoidance and 
her encapsulated belief showed further significant reduction after the withdrawal of 
the intervention. Overall, when intervention and follow-up phases were combined, PF 
showed significant improvement on all of her idiographic symptoms, except 
avoidance. 
Table 11 Summary of tau analyses comparing PF’s idiographic outcome measures 
across the study phases. 
Measure  Comparison Tau SD Tau p value 90% CI  
Depression  A x B -0.60 0.18 <.001*** [-0.89, -0.31] 
B x C  0.34 0.18 .05 [0.05, 0.63] 
A x (B+C) -0.65 0.17 <.001*** [-0.94, -0.37] 
Anxiety A x B -0.60 0.18 <.001*** [-0.89, -0.30] 
B x C 0.17 0.18 .32 [-0.12, 0.47] 
A x (B+C) -0.67 0.17 <.001*** [-0.95, -0.38] 
Rumination A x B -0.48 0.18 <.01** [-0.77, -0.19] 
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B x C -0.46 0.18 <.01** [-0.76, -0.17] 
A x (B+C) -0.55 0.17 <.01** [-0.83, -0.27] 
Avoidance A x B 0.02 0.18 .93 [-0.28, 0.31] 
B x C -0.48 0.18 <.01** [-0.77, -0.19] 
A x (B+C) -0.08 0.17 .63 [-0.37, 0.20] 
Encapsulated 
belief 
A x B -0.65 0.18 <.001*** [-0.94, -0.36] 
B x C -0.41 0.18 .02* [-0.71, -0.12] 
A x (B+C) -0.70 0.17 <.001*** [-0.98, -0.42] 
Lack of 
energy 
A x B -0.42 0.18 .02* [-0.71, -0.13] 
B x C -0.20 0.18 .25 [-0.49, 0.09] 
A x (B+C) -0.44 0.17 .01* [-0.72, -0.15] 
Note. A = Baseline phase; B = Intervention phase; C = Follow-up phase; CI = 
confidence interval; SD = standard deviation; * = p <.05; ** = p <.01; *** = p <.001 
 
Participant G (PG). Participant G spoke English as a first language. At the 
time of her assessment she lived with two friends and her partner. Her current 
depressive episode coincided with adapting to being in a relationship and losing a 
sense of independence. PG attended sessions on Tuesdays and Fridays. She attended 
all 10 available, with booster sessions one, two and four weeks post session seven.   
PG provided seven baseline data points for most of her idiographic measures, 
but only three for her chosen symptom. She provided 50 intervention phase data 
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points. Her follow-up data were collected beyond the submission deadline for this 
report and so are not reported here. PG rated “I am a failure” as her encapsulated 
belief and “despair” as her chosen symptom. PG’s idiographic measures are displayed 
in Figures PG1 to PG6. Her depression, rumination and despair ratings demonstrated 
baseline stability. Completed Tau-U analyses of her data are displayed in Table 12.  
At baseline, lines of central tendency indicate that the majority of PG’s 
idiographic symptom scores fell above 50% on her VASs. There were upward 
trajectories in trend for her depression, anxiety, and rumination scores, indicating 
deterioration of these symptoms. During the intervention phase, all of PG’s 
idiographic symptoms showed clear downward trends and reduction in central 
tendencies. PG’s most pronounced improvements were observed before her booster 
sessions began. While the majority of measures showed decreasing variances in their 
ratings during the intervention, the variability of PG’s scores was very high. One 
factor potentially influencing PG’s scores was that two days before her first session, 
her long-term relationship ended, (see *) causing PG to experience increased suicidal 
ideation. Therefore, PG’s visual analyses need interpreting with caution, plus no 
conclusions about the maintenance of her progress can be drawn. 
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Figure PG1. Depression VAS: raw data (       ), central tendency (         ) and trend (        ). 
Figure PG2. Anxiety VAS: raw data (         ), central tendency (         ) and trend (       ).
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Figure PG3. Rumination VAS: raw data (        ), central tendency (          ) and trend (        ).
Figure PG4. Avoidance VAS: raw data (       ), central tendency (          ) and trend (       ).
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 Figure PG5. Belief VAS: raw data (       ), central tendency (         ) and trend (       ).
Figure PG6. Despair VAS: raw data (         ), central tendency (          ) and trend (        ). 
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 Non-overlap analyses indicate that between baseline and intervention phases 
all of PG’s idiographic symptoms showed high proportions of improvement, and were 
significant for all measures apart from her despair, for which she provided less, and 
therefore, lower powered data. Her greatest progress was seen in her depression 
scores.   
Table 12 Summary of tau analyses comparing PG’s idiographic outcome measures 
across the study phases. 
Measure  Comparison Tau SD Tau p value 90% CI  
Depression  A x B -0.83 0.24 <.001*** [-1.00, -0.45] 
Anxiety A x B -0.71 0.24 <.01** [-1.00, -0.33] 
Rumination A x B -0.78 0.24 <.001*** [-1.00, -0.40] 
Avoidance A x B -0.81 0.24 <.001*** [-1.00, -0.42] 
Encapsulated 
belief 
A x B -0.76 0.24 <.01** [-1.00, -0.37] 
Despair A x B -0.62 0.35 .07 [-1.00, -0.05] 
Note. A = Baseline phase; B = Intervention phase; C = Follow-up phase; CI = 
confidence interval; SD = standard deviation; * = p <.05; ** = p <.01; *** = p <.001 
 
Participant H (PH). Participant H spoke English as his first language. He 
described his current depressive episode as coinciding with a couple of bereavements, 
as well as getting older and feeling as though he had less time to achieve his 
aspirations. During his treatment, PH reported that he had experienced frequent 
suicidal ideation for the past 10 years but that he had no intent to act on his thoughts. 
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PH attended sessions on Mondays and Fridays. He attended six treatment sessions in 
total, though his fifth session was only 30 minutes long and conducted over the 
telephone because PH needed to attend a job interview. After this, his involvement in 
the study ended as he got a job abroad.  
In total, PH provided seven baseline data points and 19 intervention data 
points. PH rated his belief “I am a failure”, and his chosen symptom, “sadness”. PH’s 
idiographic measures are displayed in Figure PH1 to PH6. None of PH’s measures, 
apart from his avoidance rating, were stable at baseline. Completed Tau-U analyses of 
his data are displayed in Table 13.  
At baseline, PH’s rumination, encapsulated belief, and sadness appeared to 
demonstrate decreasing trend, with ratings falling below 50% at points. All of PH’s 
scores also showed increasing variability across the phase, which could be attributed 
to instability in the majority of PH’s responses, but decreases the confidence in trends. 
All measures apart from anxiety (where a small increase was observed) showed clear 
reductions in central tendency during treatment. Consistent trends in scores were less 
clear and rather more cyclical. Indeed, the majority of PH’s scores initially increased, 
followed by negative slope appearing most pronounced between his second and third 
sessions, but then reversing between Session 3 and 4 and declining again between 
Session 4 and 6. 
Alongside baseline instabilities and high variability of all data, it was not 
possible draw concrete conclusions about PH’s progress from visual analyses. Of 
note, some of his declines in symptoms during the intervention phase occurred at a 
similar pace to declines observed over the baseline phase (e.g., rumination). Also, 
despite requesting that PH’s medication dosage was kept stable, he halved his dose at 
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approximately day 14 (see *), which may account for some rapid increases in his 
daily symptom measures. PH’s procurement of a job could also have influenced his 
outcomes.  
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Figure PH1. Depression VAS: raw data (        ), central tendency (         ) and trend (        ).  
 
 
Figure PH2. Anxiety VAS: raw data (        ), central tendency (         ) and trend (        ). 
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Figure PH3. Rumination VAS: raw data (         ), central tendency (          ) and trend (       ). 
 
Figure PH4. Avoidance VAS: raw data (       ), central tendency (        ) and trend (      ).
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Figure PH5. Belief VAS: raw data (       ), central tendency (         ) and trend (       ). 
 
Figure PH6. Sadness VAS: raw data (         ), central tendency (         ) and trend (       ). 
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 Non-overlap analyses indicate that between baseline and intervention phases 
PH showed significant reductions in all of his idiographic symptoms, apart from 
anxiety. The analyses show that his most marked improvement was in his avoidance 
levels. Therefore, overall, positive effects of the intervention were evident for the 
majority of PH’s idiographic symptoms. 
Table 13 Summary of tau analyses comparing PH’s idiographic outcome measures 
across the study phases. 
Measure  Comparison Tau SD Tau p value 90% CI  
Depression  A x B -0.80 0.26 <.01** [-1.00, -0.35] 
Anxiety A x B -0.03 0.26 .91 [-0.46,0.40] 
Rumination A x B -0.62 0.26 .02* [-1.00, -0.20] 
Avoidance A x B -0.86 0.26 <.001*** [-1.00, -0.44] 
Encapsulated 
belief 
A x B -0.56 0.26 .03* [-0.99, -0.14] 
Sadness A x B -0.74 0.26 <.01** [-1.00, -0.31] 
Note. A = Baseline phase; B = Intervention phase; C = Follow-up phase; CI = 
confidence interval; SD = standard deviation; * = p <.05; ** = p <.01; *** = p <.001 
 
Summary of patterns across participants.  The findings described illustrated 
the differential responses of eight participants all receiving time-intensive BA. Almost 
all baseline measures fell in the moderate to maximum range on VASs. Only PD, PE 
and PH’s anxiety levels, and PF’s avoidance and chosen symptom levels were below 
50% at baseline. Overall, at baseline, the majority of instability in idiographic 
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outcomes was shown in anxiety and chosen symptom ratings, whereas the least 
instability at baseline was shown in depression ratings. In addition, there did not 
appear to be clear differences in where trends in idiographic measures were identified 
at baseline. Overall, visual analyses demonstrated that the majority of participants 
(six) showed improvements in most of their idiographic symptoms, with the majority 
of change appearing maintained at follow-up. 
 Statistical analyses were mostly supportive of visual analyses. Relative to 
baseline, the majority of participants (between five and seven) made significant 
improvements in all symptoms, except for anxiety, where least improvement was 
achieved (see Table 14). For those who did not make significant change on symptoms 
between baseline and intervention phases, visual analysis confirmed that most 
participants still appeared to be improving over time, except three participants whose 
anxiety scores were increasing (PA, PD & PH), two participants whose anxiety 
appeared stable (PC & PE), and one participant whose depression appeared stable 
(PC). Highest rates of significant improvement were seen for depression and 
encapsulated belief ratings. PB was the only participant to show significant declines 
on all idiographic symptom ratings, whereas in contrast, PC only demonstrated 
significant improvement in her anxiety ratings. PB had no comorbid mental health 
diagnosis, whereas PC met criteria for GAD and had the most chronic case of 
depression. On other measures, though only observationally examined, there were no 
clear differences in demographic characteristics and baseline symptom scores 
between those who did and did not reach significant improvement in idiographic 
symptoms. As mentioned, PC and PG not demonstrating significant improvements in 
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their chosen symptoms may have been influenced by less reliability in the measure 
and a lack of power, respectively.  
Table 14 Summary of statistical change across participants. 
Idiographic 
measure  
Phase 
comparison 
Number 
significantly 
improved (P) 
No significant 
change (P) 
Significant 
deterioration 
(P) 
Depression A x B 7 (all except PC) 1 (PC) 0 
B x C  0  4 (PA, PB, PC & PF) 1 (PD) 
 A x (B+C) 3 (PA, PB & PF) 2 (PC &PD) 0 
Anxiety A x B 3 (PB, PF, PG)  5 (PA, PC, PD, PE 
& PH) 
0 
B x C 1 (PA) 3 ( PB, PC, PF) 1 (PD) 
 A x (B+C) 3 (PB, PC, & PF) 1 (PA) 1 (PD) 
Rumination A x B 6 (PA, PB, PD, 
PF, PG & PH) 
2 (PC & PE) 0 
B x C 1 (PF) 3 (PA, PB & PC) 1 (PD) 
 A x (B+C) 4 (PA, PB, PC & 
PF) 
1 (PD) 0 
Avoidance A x B 5 (PB, PD, PE, 
PG & PH ) 
3 (PA, PC & PF) 0 
B x C 2 (PC & PF) 2 (PA & PB) 1 (PD) 
 A x (B+C) 1 (only PB) 4 (PA, PC, PD & 
PF) 
 
0 
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Encapsulated 
belief 
A x B 7 (PA, PB, PD, 
PE, PF, PG & 
PH) 
1 (PC) 0 
B x C 1 (PF)  3 (PA, PB, PC) 1 (PD) 
 A x (B+C) 4 (PA, PB, PD & 
PF) 
1 (PC) 0 
Chosen 
symptom 
A x B 6 (PA, PB, PD, 
PE, PF & PH) 
2 (PC & PG) 0 
 B x C 0  4 (PA, PB, PC & PF) 1 (PD) 
 A x (B+C) 3 (PA, PB & PF) 2 (PC & PD) 0 
 
  Of those who provided follow-up data (n = 5), the majority of participants 
demonstrated no significant change in their symptoms following the withdrawal of the 
intervention. Proportions of non-overlap indicated that effects of the intervention were 
reduced, however visual analysis of those making no significant changes, confirmed 
that the majority of participants (n = 4) improvements were either maintained or 
continued. PC’s non-significant changes were only in the direction of worsening for 
her rumination and crying levels. However, all of PD’s symptoms increased 
significantly. The highest rate (2/5) for further significant improvement was shown in 
avoidance. No participants showed further significant improvement in depression or 
chosen symptom ratings at follow-up. Besides PD experiencing a traumatic event 
during her treatment, there were no clear differences between who did or did not show 
change in scores following the withdrawal of the intervention.   
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When combining scores from the intervention and follow-up phase relative to 
baseline, the majority of participants (n = 3 to 4) showed significant improvements in 
idiographic symptoms, apart from for avoidance, where only PB showed significant 
overall improvement. However, the majority of participants who showed significant 
improvement in avoidance levels following the intervention did not complete follow-
up measures, which influences this result. PC’s rumination showed added significant 
improvement. PD’s only symptom to demonstrate significant improvement overall 
was her encapsulated belief, and her level of anxiety significantly worsened. 
Therefore, combining phase B and C reduced the apparent effects of removing the 
intervention on her scores. Clear differential responses may be a result of high 
variability across the data, and participants experiencing a variety of ongoing life-
stressors.  
Weighted averages of non-overlap of data between phases (see Table 15) 
indicate that across all participants, all idiographic symptoms showed significant 
decline between baseline and intervention phases, with encapsulated beliefs 
decreasing the most and anxiety decreasing the least. Between intervention and 
follow-up phases the proportion of depression ratings that increased showed 
significance, and all other symptoms showed no significant change but decline in 
effects. When combining data from intervention and follow-up phases, relative to 
baseline, significant declines were still evident on all idiographic symptom ratings, 
with encapsulated beliefs still showing the most improvement. However, due to the 
non-concurrent design of the study, high variability in change over time demonstrated 
from individual effects, and the influence of external events, weighted averages are 
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not recommended to be the basis for drawing conclusions from this data (Parker & 
Vannest, 2012). 
Table 15 Weighted averages of non-overlap of data between phases and across all 
participants. 
 
Measure  
Comparison Tau p value 95% CI  
Depression  A x B -0.64 <.001*** [-0.80, 0.00] 
B x C  0.22 <.01** [0.08, 0.36] 
A x (B+C) -0.53 <.001*** [-0.72, -0.35] 
Anxiety A x B -0.28 <.001*** [-0.44, 0.00] 
B x C 0.07 .31 [-0.07, 0.21] 
A x (B+C) -0.25 <.01** [-0.44, -0.07] 
Rumination A x B -0.59 <.001*** [-0.74, -0.40] 
B x C 0.10 .18 [-0.05, 0.23] 
A x (B+C) -0.55 <.001*** [-0.74, -0.38] 
Avoidance A x B -0.51 <.001*** [-0.67, -0.35] 
B x C 0.02 .75 [-0.12, 0.16] 
A x (B+C) -0.32 <.001*** [-0.51, -0.14] 
Encapsulated 
belief 
A x B -0.69 <.001*** [-0.84, -0.52] 
B x C 0.04 .60 [-0.10, 0.18] 
A x (B+C) -0.64 <.001*** [-0.82, -0.46] 
Chosen 
symptom 
A x B -0.56 <.001*** [-0.73, 0.39] 
B x C 0.06 .38 [-0.08, 0.20] 
A x (B+C) -0.43 <.001*** [-0.61, -0.25] 
Note. A = Baseline phase; B = Intervention phase; C = Follow-up phase; CI = 
confidence interval; SD = standard deviation; Weighted averages = combined effect-
size; * = p <.05; ** = p <.01; *** = p <.001 
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Can time-intensive BA lead to reliable and clinically significant change on 
standardised and process measures of depression and anxiety, and are treatment 
gains maintained over a three week follow-up period?  
The MADRS, PHQ-9, GAD-7, BAD-SF, and DAS-SF were used to identify 
participants who displayed (a) reliable change (RC) and (b) clinically significant 
change (CSC; Jacobson & Traux, 1991) in their symptomatology from baseline to end 
of treatment and follow-up points. Comparison of pre and post-intervention scores 
were based on single baseline scores or an average of each participant’s baseline 
scores where they had more than one. Post-BA scores were calculated from 
participants’ final session scores. Where follow-up data were available, their final 
follow-up scores were used. 
Of note, where participants did not complete one item on outcome measures, 
missing items were replaced with substitution of a mean score calculated from 
completed scale items. Where participants did not complete entire measures or more 
than one item on outcome measures, data were considered ‘missing’, as indicated in 
Tables 17 to 21. Jacobson and Traux’s (1991) formula (see below) for calculating 
reliable change indexes (RCI) was used to calculate RCIs for the current study’s 
standardised and process measures. 
 
 
Generally, RC refers to a magnitude of observed change that is more than can 
be explained by measurement error alone. Within the formula, M
1
 refers to outcome 
scores before the intervention, and M
2
 refers to scores post-intervention. The standard 
M
1
 - M
2 
  
SEdiff 
 
RCI  =  
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error of difference (SEdiff) was calculated as √2 x SEM
2 
where SEM refers to the 
standard error of measurement. SEM is calculated as SD x √(1-r) where r refers to 
the reliability of the measure being used. The current study used Cronbach’s alphas 
(α) as measures of internal reliability. Where papers reported more than one α, for 
outcome measures the median was used. According to their formula, a RCI of more 
than +/- 1.96 would indicate statistically reliable change (Jacobson & Traux, 1991).  
In order to achieve clinically significant change (CSC), reliable change (RC) 
must be indicated first. Criterion “a” was used to determine CSC when normative data 
from a non-clinical population were not available (Morley, 2015b). This is defined as 
post-treatment or follow-up scores falling outside of the range of the clinical 
population, and being at least two standard deviations above or below baseline scores 
of a clinical sample (Jacobson & Traux, 1991). Criterion “b” was used to determine 
CSC when normative data from a non-clinical population were available. This is 
defined as post-treatment or follow-up scores falling within 1.96 standard deviations 
of the mean of the non-clinical population mean (Jacobson & Traux, 1991). Criterion 
“b” was used as opposed to criterion “c” as clinical and non-clinical norms did not 
overlap.  
Table 16 below shows the reference data used to calculate RCIs and CSC for 
each of the standardised and process measures. In accordance with its aims, the 
current study also sought to determine rates of treatment response. For participants to 
be classified as treatment responders, they had to meet criteria for both reliable and 
CSC on one or both measures of depression.  
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Table 16. Reference data used to calculate RC and CSC 
Measure Cronbach’s alpha 
(source) 
Clinical norm reference 
data (source) 
  
Non-clinical 
norm 
reference 
data (source) 
CSC 
criterion 
MADRS Median α = .93 
(Montgomery & 
Åsberg, 1979) 
Mean = 25.60, SD = 4.70 
(Cunningham, Wernroth, 
Knorring, Berglund, & 
Ekselius, 2011) 
 
 
n/a A 
PHQ-9 α = .89  
(Kroenke & 
Spitzer, 2002) 
Mean = 17.30, SD = 5.00 
(McMillan, Gilbody, & 
Richards, 2010) 
 
Mean = 3.30, 
SD = 3.80 
(Kroenke & 
Spitzer, 
2002) 
 
B 
GAD-7 α = .92 (Spitzer et 
al., 2006) 
Mean = 12.60, SD = 5.10 
(Richards et al., 2016)  
Mean = 3.20, 
SD = 3.50   
(Löwe et al., 
2008) 
 
B 
BAD-SF α = .82 (Manos et 
al., 2011) 
Mean = 21.70, SD = 7.45 
(Dimidjian et al., 2017) 
 
n/a A 
DAS-SF α = .84 (Beevers 
et al., 2007) 
Mean = 22.37, SD = 6.06 
(Beevers et al., 2007) 
 
n/a A 
Note. CSC = clinically significant change, as indicated by Jacobson & Traux, 1991 
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Reliable and clinically significant change on the MADRS. Overall analysis 
of MADRS scores indicated that by the end of their treatment, seven participant’s 
scores demonstrated RC (see Table 17). Of these, three also met criteria for CSC (PB, 
PC, & PE). Of those who provided follow-up measures (n = 5), three met criteria for 
RC, of whom two also met criteria for CSC (PB, PF). PA and PB maintained their 
treatment outcomes, and PF demonstrated further improvement post-treatment. 
However, by follow-up PC’s scores had increased to indicate that she had made no 
improvement over the longer course of the study, and in fact her final MADRS 
measure was higher than her initial measures, indicating that her symptoms of 
depression got worse. Of note, no participants MADRS scores showed stable and 
continuous decline over time. The only participant to demonstrate CSC across 
intervention and follow-up phases (PB) first indicated CSC as early on as Session 3. 
In fact, if end of treatment measures had been taken from Session 7 PD and PG would 
also have demonstrated reliable and clinically significant change.
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Table 17 Summary of participants’ weekly MADRS scores. 
   Baseline phase Intervention phase Follow-up phase 
P  Screening Assessment Baseline 
1 
Baseline 
2  
Session 
1 
Session 
3 
Session 
5 
Session 
7 
Booster 
1  
Booster 
2 
Booster 
3 
Follow-up 
1  
Follow-up 
2 
Follow-up 
3  
A 35 39 39 n/a 26 Missing 29 37 23
RC
 n/a n/a 30 18 25
RC
 
B 31 31 31 n/a 32 14 13 5 7 2
CSC
 n/a 2 2 2
CSC
 
C 38 39 39 n/a 45 35 30 13 45 9
CSC
 n/a 34 33 41 
D 36 33 37 35 31 20 41 13 10 14 36 23 Missing 37 
E 26 30 30 n/a 34 35 Missing Missing 5 7 5
CSC
 n/a n/a n/a 
F 34 35 30 25 36 30 22 Missing 20 19
RC
 n/a 15 15 14
CSC
 
G 36 36 45 n/a 48 33 29 11 20 14 18
RC
 n/a n/a n/a 
H 31 37 37 n/a 30 25 26
 RC
 n/a n/a n/a n/a n/a n/a n/a 
Note. MADRS = Montgomery Åsberg Depression Rating Scale (range: 0-60); P = participant; Reliable change (
RC
) and clinically significant change (
CSC
) indicated by 
Jacobson & Traux, 1991. 
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 A Microsoft Excel spreadsheet of The Leeds Reliable Change Indicator 
(Morley & Dowzer 2014) was used to graph reliable and CSC on the MADRS. A 
scatterplot of participants pre-treatment and post treatment MADRS scores can be 
seen in Figure 3 and a plot of their pre-treatment and follow-up scores is shown in 
Figure 4. Participants pre-treatment depression scores can be read off the x-axis and 
their corresponding post-treatment/follow-up scores can be read from the y-axis. 
 
Figure 3. Scatter plot of baseline to end of treatment MADRS scores. 
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Figure 4. Scatter plot of baseline to follow-up MADRS scores. 
 
 Reliable and clinically significant change on the PHQ-9. Overall analysis of 
PHQ-9 scores indicated that by the end of their treatment, four participants’ scores 
demonstrated RC (see Table 18). Of these, three also met criteria for CSC (PB, PE, & 
PG), and two (PB, PG) demonstrated CSC as early on as Session 2 and Session 7, 
respectively. Of those who provided follow-up measures (n = 5), three met criteria for 
reliable and CSC (PA, PB, PF). Therefore, PA and PF showed continued 
improvement on PHQ-9 scores post-intervention. 
Of note decline of scores were not stable and consistent for any participant. In 
addition, PD demonstrated making reliable and clinically significant change on the 
majority of her PHQ-9 measures. However, these effects were lost by her final 
session.   
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Table 18 Summary of participants’ weekly PHQ-9 scores. 
   Baseline phase Intervention phase Follow-up Phase 
P  Screening Assessment Baseline 
1 
Baseline 
2  
Session 
1 
Session 
3 
Session 
5 
Session 
7 
Booster 
1  
Booster 
2 
Booster 
3 
Follow-up 
1  
Follow-up 
2 
Follow-up 
3  
A 16 15 15 n/a 13 15 15 16 13 n/a n/a 12 10 10
CSC
 
B 13 10 10 n/a 13 5 6 3 2 0
CSC
 n/a 0 0 0
CSC
 
C 16 19 19 n/a 17 15 19 15 20 17 n/a 13 13 17 
D 21 18 18 15 15 10 14 8 7 6 17 Missing  Missing 16 
E 17 17 19 n/a 16 10 17 12 7 8 7
CSC
 n/a n/a n/a 
F 23 14 13 14 12 14 8 7 9 9 n/a 9 9 6
CSC
 
G 20 14 25 n/a 24 18 14 2 7 4 6
CSC
 n/a n/a n/a 
H 17 17 17 n/a 22 18 11
RC
 n/a n/a n/a n/a n/a n/a n/a 
Note. PHQ-9 = Patient Health Questionnaire (range: 0-27); P = participant; Reliable change (
RC
) and clinically significant change (
CSC
) indicated by Jacobson & Traux, 
1991. 
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Reliable and clinically significant change on the GAD-7. Overall analysis 
of GAD-7 scores indicated that by the end of their treatment, six participants’ scores 
demonstrated RC (see Table 19). Of these, five also met criteria for CSC (PA, PB, PE, 
PF, and PG). Only PB’s anxiety measures demonstrated consistent decline over time, 
and again her CSC was demonstrated by Session 3. PE had demonstrated CSC by 
Booster 1 and PF and PG had demonstrated CSC by Session 5. Of those who 
provided follow-up measures (n = 5, 63%), three met criteria for reliable and CSC 
(PA, PB, PF). Therefore, all those who made reliable and CSC post-treatment, and 
provided follow-up measures, maintained their progress on the GAD-7. Of note, PD’s 
anxiety levels did demonstrate reliable and CSC on the majority of her weekly 
measures, apart from her final session. 
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Table 19 Summary of participants’ weekly GAD-7 scores. 
  Baseline phase Intervention phase Follow-up phase 
P  Assessment Baseline 
1 
Baseline 
2  
Session 
1 
Session 
3 
Session 
5 
Session 
7 
Booster 
1  
Booster 
2 
Booster 
3 
Follow-up 
1  
Follow-up 
2 
Follow-up 3  
A 14 13 n/a 9 7 9 14 9
CSC
 n/a n/a 12 7 9
CSC
 
B 11 11 n/a 11 3 2 1 1 0
CSC
 n/a 0 0 0
CSC
 
C 18 18 n/a 16 18 17 14 17 16 n/a Missing 13 16 
D 10 12 9 7 8 12 6 4 5 10 Missing Missing 9 
E 8 10 n/a 11 11 12 10 6 6 6
CSC
 n/a n/a n/a 
F 9 10 14 14 14 9 5 7 7
CSC
 n/a 7 7 6
CSC
 
G 9 20 n/a 20 17 9 2 6 2 3
CSC
 n/a n/a n/a 
H 17 17 n/a 13 9 12
RC
 n/a n/a n/a n/a n/a n/a n/a 
Note. GAD-7 = Generalized Anxiety Disorder Scale (range: 0-27); P = participant; Reliable change (
RC
) and clinically significant change (
CSC
) indicated by Jacobson & 
Traux, 1991. 
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 Reliable and clinically significant change on the BADS-SF.  All 
participants apart from PC demonstrated RC in their BADS-SF scores. PB and PE 
demonstrated CSC; though this was calculated using PB’s Session 1 score as her 
baseline measure (see Table 20). Of note, all participants’ activation scores fluctuated 
over time. In addition, all those who made reliable or CSC had demonstrated this 
outcome at some point prior to their booster sessions.  
Table 20 Summary of participants’ weekly BADS-SF scores. 
 Baseline phase Intervention phase 
P  Baseline 
1 
Baseline 
2  
Session 1 Session 
3 
Session 
5 
Session 
7 
Booster 
1  
Booster 
2 
Booster 
3 
A 7 n/a 16 13 17 25 28
RC
 n/a n/a 
B Missing n/a 19 45 31 22 40 42
CSC
 n/a 
C 6 n/a 3  3 3 19 9 5 n/a 
D 22 20 26 28 40 38 18 32
RC
 Missing 
E 12 n/a 23 27 Missing 47 Missing Missing 43
CSC
 
F 19 21 22 24 33 33 29 30
RC
 n/a 
G 4 n/a 9 32 15 n/a n/a n/a n/a 
H 18 n/a 18 21 26 n/a n/a n/a n/a 
Note. BAD-SF = Behavioural Activation Scale - Short Form (range: 0-54); P = participant; Reliable 
change (
RC
) and clinically significant change (
CSC
) indicated by Jacobson & Traux, 1991. 
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Reliable and clinically significant change on the DAS-SF. Only PB showed 
reliable and CSC on the DAS-SF (see Table 21). PG showed reliable but not CSC, 
which was obtained by Session 5. Of note, despite all participants’ scores fluctuating 
in both directions, the majority of scores remained fairly stable. Both PC and PD 
showed deterioration in their DAS-SF scores, though not to a reliable or significant 
degree. 
Table 21 Summary of participants’ weekly DAS-SF scores. 
 Baseline Phase Intervention Phase  
P  Baseline 
1 
Baseline 
2  
Session 1 Session 
3 
Session 
5 
Session 
7 
Booster 
1  
Booster 
2 
Booster 
3 
A 25 n/a 24 26 23 25 21 n/a n/a 
B Missing n/a 21 14 12 11 12 10
CSC
 n/a 
C 20 n/a 23  21 21 22 25 24 n/a 
D 14 15 17 16 17 17 17 17 18 
E 19 n/a 19 18 18 18 18 12 17 
F 22 23 23 23 Missing Missing 23 22  
G 29 n/a 29 23 21 19 21 18 21
RC
 
H 20 n/a 20 21 Missing n/a n/a n/a n/a 
Note. DAS-SF = Dysfunctional Attitudes Scale (range:0-36); P = participant; Reliable change (
RC
) and 
clinically significant change (
CSC
) indicated by Jacobson & Traux, 1991. 
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 Summary of reliable and clinically significant change.  All participants 
showed improvements in standardised and process measures at some point over the 
study duration. At the end of their treatment, the majority of participants made RC 
(improvement) on the MADRS, whereas only half of the participants made RC on the 
PHQ-9. Conversely, by follow-up, the same three participants demonstrated RC on 
both the MADRS and PHQ-9 (PA, PB and PF).  Following the assumption that 
overall treatment responders were those who demonstrated reliable and CSC on one 
or both standardised measures of depression, half of the participants (PB, PC, PE & 
PG) were considered treatment responders at the end of their treatment. For those who 
completed follow-up data, three (PA, PB and PF) were considered treatment 
responders. Of note, at the end of treatment, although response rates were the same on 
both measures of depression, PC was only a treatment responder according to the 
MADRS, whereas PG was only a treatment responder according to the PHQ-9. At 
follow-up, PA was only a treatment responder according to the PHQ-9, and so 
response rates were higher on the PHQ-9 than they were for the MADRS. Therefore 
there were visible differences between levels of treatment response on self-report and 
clinician-rated measures.  
 The majority of participants made reliable change in their GAD-7 scores 
across intervention and follow-up phases of the study. By the end of treatment, those 
who made CSC on a measure of depression all made CSC on the GAD-7, except PC. 
By follow-up, all those who made CSC on a measure of depression also made CSC on 
the GAD-7. The GAD-7 and PHQ-9 showed the highest rates of CSC.  
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 Overall, the highest proportion of RC on all measures across the intervention 
phase was shown in BADS-SF scores, though only two participants reached CSC.  
The lowest proportion of change across all measures was found for the DAS-SF.  
  Responders versus non-responders.  Due to the small sample size, and 
incomplete follow-up measures, statistical comparison of responders and non- 
responders was deemed inappropriate. From merely observing the data, there did not 
appear to be any specific background characteristics that distinguished responders 
from non-responders at post-treatment. However, at follow-up all non-responders had 
reported experiencing more than three previous episodes of depression at baseline, 
and their baseline PHQ-9 scores also appeared higher than those of responders. Of 
note, all non-responders at follow-up had been treated at Site 2, and all follow-up 
responders had been treated at Site 1. The only known distinguishing features 
between the therapy delivered at either site, was that therapists from Site 1 had been 
qualified for longer than therapists at Site 2, and prompting was conducted by an 
Assistant Psychologist as opposed to the therapists at Site 2.  
PB was the only participant that was a consistent treatment responder across 
all phases of the study. It was observed that she did not have any comorbid mental 
health diagnoses and her therapist mentioned believing that her strong concentration 
had facilitated her outcomes. Despite PC, being considered a responder (on the 
MADRS) at her final treatment session she consistently did not show improvement on 
all other standardised and process measures. In comparison to PB (the consistent 
responder), PC had higher depression and anxiety symptomatology at baseline, a 
comorbid diagnosis of GAD and lower credibility/expectancy ratings of the treatment. 
PC also had the most chronic case of depression of all participants. PD was a 
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consistent non-responder and this is likely to have been related to her experience of a 
traumatic event during her treatment. Though not statistically analysed here, these 
differences between responders and non-responders may be related to treatment 
response.  
 Further treatment.  At the end of their treatment, six participants were not 
actively seeking further treatment for depression (PA, PB, PE, PF, PG, & PH). PC 
was referred on to IPT for depression. PD was also referred on for more sessions, 
following the traumatic incident that she experienced during her treatment. PA 
reported intending to seek further treatment for anxiety management, and PH also 
expressed a desire to re-engage in longer-term therapy when he had the time, however 
it is not yet know if these intentions were pursued. 
Do participants’ and therapists’ evaluations of the intervention indicate that it is 
considered an acceptable treatment? 
Quantitative outcomes of acceptability of the intervention. No adverse 
effects (e.g., increases in suicidal intention or persistently worsening outcome 
measure scores) were reported during treatment. A mean score of 27.86 (SD = 4.49) 
on the CSQ indicated high treatment satisfaction relative to a maximum score of 32 
(see Table 22). Of note, even those who did not recover appeared satisfied with their 
treatment, and the lowest satisfaction rating came from PE, who did recover. On 
average, participants rated time-intensive BA as highly acceptable (M = 81.43, SD = 
21.16, range = 40 - 100) relative to a maximum score of 100. PC provided the lowest 
acceptability rating of the treatment.  
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Table 22 Client satisfaction and treatment acceptability scores. 
Participant  Total CSQ score  Acceptability rating  
A 28  80 
B 32  90 
C 28 40  
D 32  100 
E 19  100 
F 26  70 
G 30  90 
Note. Percentage scores have been rounded to one whole number; PH did not 
complete the CSQ. 
Mean scores from VASs (rated 0-100) revealed that therapists viewed time-
intensive BA as highly acceptable (M = 66.67, SD = 16.33, range = 50 - 90), and 
ratings of the utility of time-intensive BA were also above average (M = 60.00, SD = 
16.73, range = 40 - 80). Therapists reported high confidence in delivering time-
intensive BA as a first-line treatment for depression (M = 66.67, SD = 23.38, range = 
30 - 90). Finally, if permitted by their services, the average likelihood of therapists 
choosing to work with BA using this time-intensive approach in future was also high ( 
M = 69.17, SD = 26.54, range = 40 - 100).  
Summary. Descriptive analyses indicated that time-intensive BA was a highly 
acceptable treatment for the majority of participants and therapists. Of note, therapists 
considered the intervention less acceptable than participants did. 
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Discussion 
This study employed a SCED and sought to explore whether or not (a) time-
intensive BA was a feasible intervention for adult outpatients with depression, (b) it 
was effective at reducing adult outpatients’ idiographic symptoms of depression, (c) it 
was associated with reliable and clinically significant change on standardised and 
process measures of depression and anxiety (d) any existing effects were maintained 
after a follow-up period, and (e) to assess what were participant and therapist 
perceptions of the acceptability of the treatment. This section summarises the key 
study findings in relation to the research questions and hypotheses and considers how 
the findings relate to existing literature in the area. Potential implications of the 
findings are then considered. Finally, strengths and limitations of the study are 
reported, and recommendations made for future research. 
The multiple baseline SCED provided data for eight participants from baseline 
to end of treatment, and five participants also completed follow-up measures. Overall, 
recruitment, retention, credibility/expectancy and treatment fidelity data indicated that 
the intervention was feasible. Visual and statistical analysis of daily idiographic data 
demonstrated that for the majority of participants (n = 5 to 7), time-intensive BA was 
associated with significant improvement in all idiographic symptoms of depression, 
except anxiety. Statistical analysis showed that seven participants made reliable 
change (Jacobson & Traux, 1991) on at least one standardised measure of depression, 
and that at the end of their treatment, four participants were considered treatment 
responders. Only three participants showed significant improvements in their 
idiographic measure of anxiety, whereas the majority of participants (n = 5) made 
reliable and clinically significant change in their standardised anxiety levels. Most 
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participants (n = 3 or 4) who completed follow-up indicated either maintenance or 
improvement of progress on both idiographic and standardised measures of 
depression and anxiety. However, only one or two participants made reliable and 
clinically significant change on their weekly process measures of activation and 
dysfunctional attitudes. On average, evaluations of the acceptability of the 
intervention were high. Overall, there seems reason to investigate further the 
development of an optimal time-intensive BA for depression.  
Is time-intensive BA a feasible intervention for adults with depression who 
present to outpatient primary care services? 
Due to the exploratory nature of this research, it was not hypothesised whether 
or not time-intensive BA would be a feasible intervention for treating adult depression 
in primary care. However, multiple sources of data have provided encouraging 
support for its feasibility. First, all potential participants who met criteria for taking 
part in the study, except one, consented to participate. This shows that the majority of 
eligible participants considered time-intensive BA a credible idea. Second, treatment 
retention was high, and all eight participants were considered treatment completers. 
The finding that no participants dropped-out of their treatment is very encouraging 
when considering the evidence to show that attrition from numerous existing 
depression treatments is so high (Cooper & Conklin, 2015). In fact, the current 
study’s drop-out rate was lower than found for other rigorous studies of BA’s 
efficacy, when delivered at the traditional rate (Dimidjian et al., 2006; Richards et al., 
2016; Sturmey, 2009), suggesting (tentatively) that delivering BA time-intensively 
might discourage drop-out. This finding supports previous qualitative research that 
concluded that TT improves client motivation, engagement and focus (Bevan et al., 
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2010). The current study’s treatment design also had lower drop-out rates than some 
previous brief and time-intensive behavioural activation treatments (Folke et al., 
2015a; Hopko et al., 2003a; Nasrin et al., 2017; Read et al., 2017; Snarski et al., 2011; 
Turner et al., 1979; Zeiss et al., 1979), which provides encouraging support for the 
amount and spacing of BA delivered herein. These differences might be accounted for 
by the majority of previous studies recruiting either non-clinical or inpatient samples. 
Thirdly, participants rated credibility of the treatment highly, indicating they had faith 
in the treatment’s feasibility. Fourth, although only a small proportion of audio 
recordings were rated using the QoBAS (n = 5), their demonstration of acceptable 
treatment fidelity shows some promise for the feasibility of the intervention being 
plausibly attributed to valid implementation of the intervention, at least for these rated 
sessions.  
Although treatment retention was high, only a small proportion of the sample 
screened was considered eligible to take part in the study, and recruitment was slow. 
This could be explained by barriers to treatment (Mohr et al., 2010), and difficulty 
finding participants who met the strict inclusion criteria but were also willing to 
commit to the research requirements. The finding that some referrals declined 
involvement in the study due to a preference to receive CBT, suggests that the lay 
population may be less aware of BA and evidence suggesting its advantages in 
comparison to other treatments (Dimidjian et al., 2006; Dobson et al., 2008; Ekers et 
al., 2008; 2014; Richards et al., 2016; Sturmey, 2009). The low rate of therapist 
recruitment into the study indicates that therapists could feel less able/willing to take 
part in research, or that busy primary care settings such as IAPT may not be the most 
feasible setting for TT or efficacy research to take place.  
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The characteristics of the sample recruited show that TT was generally 
attractive to a heterogeneous sample. The finding that all participants were out of 
work, and a high proportion of participants were single with comorbid physical health 
conditions and anxiety, supports the current understanding that depression is 
associated with pronounced secondary difficulties (Donohue & Pincus, 2007; Veale, 
2008) and comorbidity (Kessler et al., 1994; Rosenthal, 2003). However, the decision 
not to exclude participants with previous episodes of depression appeared to lead to 
the selection of participants who reported experiencing two or more previous episodes 
of depression and moderate to severe baseline levels of depression. Nevertheless, this 
finding reflects evidence of depression’s recurring nature (Richards, 2011) and 
increasing severity with subsequent episodes (Kendler et al., 2000). Still, it is worth 
highlighting the finding that none of the current sample were in full-time 
employment, and that the majority had experienced previous weekly psychological 
interventions that were not BA (and in some cases only attended a few sessions). 
While this indicates that the current samples’ demographic characteristics are likely to 
be representative of those who would be able to adhere to the time-intensive BA 
schedule, and might explain the lower drop-out rates, it also suggests that, for the 
current sample, time-intensive BA may have been attractive and credible as a new and 
potentially faster approach to promoting recovery from recurrent depression, rather 
than simply as being a more accessible treatment (e.g., for those with time restrictions 
and personal commitments). If true, this would add weight to Oldfield et al.’s (2011) 
suggestion that TT could be more attractive to those with a more immediate desire to 
recover, or those who have not responded to weekly treatment. However, these 
hypotheses are only hypothetical at this point.   
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Can time-intensive BA lead to improvement on idiographic measures of 
depression symptoms, and are treatment gains maintained over a three week 
follow-up period? 
Given the existence of research to suggest that time-intensive behavioural 
activation has promising, as opposed to detrimental effects (Folke et al., 2015b; 
Gawrysiak et al., 2009; Hopko et al., 2003a; Nasrin et al., 2017; Snarski et al., 2011), 
it was hypothesised that following the intervention, participants would have made 
improvements in their idiographic symptoms of depression, and that owing to 
similarities between their characteristics and treatment functions (Hopko et al., 2006),  
these effects would generalise to idiographic measures of anxiety. Overall, the 
majority of participants (between five and seven) showed significant decline in all 
idiographic symptom levels, except anxiety. Therefore, time-intensive BA shows 
promise as an effective intervention for reducing idiographic symptoms of depression, 
but, as some participants did not make significant improvements on all idiographic 
measures, and the lowest level of significant improvement was seen for anxiety, the 
hypothesis is only partially supported.   
The findings are consistent with previous studies that found support for the 
effectiveness of one-session or time-intensive behavioural activation for depression 
(Folke et al., 2015a; 2015b; Gawrysiak et al., 2009; Hopko et al., 2003a; Nasrin et al., 
2017; Taylor & Marshall., 1977; Snarski et al., 2011), but build on these by delivering 
the more empirically supported BA (Martell et al., 2001; Kanter et al., 2010), twice-
weekly, within a sample of outpatients who met criteria for MDD, where multiple 
therapists delivered the treatment, and treatment fidelity was rated. Therefore, the 
current study adds external validity of findings to the literature. The observation that 
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levels of non-overlap of scores generally reduced following the withdrawal of the 
intervention reflects wide understanding that strength in effects of interventions are 
not permanent. However, visual analysis confirmed that the majority of participants’ 
progress was maintained over the follow-up period, with only one participant showing 
significant deterioration in idiographic symptoms.  
It is possible that the positive findings can be explained by behavioural models 
of depression (Ferster, 1973; Lewinsohn, 1974) and BA’s mechanism of 
extinguishing unhelpful behaviours that maintain depression, while increasing 
engagement in pleasant activities and response-contingent positive environmental 
reinforcement (Martell et al., 2001). Indeed, this is indicated as the treatment fidelity 
demonstrated acceptable compliance with BA, and the majority of participants 
showed significant declines in their avoidance and rumination levels between the 
baseline and intervention phases. Significant improvements also suggest that 
emotional processing of events that coincided with depressive episodes (Rachman et 
al., 1979) extinction of unhelpful reinforcement patterns (Mackintosh, 1974 as cited in 
Oldfield et al., 2011, p. 8), and retention of session content (Grey et al., 2009) 
increased over the shorter treatment duration. However, specific mechanisms of 
change were not assessed and require further investigation to move beyond 
speculation.  
The finding that idiographic anxiety ratings showed the lowest rate of 
improvement, and that although not to significant levels, some participants showed 
increases in anxiety levels during the intervention, is aligned with previous less 
compelling evidence of one-session BATD’s effects on anxiety in students and carers 
(Gawrysiak et al., 2009; Read et al., 2016), and does not add much weight to the 
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argument for behavioural activation as an integrated treatment for anxiety and 
depression (Hopko et al., 2006; 2016). However, there are several potential 
explanations for these findings. It is known from this study and previous qualitative 
research (Bevan et al., 2011) that engaging in time-intensive therapy can be 
overwhelming. It is possible that the time-pressure of the treatment duration increased 
a sense of urgency and accountability for some participants to get better, provoking 
anxiety. What is more, unlike some of the other VASs (e.g., rumination and 
avoidance) BA does not aim to directly target specific stimulus-response patterns that 
maintain anxiety (Martell et al., 2001), and three participants whose anxiety levels did 
not improve (PA, PC and PG) had GAD. Therefore, they may have benefitted from 
further GAD-specific treatment (NICE, 2011). Furthermore, as all participants 
reported experiencing ongoing life-stressors concurrent to their treatment, it is 
understandable that anxiety levels did not reduce for everyone. The finding that some 
participants showed improvement in anxiety levels after the withdrawal of the 
intervention supports that time-intensive BA could have had a more gradual impact on 
individual’s anxiety, as shown in previous research following time-intensive dental 
phobia treatment (Haukebo et al., 2008). As proposed by Abramowitz et al., (2003), 
an explanation for this pattern of change could be that participants were more able to 
generalise their therapy skills to new and varied real life contexts.  
The discovery that idiographic measures of encapsulated beliefs showed the 
most marked decline overall provides support for component analysis studies, which 
show that cognitive strategies are not necessary for eliciting cognitive change 
(Longmore & Worrell, 2007). Therefore, this finding highlights the promise of BA’s 
focus (through functional analysis of covert behaviours) on the utility as opposed to 
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the content of thoughts, which was further supported by the high rates of reductions in 
rumination levels.  
It is worth highlighting other general explanations of where significant 
improvements were not made on idiographic measures. These include participants 
having lower baseline levels of symptoms (e.g., PE’s anxiety and PF’s avoidance) to 
begin with, and smaller data sets being subject to Type II error (e.g., PG’s despair). 
Furthermore, the variability of idiographic data was consistently high. In line with 
previous evidence to suggest that individual differences predict variability in the 
course of depression (Bennabi et al., 2015), ongoing life-stressors reported by all 
participants may also have moderated outcomes. Indeed, this was most clearly 
indicated where PD’s scores reversed following her experience of a traumatic 
incident. It is also possible that variability of data signified some participants having 
more cyclical depression. These potential explanations require further investigation. 
Can time-intensive BA lead to reliable and clinically significant change on 
standardised and process measures of depression and anxiety, and are treatment 
gains maintained over a three week follow-up period? 
Reliable and clinically significant change in standardised depression 
scores. As above, it was hypothesised that following the intervention, participants 
would have made improvements (reliable change) in their standardised measures of 
depression symptoms. Owing to the lack of existing research on time-intensive BA in 
outpatient services, the current study did not set out directional hypotheses on whether 
or not such improvement would reach criteria for reliable and clinically significant 
change. As seven participants made reliable change on at least one standardised 
measure of depression, the hypothesis was accepted. However, 50% (4/8) to 60% 
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(3/5) of participants being considered treatment responders (meeting reliable and 
clinically significant change on one or both standardised measures of depression) at 
the end of treatment and follow-up periods, respectively, indicates that, according to 
standardised measures, time-intensive BA was clinically and significantly effective 
for some but not all participants. The current study’s response levels are lower than 
the 76% found to make significant symptomatic improvement (50% decrease in 
outcome scores from baseline) following a trial of weekly BA (Dimidjian et al., 
2006), which could be explained by their noted potential bias of allegiance effects and 
differences in the studies sample characteristics. In fact, contrary to the current study, 
Dimidjian et al., (2006) excluded participants who had not responded to treatment for 
depression within the previous year. The current study’s response rate is more 
comparable to the 64% of responders (50% decrease in outcome scores from baseline) 
obtained from the most recent non-inferiority trial of weekly BA in comparison to 
CBT (Richards et al., 2016), and general depression treatment response rates found 
within IAPT services (Richards & Borglin, 2011). These similarities could potentially 
be explained by the studies targeting similar UK populations, however, importantly, 
the findings show that our time-intensive BA could be as effective as existing, 
empirically supported and recommended pacing of BA.  
In terms of existing time-intensive behavioural activation literature, the current 
findings compare favourably to intensive behavioural group therapy (Barrera, 1979), 
and a 90 minute session of BATD delivered as a preventative intervention for non-
depressed carers (Read et al., 2016). The current study’s self-report response rates at 
the end of treatment (n = 3, 38%) are consistent with self-reported levels of treatment 
response following time-intensive BATD in inpatient settings (Folke et al., 2015b). 
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However, the current study findings are more modest in comparison to levels of 
responders (n = 3, 50%) found on clinician-rated measures of inpatient response.  
Gawrysiak et al., (2009) also found superior response rates (n = 13, 93%) following 
their 90 minute one-session BATD treatment for depressed university students. 
Besides true differences in treatment effects, discrepancies in the proportions of 
participants considered to be treatment responders across studies could be explained 
by methodological differences between study designs, such as therapy settings, 
samples recruited, sensitivities of the outcome measures, use of different types of 
behavioural activation, and different definitions of treatment response.  
Although only five participants completed follow-up measures, the finding of 
higher response rates at follow-up in comparison to end of treatment, due to additional 
participants meeting response criteria, indicates that for some participants symptoms 
of depression that were measured by standardised questionnaires continued to decline 
after the withdrawal of the intervention. This change could be explained by 
participants’ therapy skills (e.g., individual functional analysis) improving after more 
independent practice. In addition, some activation might have required more gradual 
and repeated (as opposed to immediate) reinforcement (Lewinsohn, 1974; Folke et al., 
2015b). Future empirical research is needed to test these assumptions.  
It is interesting that levels of treatment response, as well as which participants 
were considered responders, differed on the MADRS and the PHQ-9 at follow-up. 
Discrepancies between these clinician and self-report rated measures could be 
explained by reporting bias, clinicians and participants having different standards for 
outcomes, or variation in the content and weighting of items of the MADRS and 
PHQ-9 (Cuijpers et al., 2010). For example, the PHQ-9 relies more on physical 
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symptoms of depression than the MADRS does. Other possible explanations that 
could account for the findings include individual demographic differences such as 
gender, baseline depression, comorbidity severity (Carter, Frampton, Mulder, Luty, & 
Joyce, 2010), cognitive deficits (Shenal, Harrison, & Demaree, 2003), and personality 
dimensions (Rane et al., 2010) of those who completed follow-up measures. 
Discrepancies could also be a result of extraneous variables such as incidental 
measurement error. These assumptions are neither supported nor rejected here as the 
current study did not examine moderators of effects, or how outcomes were 
conceptualised by clinicians and participants. Regardless, the discrepancies support 
evidence that clinician and self-report rated measures are not equivalent (Uher et al., 
2012).  
Another interesting observation was the speed at which some participants 
responded to treatment. PB was considered a treatment responder as early as Session 
2, and, although visual analyses indicated that there were no clear patterns of 
treatment sessions leading to immediate decreases in idiographic symptom scores, 
trend lines of four participants indicated that the bulk of their progress had occurred 
before booster sessions. This is supportive of previous research that concluded that 
rates of symptom change are associated with session frequency (Bohni et al., 2009; 
Ehlers et al., 2010), regardless of the total number of sessions attended (Erekson et al., 
2015; Gutner et al., 2016; Reese et al., 2011). Considering that the current NICE 
guidelines for depression (2009) recommend that behavioural activation consists of 16 
to 20 sessions delivered over 12 to 16 weeks, the findings show that individuals 
respond to treatment at different rates, and that some clients with depression will 
require lower quantities of therapy. Indeed, this is also supportive of previous 
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evidence that success and temporal response following treatment are heterogeneous, 
and that behavioural activation is applicable for some but not all clients with 
depression (Manos et al., 2011; Santos et al., 2016; Stavrakakis et al., 2015). While 
such findings are no doubt in part attributed to extraneous variables, where some 
clients respond to treatment faster than others, there may be scope for service waiting 
list times to reduce following the delivery of time-intensive BA.  
Reliable and clinically significant change in standardised anxiety scores. 
In contrast to the idiographic measure outcomes, standardised anxiety measure 
outcomes were consistent with the hypothesis that time-intensive BA leads to 
improvement in anxiety levels. The majority of participants made reliable and 
clinically significant change in their anxiety levels, at both the end of their treatment 
(n = 5) and at follow-up points (n = 3). These findings are supportive of previous 
studies that have shown anxiety levels according to the GAD-7 decrease following 
weekly BA (e.g., Richards et al., 2016), and that TTs of anxiety have shown efficacy 
(Ehlers et al., 2014; Storch et al., 2007). Five out of six participants (83%) who were 
considered treatment responders on depression measures also made reliable and 
clinically significant change in their anxiety scores, and all depression responders also 
met reliable and clinically significant change in their anxiety scores. Therefore, the 
finding here does support the theory that anxiety and depression have a shared 
diathesis (Barlow & Campbell, 2000; Minneka et al., 1998), and that there may be 
reason to use transdiagnostic interventions for mixed anxiety and depression (Hopko 
et al., 2006). On the other hand, the increasing rate of participants showing reliable 
and clinically significant change on their GAD-7 scores by follow-up was also 
supportive of treatment effects continuing over-time (Haukebo et al., 2008), as shown 
166 
 
by some participants’ idiographic measures of anxiety. Explanations for 
inconsistencies between idiographic and standardised measure outcomes are 
considered below (see Idiographic vs. standardised measures).    
Reliable and clinically significant change in standardised activation 
scores. In comparison to baseline, the majority of participants made reliable change in 
their levels of activation on the BADS-SF. Therefore, the hypothesis that participants 
would make improvement in BADS-SF scores is accepted. It is promising that the 
relatively new and less empirically researched BADS-SF supports idiographic 
measures of avoidance, as this further implies validity of the study findings and BA’s 
mechanism of increasing activation levels (Ryba, Lejuez, & Hopko, 2014; Santos et 
al., 2016). However, only two participants met criteria for clinically significant 
change in activation levels, which seems surprising, considering that four participants 
were deemed responders on depression measures. Explanations for this discrepancy 
are unclear given the existence of contradictory evidence that amount of activity is 
(Busch et al., 2010; Mazzucchelli et al., 2009) and is not (Herschenberg et al., 2014; 
Ryba et al., 2014) associated with positive change following behavioural activation. 
However, the current study’s BADS-SF findings are consistent with those of Folke et 
al., (2015b) who found that, following their intensive BA/TD intervention, their entire 
inpatient sample met criteria for reliable change on the BADS-SF, whereas no one 
made clinically significant change. The finding could be explained by the current 
time-intensive BA not allowing enough time in between sessions for some 
participants to practice therapy skills to a sufficient level for clinically significant 
change. Not reaching clinically significant change could also indicate that participants 
had not reaped the full potential of the intervention. Perhaps they had not returned to 
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their normal repertoires, achieved all of their activation goals, or maybe their goals 
had been less value-based. Furthermore, our time-intensive BA might not have 
allowed enough time for functional changes in brain regions that mediate reward 
responsiveness to occur (Dichter et al., 2009). In addition, it may be that activation 
was not a predominant mechanism of change for all (Santos et al., 2016). As 
suggested by Barrera (1979), participants’ activation levels might have benefitted 
from a longer self-monitoring period. Moreover, due to the lack of existing rigorous 
research that has used the BADS-SF, within similar designs to the current study, the 
reference statistics that were used to calculate cut-offs for clinically significant change 
were less representative of the current sample, and could have influenced results.  
As process measures were not collected over the follow-up phase, it is not 
possible to draw conclusions about the maintenance of change in activation levels. It 
would have been interesting to observe whether or not levels of activation reached 
clinical significance in a larger proportion of participants after a longer-term follow-
up period of putting therapy skills into practice, and whether or not they continued to 
mirror idiographic measures of avoidance. However, further research is needed to 
answer these queries, as well as proposed explanations of the findings. 
Reliable and clinically significant change in standardised dysfunctional 
attitude scores. The smallest proportion of reliable and/or clinically significant 
change on any standardised/process measures was found for levels of dysfunctional 
attitudes (DAS-SF). This is contrary to the finding that encapsulated belief strengths 
demonstrated the highest proportion of change of all idiographic measures, and 
indicates that time-intensive BA was not associated with improving more general 
negative self-cognition. Therefore, the hypothesis that DAS-SF scores would show 
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improvement associated with the intervention is rejected. As four participants were 
considered treatment responders, despite not making reliable and clinically significant 
change on the DAS-SF, the findings were still aligned with one of Longmore and 
Worrell’s (2007) arguments that cognitive change is not a necessary mediator of 
symptomatic improvements.  
Idiographic vs. standardised and process measures 
 
 Clearly, the patterns of change in participants’ idiographic measures were not 
always reflected in their standardised measures of depression and anxiety and vice-
versa. For example, seven out of eight participants showed significant decline in their 
idiographic measures of depression following the intervention, yet at this same point, 
only four were considered treatment responders on standardised measures of 
depression. One explanation for this could be that the adaptations made to the PHQ-
9’s measurement period could have reduced the reliability and sensitivity of the 
measure. In addition, as standardised measures are more global symptom measures 
than idiographic measures, they are less able to capture subtle changes that occurred 
following the intervention and on a daily basis (McCormack et al., 1988). This would 
support the discrepancies between levels of change on idiographic VASs of 
encapsulated belief strength and DAS-SF scores. Conversely, discrepancies between 
measures in the opposite direction, such as PC responding on the MADRS but not 
showing significant decline on her idiographic measure of depression, and PA and PE 
not making significant declines in their idiographic ratings of anxiety, yet showing 
reliable and clinically significant change in their GAD-7 scores, imply that some 
participants did not define their idiographic experience of depression or anxiety by the 
nomenclature being rated on standardised measures of symptomatology. This 
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suggestion is supported by the finding that some of the participants’ main (chosen) 
symptoms of depression that they rated on VASs were not captured by standardised 
symptom measures, such as “crying” and “despair”. However, this difference could 
also be explained by ingrained negative thinking biases reducing individuals’ abilities 
to recognise their own progress (Rush, Hiser, & Giles, 1987). Furthermore, one-item 
VASs are less reliable and valid than multi-item standardised measures 
(Diamantopoulos, Sarstedt, Fuchs, Wilxzynski, & Kaiser, 2012), and the current study 
did not measure psychometric properties of its VASs. It is possible that similarities 
between measures may become more apparent over longer periods of time, and again 
further research is needed to determine the validity of the assumptions described. 
Overall though, clearly idiographic and standardised measures of depression also 
provide unique indicators of progress. 
Responders vs. non-responders 
 
When comparing responders to non-responders, the observation that non-
responders at follow-up had experienced more than three previous episodes of 
depression and had higher baseline PHQ-9 scores is consistent with the general 
finding that over time and subsequent episodes, the severity of depression increases 
(Kendler et al., 2000) and the rate of recovery slows (Richards, 2011). It is possible 
that clients with these characteristics were less suited to time-intensive BA. The 
observation that all non-responders at follow-up had been treated at Site 2, whereas 
responders had been treated at Site 1, could be explained by therapists at Site 2 being 
less experienced; however, this would contradict more rigorous evidence that shows 
that BA is as effective when delivered by less highly trained professionals (Ekers et 
al., 2011; Richards et al., 2016).  
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Additional differences that were observed between PB’s (the only consistent 
treatment responder), and PC’s (who consistently did not improve on the majority of 
her measures) idiographic and standardised measures suggest that concentration, 
depression severity, comorbidity and treatment credibility/expectancy could mediate 
treatment response. In fact, in hindsight, PC was thought to meet criteria for persistent 
depressive disorder (APA, 2003), which is associated with poorer clinical outcomes in 
comparison to MDD (Russell et al., 2004), and, indeed, following the intervention her 
referral to IPT reflected clinical judgement that she was not suitable for BA. 
However, until more rigorous investigation and inferential statistics are used to draw 
comparisons between responders and non-responders, these observations are only 
hypotheses.  
Do participants’ and therapists’ evaluations of the intervention indicate that it is 
considered an acceptable treatment? 
Due to the exploratory nature of this research, it was not hypothesised whether 
or not the intervention would be deemed acceptable by participants or therapists. 
However, multiple sources of data have provided encouraging support to show that 
time-intensive BA is considered an acceptable treatment provision within primary 
care. Firstly, mean client satisfaction ratings were high. This extends previous 
findings that time-intensive BA/TD was considered highly satisfying by inpatient 
samples, (Folke et al., 2015a; 2015b), to Martell’s (2013) BA intervention, delivered 
at a more spaced rate, and within outpatient populations. Secondly, both participant 
and therapists’ mean ratings of the treatment acceptability were high, with therapists 
also indicating that, if permitted, they would be highly likely to deliver time-intensive 
BA again.  
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Clinical and research implications 
 
As the current study is exploratory, the majority of its implications are for 
future research (see Future research). However, the findings that time-intensive BA 
can be feasible, acceptable, and effective for some adult outpatients with depression 
has added to the evidence base and should be widely disseminated, as some clinicians 
and researchers working in this area will offer and continue evaluating the treatment.  
As BA cannot be assumed to uniformly reduce depression and anxiety levels 
for everyone, until more rigorous research is conducted, the Principal Investigator 
recommends that clinicians should continue to follow the NICE guidelines (2009) for 
depression, and as a minimum, when implementing BA they should more consistently 
adhere to Dimidjian et al.’s (2006) empirically supported intention for BA to be 
delivered bi-weekly for the first few weeks, and address any preventative barriers. As 
all non-responders in the current study reported experiencing three or more previous 
depressive episodes, yet none had received previous MBCT, services should ensure 
that they are routinely following the NICE guidelines (2009) and offering MBCT 
when recommended. For clients with comorbid anxiety, clinicians should remember 
to make use of other therapeutic strategies (e.g., mindfulness and anxiety 
management), that can be incorporated into BA (Martell et al., 2013), and to consult 
the NICE guidelines for treating comorbid GAD (NICE, 2011).  
In-view of the scientist-practitioner role of clinical psychologists, and low 
recruitment of therapists within the current study, services should encourage 
therapists to evaluate new treatments. However, as the findings show that reasons for 
not taking part in the study were working part-time, having a full case-load and not 
yet being fully qualified, IAPT services should carefully consider whether or not they 
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can support time-intensive interventions, or research into their efficacy. Services who 
do not feel able to facilitate time-intensive BA should generate creative ways of 
enhancing how ‘user-friendly’ the treatment is, that they would be able to manage 
within their resource confines (e.g., sending automatic text prompts). Such planning 
will require discussion of costs and funding with service managers and clinical 
commissioning boards. 
The current findings show that some elements of the existing treatment design, 
such as having a break during longer sessions, and the use of prompting should be 
retained. The high treatment retention also shows that the pacing and spacing of the 
intervention could be retained for some. The Principal Investigator also recommends 
that practical issues considered herein should continue to be considered when 
conducting further evaluations of time-intensive BA within similar settings. For 
example, to avoid staff burn-out, clinicians within IAPT services should be made 
exempt from other responsibilities of equal weighting, caseloads, session times, 
session preparation time and boundaries regarding missing sessions should be 
organised and agreed in advance of treatment commencing (e.g., offering a telephone 
session instead), and clinicians and clients should ensure that they set realistic 
activation assignments for the amount of time that clients have in-between sessions.  
Due to some potential participants opting for CBT as opposed to BA, in order 
to target treatment doubts and promote participation in research, service triages should 
include detailed descriptions of different treatment options, highlighting the evidence 
to demonstrate BA’s non-inferiority (Dimidjian et al., 2006; Ekers et al., 2014), as 
well as the advantages of time-intensive BA. In addition, given that all participants in 
the current study had experienced multiple previous episodes of depression, and the 
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majority had received previous psychological treatment, clinicians should assess 
reasons why clients would like TT, and remain vigilant of those who could be seeking 
a ‘quick fix’ with less intention to fully engage in therapy. Nevertheless, the finding 
that no participants dropped-out suggests that time-intensive BA or an increasing 
intensity of some sessions could be offered to promote treatment retention for those 
who struggle to engage. Screening of participants for bi-weekly sessions could 
include a motivational interviewing component to ensure suitability. In addition, as 
observational comparisons of responders versus non-responders suggested that those 
with more severe and chronic depressive episodes were least responsive to time-
intensive BA, clinicians intending to continue investigating the effects of time-
intensive BA should begin with individuals who express preference for a condensed 
treatment or urgency to recover, but less severe, recurrent or chronic MDD. Also, 
given the findings that the majority of participants had ongoing life-stressors, 
clinicians should carefully consider when more than one session a week would be 
deemed ‘too much’ for clients, and re-formulate as new stressors arise. 
As two participants found outcome monitoring distressing, outcome measure 
collection appears poorly tolerated by a subset of clients with depression, which 
should be considered when planning future symptom monitoring. However, as 
differences in outcomes were observed across idiographic, self-report and clinician-
rated measures, where possible, services should continue to collect examples of each 
to enhance treatment guidance. Finally, considering the discrepancies between 
measures reported here, idiographic measures should be operationalised to represent 
more proximal measures of depression (e.g., hopelessness as opposed to general 
depression), in order to provide more specific understanding of progress.  
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Study strengths 
 
The present study is the first to define a novel application of time-intensive 
BA treatment, and explore its efficacy within adult primary care settings. Therefore, it 
makes an important contribution to the research field.  
Design. The study was carefully designed to consider service user feedback 
and meet SCED standards (Kratochwill et al., 2010). Including a baseline phase 
enabled participants to act as their own controls, and replication of the intervention 
across settings, therapists and participants, including randomisation to multiple 
baselines, reduced the effects of history and maturation on the internal validity of the 
study outcomes. Statistical analysis of idiographic measures controlled for instability 
in baseline trends, enhancing confidence in outcome change being attributed to the 
intervention, and the inclusion of follow-up symptom monitoring, where possible, 
enabled some tentative conclusions to be drawn about the short-term durability of the 
treatment. The intervention itself did not interfere with referral routes or waiting list 
durations, and appeared to be reliably adhered to by sufficiently competent therapists, 
enhancing the study’s external validity. 
Sample. The sample recruited all met diagnostic criteria for MDD (APA, 
2013), enhancing the validity of the study outcomes. What is more, the sample 
recruited was heterogeneous in some ways, which implies that the intervention effects 
apply to varying groups. The sample size was larger than previous studies with similar 
designs (e.g., Folke et al., 2015), demonstrating its enhanced power. Also, 
participation in the study was not biased by ulterior motives such as monetary 
compensation, potentially reducing selection bias.  
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Measures. Collecting a variety of repeated idiographic outcome measures 
increased the study’s power. Furthermore, the completion of idiographic measures as 
primary outcomes enabled the findings to be more closely attributed to the 
intervention itself. Also, allowing participants to choose two of their VASs promoted 
clients’ motivation to complete measures. Completion of standardised self-report 
measures reduced the threat of instrumentation on outcomes, and the inclusion of a 
clinician-rated measure (the MADRS) further promoted the reliability of responses 
(Cuijpers et al., 2010).  
Study limitations 
 
Design. The study was a non-concurrent multiple baseline SCED, meaning the 
BA was not manipulated to all participants simultaneously. Therefore the design had 
less control over confounding variables (history effects in particular) than if the 
intervention had been replicated to participants simultaneously, reducing the study’s 
external validity (Carr, 2005). Still, greater flexibility in the recruitment of 
participants and therapists than a concurrent design would have enabled was 
considered essential by all recruitment services.  
Due to practical issues, participants did not all receive the same number of 
sessions, or types and amounts of prompting. In fact, though not as ‘brief’ as some 
other time-intensive behavioural activation (e.g., Hopko et al., 2003a), no participants 
received the recommended duration of treatment (NICE, 2009).  Evidence to show 
that TT leads to faster recovery irrespective of the number of sessions (e.g., Reese et 
al., 2011) deems this less problematic; however, differing sequences of treatment 
might have predicted some variation in outcome measures. Moreover, only five 
participants completed follow-up measures, and follow-up only lasted three weeks, 
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which is a shorter period of time than has been monitored for existing studies of BA’s 
efficacy (Ekers et al., 2014), severely limiting conclusions about the treatment 
durability.  
 Sample. The final sample size was fewer than the intended 11 participants, 
preventing the study power from exceeding the desirable 0.8 power level (Shadish, et 
al., 2014), and limiting the generalizability of the findings. Furthermore, the strict 
inclusion criteria, as well as the fact that participants needed to be seeking treatment, 
meant that recruitment was limited by selection bias, with all participants being 
unemployed, and findings cannot be generalised to the wider population with 
depression. In addition, severe mental illness was not formally assessed, and if present 
could have influenced individual outcomes. Furthermore, for participants with 
English as a second language, language may have been a confounding variable 
influencing the comprehension, and, in turn, reliability, of some outcome measure 
completion. Indeed, having treatment in their mother-tongue would have enabled 
them to communicate more effectively (Costa, 2010).   
  Therapist sample size was also small and their selection was subject to bias 
too. IAPT recruitment sites were asked to permit high-intensity therapists to see 
participants first, contradicting the stepped-care model. Therapists needed to be 
willing to take on time-intensive participants, which required their availability over a 
fixed 22-day period. As with participants, this limits the study power and 
generalisability of the findings. Of importance, views on acceptability of the 
intervention are not generalizable to all therapists and clinical settings. 
Measures. Participants were expected to complete a significant number of 
repetitive outcome measures. This was time-consuming and two participants reported 
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that outcome measure completion was aversive. Furthermore, the majority of 
measures were self-reported and were often completed in front of therapists or handed 
to them upon completion. Therefore, the reliability of the findings is likely to have 
been negatively influenced by fatigue, demand characteristics, desirability bias, 
acquiescence and extreme reporting. The reliability of the QOBAS and all VASs were 
also limited as they are not standardised measures. 
Experimenter bias could also have limited the reliability of the study 
measurements. The Principal Investigator conducted all screening measures, and 
although participant suitability was checked with service leads, screening measures 
were not inter-rated for reliability, which could have biased participant recruitment. 
Furthermore, clinician-rated measures were also not inter-rated for reliability or rated 
by blind-assessors. However, as idiographic measures were the primary outcome 
measures for the current study, they were considered of prime importance for deriving 
efficacy of the intervention.  
The measurement of treatment fidelity was also limited, as it was based on just 
five audio recordings of sessions, one from each participant who consented to having 
their sessions recorded. Therefore, the reported fidelity outcome cannot account for 
the remaining 63 sessions that were implemented. In addition, the Assistant 
Psychologists who completed the treatment fidelity ratings, though trained in BA, 
were not qualified or practicing clinically using BA, which may have biased their 
fidelity ratings.  
 Other confounding variables. The study was subject to numerous 
confounding variables, which limit the external validity of the findings. Participants 
were told that they could receive treatment as usual if their time-intensive BA was 
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ineffective, which could have biased the results of those who wanted further 
treatment. However, participants were also aware that they would need to go back 
onto service waiting lists to receive further treatment.  
Furthermore, due to high variability in the data and all participants 
experiencing on-going life-stressors (e.g., bereavements and relationship 
breakdowns), outcomes were subject to high history effects. It is a limitation of the 
study that specific dates of aversive incidents were not always known, and the 
influence of life-stressors on outcomes were not analysed statistically. Though not 
considered empirically, life-stressors may have influenced participants’ abilities to 
benefit from the intervention. For example, as postulated by Ehlers et al., (2010), 
discussion of daily difficulties and life events might have dominated therapy 
discussions. Likewise, life-changes such as returning to work (a form of increasing 
activation) or even natural fluctuations in mood (Cuijpers et al., 2012) could have 
predicted positive symptom change in some. Indeed, PE confirmed that his experience 
of bereavement led him to feel more normal and in turn, less depressed. In addition, 
the majority of participants were taking prescribed antidepressant medication. Despite 
requesting that GPs keep participants’ medication levels stable, one participant halved 
his dosage without consulting his GP. These issues imply that the study effects are 
less attributable to the intervention alone and require tentative interpretation. Of note, 
the fact that the majority of responders had previously received psychological 
treatment was not considered a confounding variable given that most previous 
depression treatment had taken place six months or more prior to the current study 
beginning, and all participants met criteria for MDD at baseline. 
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 Finally, though experienced in delivering BA, none of the therapists had 
delivered it time-intensively before. In turn, it is possible that they may have relied 
more heavily on the treatment guides that they were provided with, increasing the 
likelihood of the intervention being protocolised, which is not its intended efficacious 
mode of delivery (Dimidjian et al., 2008). 
Future research 
 
As this study was a proof-of-concept study, it provides a starting point for 
research that is intended to be developed into larger experiments. Future research 
should aim to rectify the limitations of the current study whilst adding to existing 
knowledge to the area. The current study is already intended to collect follow-up data 
at six, 12 and 18-months post-treatment at which point recovery rates (Bockting, 
Hollon, Jarrett, Kuyken & Dobson, 2015), and longer-term durability of outcomes can 
be evaluated.  
The study should now be replicated across different samples, therapists, 
settings and time-periods, while relaxing the exclusion criteria, in order to generalise 
the findings to a wider population. To begin with, more SCEDs should be conducted, 
delivering concurrent treatments across individuals where possible, in order to reduce 
the influence of extraneous variables on the outcomes. Within larger samples, more 
standardised population based outcome measures, or even objective measures (e.g., 
heart rate), should be collected, less frequently, in order to increase the reliability of 
outcomes while reducing the burden of their completion. Parallel self-report and 
clinician-rated measures of depression with matching content should be collected to 
enhance the concurrent validity of findings. Future studies should also inter-rate 
measures and ensure that self-report measures are not given directly to clinicians but 
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instead processed anonymously by independent raters, in order to increase the 
reliability of the study findings. Furthermore, future research should employ more 
rigorous measurement of the treatment fidelity, rating all available audio recordings of 
sessions, and recruiting qualified clinicians to do so.  
Recruiting larger samples would also yield more powerful results, and the 
ability to conduct more comparative and predictive analyses. Regression analyses 
should be conducted to determine whether or not treatment characteristics (e.g., 
duration, session number, session spacing, and prompting), service characteristics 
(e.g., private or NHS), therapist characteristics (e.g., experience and number), and 
participant characteristics (e.g., history, comorbidity, life-stressors and social support) 
predict or moderate treatment response, and perceived feasibility and acceptability of 
the treatment. Coding frameworks should also be used to determine and track specific 
(e.g., homework levels) and non-specific (e.g., therapeutic relationship strength) 
mechanisms of change that occur in each session, their temporal relationships to 
outcomes, and whether or not they are crucial to recovery following time-intensive 
BA. In addition, it will be important for future research to conduct a carefully 
designed qualitative study investigating client and therapists’ subjective experiences 
of the intervention, such as what they might have found helpful or problematic about 
it and their suggestions for its future development. Such findings could then be used 
to guide the development of an optimized time-intensive BA for both individuals with 
depression and therapists. Perhaps, TT will be considered best for unemployed 
individuals, as a preventative ‘top-up’ intervention for relapsing/treatment-resistant 
individuals, or even as part of a transdiagnostic intervention where depression 
requires treatment before an existing comorbidity. Alternatively, Dimidjian at al., 
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(2008) may have had it right all along with their recommendation that only initial 
sessions should be time-intensive. Importantly, future research should adopt our same 
definition of ‘time-intensive’, and treatment ‘responder’ in a bid to move towards 
standardisation of terminology and outcomes. 
Finally, in the longer-term future, RCTs should be conducted to determine the 
efficacy and cost-effectiveness of different time-intensive BA designs in comparison 
to control and/or recommended active control conditions (e.g., weekly BA or time-
intensive CBT for depression). Only then will it be possible to conclude whether or 
not time-intensive BA is an adequate first-line treatment of depression.  
Conclusions 
 
In summary, the current study provides new and tentative evidence 
highlighting the potential of time-intensive BA as a feasible, acceptable, and effective 
intervention for some adult outpatients with depression. This supports previous 
findings that point to the promise of time-intensive treatments and constitutes an 
essential step in attempting to increase patient choice and access to depression 
treatments. While this study found that the majority of participants showed 
improvements in their idiographic symptoms of depression, and four out of eight 
participants were considered treatment responders on standardised depression 
measures, it is not possible to generalize the findings to wider populations, and 
recommend the use of time-intensive BA for everyone with depression. The findings 
also do not provide conclusive evidence for justifying limiting of resources. Instead, 
where possible, clinicians within primary care may wish to offer time-intensive BA to 
suitable referrals and evaluate their progress. Moreover, the promising findings of this 
exploratory study now warrant further evaluations in RCTs to substantiate its results, 
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identify the long-term durability of the treatment effects, clarify hypotheses made in 
this discussion, and the conditions under which the intervention will be optimally 
effective. Overall, it is not surprising that such a heterogeneous affliction appears to 
show heterogeneous responses to different treatment approaches, however it is hoped 
that this treatment approach can go on to reduce depression’s ubiquitous burden and 
promote the well-being of the population.  
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Appendices 
Appendix 1. Summary Table of Abbreviations 
 
Abbreviation Meaning 
ADM Antidepressant Medication 
APA American Psychological Association 
BABCP British Association of Behavioural and Cognitive 
Psychotherapies 
BA/TD Behavioural activation protocol that was a blend 
of BA and BATD (Kanter et al., 2009) 
BATD Behavioural Activation Treatment for Depression 
(Lejuez et al., 2001) 
BA Behavioural Activation (Martell et al., 2001) 
BADS-SF The Behavioural Activation for Depression Scale 
- Short Form 
BAI Beck Anxiety Inventory 
BDI Beck Depression Inventory 
BMED Broadened Median 
BT Behavioural Therapy 
CBT Cognitive Behavioural Therapy 
CT Cognitive Therapy 
CEQ The Client Expectancy/Credibility Questionnaire 
CSQ The Client Satisfaction Questionnaire 
CSC Clinically Significant Change 
CT Cognitive Therapy 
DAS-SF The Dysfunctional Attitudes Scale - Short Form 
DOH Department of Health 
ERP Exposure and Response Prevention 
HRA Health Research Authority 
GAD-7 The Generalized Anxiety Disorder Scale 
IAPT Improving Access to Psychological Therapies 
ICC Intra-Class Correlation 
IPT Interpersonal Therapy 
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MADRS Montgomery-Åsberg Depression Rating Scale 
MBCT Mindfulness-Based Cognitive Therapy 
MDD Major Depressive Disorder 
NCCMH National Collaborating Centre for Mental Health 
NICE National Institute for Health and Clinical 
Excellence 
NHS National Health Service 
OCD Obsessive-Compulsive Disorder 
PA Participant A 
PB Participant B 
PC Participant C 
PD Participant D 
PDSQ Patient Diagnostic Screening Questionnaire 
PE Participant E 
PF Participant F 
PG Participant G 
PHQ-9 The Patient Health Questionnaire 
PH Participant H 
PTSD Post-Traumatic Stress Disorder 
QoBAS The Quality of Behavioural Activation Scale 
RC Reliable Change 
RCI Reliable Change Index 
RCT Randomised-Controlled Trial 
RM2/3/5 Running Median of 2/3/5 
SCED Single-Case Experimental Design 
SEM Standard Error of the Mean 
TR Trended Range 
TT Time-Intensive Treatment 
VAS Visual Analogue Scale 
WHO World Health Organisation 
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Appendix 2. Participant Information Sheet  
 
Can intensive behavioural activation treat depression in only 3 
weeks? 
 
We would like to invite you to take part in a study investigating the effectiveness of a 
condensed behavioural activation treatment for depression that takes place over three 
weeks  
 
For further information, please read the following participant information sheet. 
                                                   
INFORMATION SHEET 
 
To help you decide whether you would like to take part please take time to read the 
following information carefully. Talk to others about the study if you wish. 
Please do not hesitate to ask us if there is anything that is not clear or if you would 
like more information. Contact details can be found at the end of the document. Take 
time to decide whether or not you wish to take part. 
Thank you for taking the time to read this information. 
1. What is the purpose of the study? 
The aim of the study is to test whether or not depression can be treated in a shorter, 
more condensed time period than usual. Usually depression is treated with one 
therapy session a week, across 12 to 16 weeks. We would like to see whether or not 
the same results can be achieved from delivering a recommended depression 
treatment, called behavioural activation, intensively, on just 7 extended sessions over 
22 days.  
We already know that behavioural activation delivered once a week over 12 to 16 
weeks is considered to be no less effective at treating depression as other 
interventions such as medication and a different psychological therapy called 
cognitive behavioural therapy. Existing research has also found that other mental 
health difficulties such as obsessive compulsive disorder and phobias can be treated in 
this condensed way. We hope this study will show that depression can be treated 
faster, which would hopefully make treatment more accessible and cheaper to treat as 
well as reducing client waiting list times.  
213 
 
Once completed, we will look at how strong the treatment effects are and whether or 
not treatment outcomes last over time. We will also ask participants to give feedback 
on how they have found the condensed treatment.  
The study is taking place as part of a Doctorate of Clinical Psychology research 
project but is intended to be published and disseminated. 
2. Why have I been chosen? 
You have been chosen because you are seeking treatment for depression on an 
outpatient basis. 
3. Do I have to take part? 
No, it is up to you to decide whether or not to take part. We will give you an 
opportunity to ask any questions you may have after reading this information. Then 
we will ask you some questions to ensure that the treatment is the most suitable 
approach to meeting your needs. If we would recommend the treatment for you, and 
you agree to take part, we will then ask you to sign a consent form to show you have 
agreed to take part. However, even after giving consent to take part, you are free to 
withdraw at any time, without giving a reason.  
4. What will happen to me if I decide to take part? 
The flow diagram below summarises what will happen to you if you decide to take 
part, and is followed by a more detailed description: 
 
 
Express interest in taking part 
Answer questions (e.g. about depression symptoms / 
availability for travelling to the service) 
Randomised (picked out of a hat) to start therapy 
sessions  after a wait of between 7 and 21 days  
Treatment: Attending face-to-face therapy sessions on 
7 days over a 3 week period and completing your goals 
in the community whilst being contactable on the 
telephone every day in-between 
Complete a number of questionnaire measures before, 
during and after finishing treatment 
Provide feedback on your experince  
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The treatment that you will be given is called behavioural activation and it is a 
recommended treatment for persons with depression, like yourself. The treatment 
consists of developing an understanding of what is causing and maintaining your 
depression, and then engaging in more activities that keep you feeling better and 
driven to stay busier. The treatment content will be the same as standard 
recommended behavioural activation for depression. The only differences are a) that 
you are being offered the treatment over a shorter period of time, with shorter gaps in-
between treatment sessions, and b) that you will be asked to complete 6 more 
questionnaires than the usual 5 required in standard IAPT care. These additional 
questionnaires will measure your expectations of the treatment, your depression 
symptoms and your satisfaction with the treatment.  
When you begin the treatment, you will have one therapist assigned to you for your 
face-to-face treatment sessions and either the same or a different therapist assigned to 
you to contact you via telephone on days where you don’t have a face-to-face session.  
 
Treatment day start times will be determined by whether or not you would prefer to 
be seen in the morning or afternoons, and the therapist’s availability.  The first two 
treatment days will be three days apart and will include discussions with your 
therapist about understanding your problem, goal setting and treatment planning.  On 
these days you will need to have a break at some point, because the initial sessions are 
likely to be 2 hours long, but you will be able to decide break times with your 
therapist. The days in-between the first two treatment sessions will consist of 
monitoring your activity levels, or in other words, monitoring what you’re doing with 
your day. The rest of the treatment will consist of goal-focused activation in the 
community that will be prompted and reinforced by short yet frequent telephone calls 
or texts from either the same therapist that you see face-to-face, or a different one. 
Frequency of telephone prompts will be flexible.  
 
Following activation periods you will return for 1 hour face-to-face review sessions 
with your therapist where barriers to activities will be problem solved and the next 2 
to 3 days of activities will be planned. This pattern will repeat across 22 days. 
Therefore, after your initial two days of therapy sessions you will have 5 more face-
to-face sessions (making a total of 7). It is expected that your minimum treatment 
duration, including face-to-face sessions and telephone prompts will sum to 12 hours. 
After completing your treatment you will be offered 3 optional booster sessions to 
review your progress with your therapist, problem solve any barriers getting in the 
way of you completing your goals and to plan for the future. These booster sessions 
will be offered 1, 2 and 4 weeks after your core treatment. 
During your treatment you will be asked to complete homework after each face-to-
face session, but this will consist of completing activities planned in sessions.  
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Across the research study you will be asked to complete a number of different 
questionnaires, measuring your beliefs and your symptoms of depression. Some 
measures will need to be completed every day, others will need completing once a 
week. One measure that you will be asked to complete once at the beginning of the 
study, is a new questionnaire that is being trialed as part of the study. Daily measures 
should not take more than 5 minutes to complete, but the measures we ask you to 
complete once a week could take 30 minutes to complete. You will be asked to 
complete these so that your progress can be monitored over time, which is useful to 
therapists and researchers for considering how therapy can be made most effective for 
individuals. You will be given paper copies of questions to complete, which you can 
return at your next therapy sessions. You will also have the option to complete 
questions over the phone, online or to send your responses via email.  
Following your 3 week treatment you will be asked to continue completing measures 
of your symptoms and beliefs during what is called a follow-up period. Follow-up 
measurement collection allows researchers to see if the therapy’s effects are 
maintained over longer periods of time, and not just until the end of treatment. We 
hope that you will continue to complete measures for a few months after the treatment 
ends. When it is time to complete follow-up measures we will contact you. Follow-up 
information can be collected over the phone, online, face-to-face, via email or mail. 
You will also be asked to provide feedback comments on how you found the 
treatment.  Feedback you provide will then be considered by professionals so that they 
can fine-tune the treatment to be more relevant and user friendly where necessary.  
During treatment we will ask to audio record sessions. A random sample of the 
recordings will be listened to, to assess the quality of the delivery of the therapy, and 
not to assess you or the content of the therapy. Audio recording sessions requires your 
consent and you do not have to agree to it. Your therapist may recommend that you 
record your therapy sessions on your own recording device too, as it can be useful to 
have the option to listen back over your sessions. 
5. What do I have to do? 
You will be expected to attend your face-to-face treatment sessions 7 times over a 3-
week period. Therefore you will need to be available for up to 3 hours on each of the 
first two treatment sessions and 1 hour for each of the remaining 5. You will also be 
required to be contactable over the telephone every day in-between your face-to-face 
sessions so that you can receive a call or text message to see how you are doing with 
your activities. This means that you will need to take time out of work or other 
commitments. We will ask that you organize your commitments (e.g. child care) in 
advance of the 3-week treatment so that you can fully focus on the treatment. 
You will need to complete the questionnaire measures a) before starting the treatment, 
b) each day while completing the program, and c) after finishing the program. 
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6. What are the side effects of taking part? 
You may find answering some of the questions or completing some aspects of the 
treatment distressing due to their sensitive nature.  Should you feel any distress during 
or after you have filled out the questionnaires, spoken with a therapist, or had a 
treatment session, then the project team will be there to support you at the contact 
details below. In addition we will share details of support services with you, should 
you need to speak to someone from a particular service. 
You are also free to withdraw from the study at any time without giving a reason or 
can always miss out any questions from questionnaires or programme activities that 
you do not feel comfortable with answering. 
7. What are the possible benefits of taking part? 
One benefit of taking part in the study is that your wait time for treatment will be 
shorter that that your wait on the waiting list would be for standard weekly treatment. 
We cannot promise the study will help you, but behavioural activation, which is the 
treatment you will receive, is a recommended treatment for persons with depression. 
It is hoped that you will develop an increased understanding of your depression and 
that you will experience reduced symptoms of depression as a result of receiving this 
treatment. If successful, it is hoped that you will experience a more rapid reduction in 
symptoms.  
Information we get from this study will help us better understand whether or not 
depression can be treated over a shorter time-period and whether or not more 
intensive treatment is acceptable at providing positive outcomes to clients like 
yourself. Conducting research of this nature has benefits to the wider society because 
it has the potential to guide future service delivery. 
8. What are the possible disadvantages or risks of taking part? 
The study is testing a new way of delivering a treatment (behavioural activation) that 
is already recommended. You will be asked to complete a number of assessments and 
questionnaires. Initial assessments may take up to 30 minutes. Daily measures will 
take 5 minutes to complete and weekly measures may take up to 30 minutes to 
complete. 
You are free to withdraw from the study at any time without giving a reason or can 
always miss out any questions from questionnaires or programme activities that you 
do not feel comfortable with answering. 
9. What if new information becomes available? 
Over the course of the research if any new information becomes available that is 
relevant to your participation we will be sure to contact you as soon as possible to let 
you know. 
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10.  What if something goes wrong? 
If you have a concern about any aspect of this study, you should ask to speak to Sarah 
Miles (the Principal Investigator) who will do her best to answer your questions (see 
contact details below). If you remain unsatisfied and wish to complain formally, you 
can do this through the NHS Complaints mechanism. The telephone number to call in 
order to make a complaint is 0345 015 4033. 
For further details, you can visit the NHS complaints procedure website at 
http://www.nhs.uk/choiceintheNHS/Rightsandpledges/complaints/Pages/NHScomplai
nts.aspx 
Additional information can also be obtained by the service that you are seen at.  
In the event that something does go wrong and you are harmed during the research 
and this is due to someone’s negligence, then you may have grounds for a legal action 
for compensation against Royal Holloway University of London, but you may have to 
pay your legal costs. 
11. Will my partner / carer / friend be able to come with me? 
You will be allowed to attend your assessment session with one significant other. It 
can also be helpful to have someone acting as your “cheerleader” who can check in on 
how you are doing, or even escort you to and from your therapy sessions, or 
accompany you when you complete your homework activities. 
12. What happens when the research study stops?  
After receiving the three week behavioural activation, you will have a clinical review 
to see if you require further psychological or medical treatment. If you do require 
further treatment this will be provided and at the usual weekly frequency.  
You will be provided with a summary of the main research findings and if the 
findings are published you will be given a copy of the publication article. 
Your data will be kept for a maximum of 5 years while publication and further 
research procedures, and auditing for research governance monitoring might take 
place. 
. 13. What will happen if I don’t want to carry on with the study? 
 You can withdraw from the study at any time without giving a reason and without 
your current care being affected. Any identifiable data collected will be destroyed. 
Data that is not identifiable may still be used.  
If you decide not to take part you will remain on the waiting list to be seen for 
standard weekly treatment for depression. This will not affect the care you receive. If 
you withdraw from the study  after starting your treatment you will be offered a 
clinical review to see if you require a higher intensity psychological treatment (such 
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as cognitive behavioural therapy), and if you do, you will be offered a place on the 
waiting list for it.  
14. What will happen to the results of the research study? 
The results of the research will submitted for publication in a scientific journal. 
Findings will also be publicised at psychological conferences and in the media. You 
will be given a summary of the results and may request a copy of any successful 
publications. You will not be identified in any report or publication arising from the 
research.  
The results may also have implications for further psychological research. If the 
intervention is found to be successful it could go on to be compared to treatment as 
usual for depression. Future research could also be conducted to “fine-tune” the 
intervention, to identify its most effective form of delivery (e.g. ideal session number / 
duration) and for whom it is most effective. The long-term aim will be for the results 
to guide whether or not a more effective and more rapid form of depression treatment 
can be rolled out in services. 
 15. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be 
kept strictly confidential. You will be assigned a participation code at the beginning of 
the study, which will be associated with all of your data. Any identifiable data such as 
your name and address will not be associated with the data that we collect from you 
during the research. A list linking the names of participants to their participation 
codes will be kept separate from the data, in a locked filing cabinet. 
Electronic copies of data will be stored on computers with username and password 
security required to gain access. Any data transferred to portable data devices will still 
be anonymous and will also be password protected. Hard paper copies of any 
information you share with us will be kept in folders in a locked filing cabinet. 
Computers and filing cabinets to be used will be stored at your treatment service or 
Royal Holloway University of London. All filing cabinets will be locked and housed 
within buildings that are also locked with a security code and alarm system. 
You will be asked if you would like your GP to be informed of your participation in 
the research. This is because it can be useful for your medical records to note any 
form of intervention you have received. However, this decision will be yours, and if 
you do decide that it is OK for us to inform your GP, this information will still remain 
confidential in line with client information legislation. 
Your personal contact information will be available to your therapist, as is standard 
procedure. It will also be available to the Principal Investigator of the research study 
so that you can be contacted with important information (e.g. your session times and 
the study findings). Your anonymised data will be accessible to therapists at your 
psychology service and members of the research team. Numerical anonymised data 
219 
 
based on audio recordings of your sessions (if you consent to audio recording) will be 
shared with a research team we are collaborating with at University of Colorado 
Boulder.  As mentioned above, no identifiable data will be stored with your 
anonymised data.  
 
16. Who has reviewed the study? 
The study has been reviewed by the Royal Holloway research committee, leading 
clinicians at each research site, experts in the field of depression research, and the 
Central London Research Ethics Committee.   
17. Who is organising and funding this study? 
This study is being organised by clinical and research teams at Royal Holloway 
University, Southwark IAPT, and Hackney IAPT. No external funding has been 
provided for the conduction of this research. 
 
18. How have clients and the public been involved in designing this study? 
Service users with depression, like yourself, have been involved in designing the 
treatment layout, study materials, the content of sessions and the outcome measure 
administration. They will also be involved in helping to share the study findings.  
 
.Contact for Further Information 
For further information, please do not hesitate to discuss the study with Sarah Miles, 
the Principal Investigator. 
By email: sarah.miles.2014@live.rhul.ac.uk 
By post: Royal Holloway University of London 
  Clinical Psychology Department 
  Egham 
  Surrey 
                        TW20 0EX  
 
By telephone: 07512508390 
 
You will be given a copy of the information sheet and a signed consent form to keep.  
Thank you for considering taking part in the study.  
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Appendix 3. Adapted version of The Quality of Behavioural Activation Scale  
 
Removed for Copyright purposes. 
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Appendix 4. Royal Holloway University of London Research Committee 
Approval Document 
 
Memorandum 
To:   Sarah Miles 
From:  Gary Brown (on behalf of the Research Sub- 
Committee and Course Executive) 
Date:   9
th
 February 2016 
Copy To:  
Re:   Main Research Project Proposal 
The Research Sub-Committee has considered your Main Research Project Proposal 
response and has decided to give you Approval.  Your research costs have also been 
approved.  Please note that if these costs change and you do not re-submit an amended 
form for approval prior to incurring any additional costs, these additional costs will 
not be reimbursed. 
 
 
 
 
 
 
 
Now that you have received approval it is time to apply for ethics.   
Please provide Annette with copies of all applications, letters and 
approvals.  Also, please ensure that if RHUL is your sponsor, 
Annette is sent all participant signed consent forms. 
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Appendix 5. National Research Ethics Service Ethical Approval Documents 
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Appendix 6. National HRA Approval Documents 
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Appendix 7. Homerton University Hospital NHS Foundation Trust Research and 
Development Approval 
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Appendix 8. South London and Maudsley NHS Foundation Trust Research and 
Development Approval 
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Appendix 9. The Demographic Variable Questionnaire 
Demographic Questions at Screening 
Number of Previous Depressive Episodes 
 
Please provide details of any previous depressive episodes and when these were: 
 
 
 
 
Previous Hospital Admissions 
Please provide details of any previous hospital admissions, when these were, and what 
they were for: 
 
 
 
 
 
Current Comorbidity 
Besides depression, have you been given any other mental health diagnoses? If so, 
when? 
 
 
 
 
 
Medication (name, duration and dosage) 
Please provide information such as the name, dosage and duration that you have been 
taking any medication for. This should include medication that you are taking 
currently, and medication you have taken previously. It would be helpful to provide 
information on both prescribed medication (such as antidepressants or contraception) 
and medication that you purchase over-the-counter (such as St. John’s Wort or 
paracetamol).  
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Health 
 
Do you have a disability? (Please tick one)              Yes                  No  
 
If yes, please specify 
____________________________________________________ 
Do you have any physical health diagnoses, long-term conditions (such as diabetes, 
heart disease, cancer) or medically unexplained symptoms (such as chronic pain)? If 
yes, please describe.  
 
 
 
 
 
Do you drink Alcohol?           Yes              No  
 
If yes, how much do you consume each week?       
 
_______________________________________________________________ 
 
_______________________________________________________________ 
 
Do you take any recreational drugs?             Yes                   No  
 
 
If yes, what do you take, and how often? 
 
_____________________________________________________________ 
 
_____________________________________________________________ 
 
Psychological Treatment 
Are you receiving any current psychological treatment (such as cognitive behavioural, 
psychodynamic or family therapy?) Please tick one. 
 
Yes                 No 
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If yes, which type, how often and how long for?   
_________________________________________________________________ 
Have you had any form of psychological treatment previously?  
 
Yes                 No 
 
If yes, which type, how often and how long for?   
_________________________________________________________________ 
Previous Life Events  
 
Please describe any previous life events (such as being involved in an accident, 
moving house, going through a relationship breakdown, or bereavement) that you 
have experienced: 
 
 
 
 
 
 
Are you experiencing any “life events” or going through any significant life changes 
currently? If yes, please describe. 
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Appendix 10. The Patient Diagnostic Screening Questionnaire (PDSQ; 
Zimmerman & Mattia, 2001) 
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Appendix 11. The Credibility / Expectancy Questionnaire (Devilly & Borkovec, 
2000) 
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Appendix 12. Idiographic Visual Analogue Scales 
Daily Record Sheet  
Measure of Mood 
Over the last 24 hours, how depressed have you felt? Please rate the intensity of your depression on a scale of 0 to 100 
where 0 is “not at all depressed”, 100 is “the maximum possible” and 50 is “moderately depressed”.  
 
 
 
 
Measure of Anxiety 
Over the last 24 hours, how anxious have you felt? Please rate the intensity of your anxiety on a scale of 0 to 100 where 
0 is “not at all anxious”, 100 is “the maximum possible” and 50 is “moderately anxious”.  
 
 
 
 
    0         10         20         30          40         50         60         70         80         90       100 
Not at all                                                             Moderately Depressed                                                    The Maximum 
                                                                                                                                                                           Possible                                                                                                                                                                                                                                                                 
    0         10         20         30          40         50         60         70         80         90       100 
Not at all                                                             Moderately Anxious                                                    The Maximum 
                                                                                                                                                                           Possible                                                                                                                                                                                                                                                                 
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Measure of Rumination  
 Over the last 24 hours, how frequently have you ruminated? Ruminating is repetitively thinking about your emotional 
experience of depression, how it was caused and its consequences. You might refer to this as brooding or analysing. 
Please rate how frequently you have ruminated / brooded / analysed on a scale of 0 to 100 where 0 is “not at all”, 100 is 
“all of the time” and 50 is “half of the time”. 
 
 
 
 
Measure of Avoidance Behaviour 
Over the last 24 hours, how frequently have you avoided doing things that you needed to do? Please rate how much you 
have avoided doing things on a scale of 0 to 100 where 0 is “not at all”, 100 is “completely avoided doing things” and 50 
is that you have “equally avoided and did not avoid doing things”.  
 
 
 
 
    0         10         20         30          40         50         60         70         80         90       100 
Not at all                                                                  Half of the time                                                           All of the time 
    0         10         20         30          40         50         60         70         80         90       100 
Not at all         Equally            Completely 
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Measure of Belief 
Over the last 24 hours, how true has your belief   
 
“_______________________________________________________________________________________________”  
felt?  
 
Please rate how true it has felt on a scale of 0 to100 where 0 is “not at all true”, 100 is “the maximum possible”, and 50 
is “50% true”.  
 
 
 
 
 
 
 
 
 
    0         10         20         30          40         50         60         70         80         90       100 
Not at all                                                                        50% true                                                              The Maximum 
                                                                                                                                                                           Possible                                                                                                                                                                                                                                                                 
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Measure of Chosen Symptom 
For this scale please rate your symptom of depression that you have chosen to monitor across the duration of your 
treatment and the research study. Your therapist should have helped you to decide on this. Please write in what you are 
measuring and how it is rated on the scale (“not at all”, “completely”). 
 
I am measuring ______________________________________________________________________________________________ 
 
_____________________________________________________________________________________________________________ 
 
 
 
                   ____________                                                                   _____________                                                              ____________ 
    0         10         20         30          40         50         60         70         80         90       100 
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Appendix 13. The Montgomery-Åsberg Depression Rating Scale (MADRS; 
Montgomery & Åsberg, 1979) 
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Appendix 14. The Patient Health Questionnaire (PHQ-9; Kroenke & Spitzer, 
2002)  
Over the last week, how often have you been bothered by 
any of the following problems? Not at 
all 
Several 
days 
More 
than 
half the 
days 
Nearly 
every 
 day 
1 Little interest or pleasure in doing things 0 1 2 3 
2 Feeling down, depressed, or hopeless 0 1 2 3 
3 Trouble falling or staying asleep, or sleeping too much 0 1 2 3 
4 Feeling tired or having little energy 0 1 2 3 
5 Poor appetite or overeating 0 1 2 3 
6 
Feeling bad about yourself — or that you are a failure or 
have let yourself or your family down 
0 1 2 3 
7 
Trouble concentrating on things, such as reading the 
newspaper or watching television 
0 1 2 3 
8 
Moving or speaking so slowly that other people could 
have noticed?  Or the opposite — being so fidgety or 
restless that you have been moving around a lot more 
than usual 
0 1 2 3 
9 
Thoughts that you would be better off dead or of hurting 
yourself in some way 
0 1 2 3 
  A11 – PHQ9 total score  
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Appendix 15. The Generalized Anxiety Disorder Scale (GAD-7; Spitzer, 
Kroenke, Williams, & Löwe, 2006) 
Over the last week, how often have you been bothered by 
any of the following problems? Not at 
all 
Several 
days 
More 
than 
half the 
days 
Nearly 
every 
 day 
1 Feeling nervous, anxious or on edge 0 1 2 3 
2 Not being able to stop or control worrying 0 1 2 3 
3 Worrying too much about different things 0 1 2 3 
4 Trouble relaxing 0 1 2 3 
5 Being so restless that it is hard to sit still 0 1 2 3 
6 Becoming easily annoyed or irritable 0 1 2 3 
7 Feeling afraid as if something awful might happen 0 1 2 3 
  A12 – GAD7 total score  
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Appendix 16. The Behavioural Activation for Depression Scale - Short Form 
(BADS-SF; Manos, Kanter, & Luo, 2011)  
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Appendix 17. The Dysfunctional Attitudes Scale - Short Form (DAS-SF; Beevers 
et al., 2007)  
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Appendix 18. The Client Satisfaction Questionnaire (Larsen et al., 1979 
Client Satisfaction Questionnaire-8 (CSQ-8) 
(Larsen, Attkisson, Hargreaves, & Nguyen, 1979) 
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Appendix 19. Client Feedback Form 
Client Feedback Form 
 
“I believe that time-intensive behavioural activation is an acceptable treatment 
for outpatients with depression”.  
 
Please rate how much you agree with the statement above on the scale from 0 to 100 
where 0 is “not at all”, 100 is “completely agree” and 50 is “moderately agree”.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  0         10        20        30        40       50       60        70         80       90       100 
       Not at all                                                Moderately                                                Completely
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Appendix 20. Therapist Feedback Form 
Therapist Feedback Form 
Please take the time to answer the following questions.  
You may wish to look back at any comments you made in your therapy guides to aid 
your reflection.  
1. How acceptable do you view time-intensive BA to be for clients? Please rate your 
answer on a scale from 0 to 100 where 0 is “not at all” and 100 is 
“completely”. 
 
 
 
2. How useful do you view time-intensive BA to be for clients referred to your 
service? Please rate your answer on a scale from 0 to 100 where 0 is “not at 
all” and 100 is  
“completely”. 
 
 
 
 
3. How confident would you feel using time-intensive BA as a first-line treatment 
for depression? Please rate your answer on a scale from 0 to 100 where 0 is 
“not at all” and 100 is “completely”. 
 
 
 
 
4. If your service enabled you to work using an intensive approach, how likely do 
you think you would be to choose to deliver intensive BA again? Please rate 
your answer on a scale from 0 to 100 where 0 is “not at all” and 100 is 
“completely”. 
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Appendix 21. The Quality of Behavioural Activation Scale (Dimidjian et al., 
2016) 
 
Removed for Copyright purposes.  
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Appendix 22. Participant Consent Form 
 
CONSENT FORM 
Study Title: Can intensive behavioural activation effectively treat depression in 
only 3 weeks? 
Principle Investigator: Sarah Miles  
Participant ID number: 
Study site: 
                                                           Please initial the box 
1. I confirm that I have read and understand the participant information sheet 
for the above study and have had the opportunity to ask any questions  to the  
investigator(s) and have had these questions answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
 withdraw at any time, without giving any reason, and without my medical 
 care or legal rights being affected. 
 
3. I understand that the information I provide will be collected fairly,  
will remain secure and confidential, and held no longer than necessary for  
the purposes of this research. 
 
4. I understand that the information collected about me will be used to  
support other research in the future, and may be shared anonymously with  
other researchers. 
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5. I understand that relevant sections of my medical notes and data collected 
 during the study may be looked at by individuals from the Royal Holloway 
 University of London Research Team, from regulatory authorities or from the NHS 
Trust, where it is relevant to my taking part in this research. I give  
permission for these individuals to have access to my records.” 
 
6. I consent to the audio recording of my therapy sessions. I understand that  
the tapes / files will be stored securely and deleted at the end of the study 
 duration. 
7. I agree to my General Practitioner being informed of my participation  
in the study.   
 
8. I want to be informed about the results of the study. 
 
9. I agree to take part in the above study. 
 
          
Name of participant:   Date:   Signature: 
I have explained the study to the participant and answered their questions honestly 
and fully 
 
           
Name of Consenter   Date    Signature 
 
 
PLEASE KEEP YOUR COPY OF THE INFORMATION SHEET AND 
CONSENT FORM DOCUMENT.  (A COPY WILL BE RETAINED BY THE 
RESEARCHER) 
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Appendix 23. Participant Orientation Form 
PARTICIPANT ORIENTATION SHEET 
Session                                      Date Duration of 
Session   
Time of Session 
Assessment  2 hours   
1  2 hours  
2  2 hours  
3  2 hours   
4  1 hour  
5  1 hour  
6  1 hour  
7  1 hour   
Optional 
Booster 1 
 1 hour  
Optional 
Booster 2 
 1 hour  
Optional 
Booster 3 
 1 hour  
Each day you will be asked to complete brief measures rating your symptoms of 
depression. Time required for you to complete these measures has been factored into 
the time that you have been asked to arrive at the service. The completion of these 
measures is very important so please be on time.    
Most of your face-to-face treatment sessions will last for 1 hour. Your first 3 face-to-
face treatment days will last for up to 2 hours. Your booster sessions are optional and 
will last for up to 1 hour.  
You and your therapist might decide to have a short break in your 2 hour sessions. 
There will be no break in each 1 hour session. You will be able to break to go to the 
toilet whenever you need to. We might ask you to do an activity/task in your break. It 
would be good to bring something with you that you could do during your break. 
We will ask you to try some activities/tasks between sessions, but we can agree how 
much you feel able to do. 
You will also be given brief outcome measures to complete at home, in-between your 
sessions. It will be important to complete all of these. At the end of the course of 
treatment sessions you will be asked to complete some measures again.  
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We are available any time, Monday to Friday, 09.00-17.00 if you have any questions 
or concerns.  
 
Things to remember: 
 
Please check this sheet before each of your sessions 
 
1. Attend all of your sessions. If you have an emergency and are unable to attend 
one of your sessions, please try to inform us by calling the reception desk. 
 
2. Please bring your own diary / calendar to all of your sessions. If you do not have 
a diary at the moment then please purchase one. 
 
3. Please bring your own audio recording device to your sessions so that you can 
record your sessions and listen back to them another time.  
 
4. Please bring any homework sheets with you to your sessions. Going over your 
homework will be an import part of your treatment. 
 
5. Please bring all of the outcome measures that you have completed in-between 
each session to your following session. 
 
6. Please bring something with you that you can do during the break, if you have 
one.  
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Appendix 24. Extract from Therapist Folders  
Session 1 - Face-to-face Treatment - Day 1  
Date: ________ Patient’s ID:______ Therapist ID: ________  
Overview:  This session is advised to be up to 2 hours long (though durations will 
vary). This time would usually be recommended for orienting the participant to 
treatment, beginning their formulation and explaining activity monitoring. You may 
also need to ask some more assessment questions. However, BA is not protocol 
driven. Please use your clinical judgement when necessary.  
Remember, treatment sessions should occur no longer than 2 or 3 days apart.  
Materials needed: (see worksheets section) 
1. Audio recording device  
2. Scales 
1. Visual Analogue Scales  
2. Patient Health Questionnaire 9 
3. Generalized Anxiety Disorder  Scale 7 
4. Behavioural Activation Scale - Short Form 
5. Dysfunctional Attitudes Scale - Short Form 
6. Montgomery-Åsberg Depression Rating Scale 
3. Session Summary and Homework sheet 
4. Client Expectancy Questionnaire  
5. Outcome measures to complete between this session and the next session 
Other BA worksheets available: (see worksheets section) 
6. 10 principles of BA  
7. The BA model 
8. Activity Monitoring form 
Agenda: 
1. Collect outcome measures completed over the baseline period and tick when 
completed  
 
Visual Analogue Scales completed over the baseline period (7, 14 or 21 sets, 
depending on length of baseline)  
Patient Health Questionnaires completed over the baseline period (1, 2, or 3 sets, 
depending on length of baseline) 
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Behavioural Activation Scale - Short Form completed over the baseline period (1, 2, 
or 3 sets, depending on length of baseline)  
Dysfunctional Attitudes Scale - Short Form completed over the baseline period (1, 2, 
or 3 sets, depending on length of baseline)  
Generalized Anxiety Disorder Scale 7 completed over the baseline period (1, 2, or 3 
sets, depending on length of baseline) 
 
2. Collect new outcome measures data (completed today) and tick when completed. 
 
 
Visual Analogue Scales   
Patient Health Questionnaire 9  
Generalized Anxiety Disorder Scale 7  
Behavioural Activation Scale - Short Form 
Dysfunctional Attitudes Scale - Short Form 
 
(Note - you will have completed the Montgomery-Åsberg Depression Rating Scale 
1, 2 or 3 times over the phone during the baseline phase).  
 
3. Complete Montgomery-Åsberg Depression Rating Scale and tick when completed 
   
 
Completed measures can be added to the plastic wallet at the back of this 
session guide.   
 
4. Start audio-taping if consented (on therapist and participant devices). 
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5. Review mood, outcomes and homework. Don’t forget to assess risk. 
 
 
6. Collaboratively develop an agenda for the session including when the break will 
be. 
 
7. Psychoeducation / orientation to treatment   
 
 
8. Ask any remaining assessment questions including whether or not the participant 
wanted to include a ‘cheerleader’ in their treatment. 
 
9. Formulate together (refer to your functional analysis completed during the 
assessment session). 
 
10. Refine treatment goals (if necessary) to be in line with the formulation (e.g., so 
that avoidance becomes a target). Alternatively, goals could be set for 
homework. 
 
11. Explain activity monitoring, how to use the activity monitoring sheet (see 
worksheets section) and the rationale for it. 
 
 
12. Session summary (see summary and homework sheet in worksheets section) 
 
 
 
13. Set homework task and solicit feedback - fill in the homework sheet (see summary 
and homework sheet).  
Homework for this session should be activity monitoring.  
 
14. Give Visual Analogue Scales to complete between today’s session and the next 
session (see worksheets section). Remind participants of the rationale for 
completing these. 
 
15. Orient to prompts.  
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16. Discuss the plan for the next session. 
 
17. Ask clients to complete the Client Expectancy Questionnaire (see worksheets 
section) before leaving the service. They can either complete it in remaining 
time in the session, or hand it in at reception after completing it in the waiting 
room. 
 
Tick when completed    
 
Photocopy any completed worksheets that participants are going to take home 
with them and store a copy in the wallet provided for this session. Tick when 
completed  
 
Note down the session duration here _____________________ 
 
Note down how long the session break was, and what the client did 
during the break (if you had one) here: 
 
 
Therapist’s Observations:  
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Between Session Guidance for Therapists  
1. You now have two/three days before seeing your participant again (all working 
days/the weekend). It will be important to set aside some time to add to your 
formulation if necessary.  
2. Read the plan for the next session and any relevant pages from the BA clinician’s 
guide. 
3. Seek supervision. 
4. An automated text message will be sent to your participant(s) to remind them 
about their next appointment time. You may want to check that this has been 
set up and is working.  
5. You can send encouraging text messages/emails to your participant or telephone 
them at any point.  
 
You can log your prompts using the following table: 
Date Prompt Type Tally Duration of 
Contact 
 Telephone 
Call 
Text Voicemail Email  
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Appendix 25. PA’s Variability Analysis (Trended Range)  
 
 
Figure PA7. Depression VAS: trended range 
 
 
Figure PA8. Anxiety VAS: trended range 
 
 
Figure PA9. Rumination VAS: trended range 
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Figure PA10. Avoidance VAS: trended range 
 
 
 
Figure PA11. Belief VAS: trended range 
 
 
Figure PA12. Procrastination VAS: trended range 
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Appendix 26. PB’s Variability Analysis (Trended Range)  
  
 
Figure PB7. Depression VAS: trended range 
 
 
 
Figure PB8. Anxiety VAS: trended range 
 
 
 
Figure PB9. Rumination VAS: trended range 
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Figure PB10. Avoidance VAS: trended range 
 
 
Figure PB11. Belief VAS: trended range 
 
 
Figure PB12. Guilt VAS: trended range 
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Appendix 27. PC’s Variability Analysis (Trended Range)  
 
 
Figure PC7. Depression VAS: trended range 
 
 
Figure PC8. Anxiety VAS: trended range 
 
 
Figure PC9. Rumination VAS: trended range 
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Figure PC10. Avoidance VAS: trended range 
 
 
Figure PC11. Belief VAS: trended range 
 
 
Figure PC12. Crying VAS: trended range 
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Appendix 28. PD’s Variability Analysis (Trended Range)  
 
 
Figure PD7. Depression VAS: trended range 
 
 
Figure PD8. Anxiety VAS: trended range 
 
 
Figure PD9. Rumination VAS: trended range 
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Figure PD10. Avoidance VAS: trended range 
 
 
Figure PD11. Belief VAS: trended range 
 
 
Figure PD12. Withdrawn VAS: trended range 
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Appendix 29. PE’s Variability Analysis (Trended Range)  
 
 
Figure PE7. Depression VAS: trended range 
 
 
 
Figure PE8. Anxiety VAS: trended range 
 
 
 
Figure PE9. Rumination VAS: trended range 
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Figure PE10. Avoidance VAS: trended range 
 
 
 
Figure PE11. Belief VAS: trended range 
 
 
 
 
Figure PE12. Apathy VAS: trended range 
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Appendix 30. PF’s Variability Analysis (Trended Range)  
 
 
Figure PF7. Depression VAS: trended range 
 
 
 
Figure PF8. Anxiety VAS: trended range 
 
 
 
Figure PF9. Rumination VAS: trended range 
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Figure PF10. Avoidance VAS: trended range 
 
 
 
Figure PF11. Belief VAS: trended range 
 
 
 
Figure PF12. Lack of Energy VAS: trended range 
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Appendix 31. PG’s Variability Analysis (Trended Range)  
 
 Figure PG7. Depression VAS: trended range 
 
 
Figure PG8. Anxiety VAS: trended range 
 
 
 
Figure PG9. Rumination VAS: trended range 
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Figure PG10. Avoidance VAS: trended range 
 
  
Figure PG11. Belief VAS: trended range 
 
 
Figure PG12. Despair VAS: trended range 
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Appendix 32. PH’s Variability Analysis (Trended Range)  
 
 
Figure PG7. Depression VAS: trended range 
 
  
Figure PG8. Anxiety VAS: trended range 
 
 
Figure PG9. Rumination VAS: trended range 
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Figure PG10. Avoidance VAS: trended range 
 
 
Figure PG11. Belief VAS: trended range 
 
 
Figure PG12. Sadness VAS: trended range 
 
 
